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Cognitive impairments, including deficits in attention processing, represent 
major and central elements of schizophrenic symptoms. First- and second-
generation antipsychotic drugs can effectively mitigate the florid symptoms of 
psychosis. However, treating schizophrenia’s cognitive deficits remains 
problematic and has met with limited success. Evidence indicates that the basal 
forebrain cholinergic system (BFCS) is an essential component of the neuronal 
circuitry involved in mediating attention processing attention processing- an 
important aspect of cognition. The present thesis is based on the core hypothesis 
that cholinergic dysregulation contributes to the cognitive impairments associated 
with schizophrenic symptoms. Using a repeated-amphetamine (AMPH) rat model 
of schizophrenia, the following main hypotheses are tested:  
1) Repeated, escalating AMPH administration, followed by ‘AMPH-
challenges’ at previously innocuous doses, results in performance 
impairments on a task that measures sustained attention.  
2) The consequences of repeated-AMPH administration and 
subsequent challenge dosing in task-performing animals include 
dysregulated cortical cholinergic transmission.   
3) In AMPH-pretreated animals performing a sustained attention task; 
sub-chronic, low-dose administration of antipsychotic drugs will 
attenuate performance impairments.  
 
The present findings provide evidence for aberrant regulation of the basal 
forebrain cholinergic system and impaired sustained attention processing in a 
repeated-AMPH model of schizophrenia. Specifically, pretreatment with AMPH 
resulted in markedly attenuated performance associated cortical cholinergic 
 viii
 
transmission. This effect was evident only under the condition of task 
performance, and was not apparent in passive, non-performing animals. 
Cholinergic abnormalities were found to actually precede task onset, indicating 
that they contributed to rather than resulted from impaired performance. In 
addition, low doses of commonly prescribed first- and second-generation 
antipsychotic drugs were found to attenuate these attentional impairments 
effectively, although the effects on cortical cholinergic transmission in task-
performing animals remain speculative. The present data are consistent with the 
hypothesis that the basal forebrain cholinergic system represents a principle 
component in the neuronal dysregulation mediating schizophrenia’s cognitive 
impairments. Expanding upon this hypothesis, the present data elucidate the 
dynamic nature of this dysregulation in response to different stimulus 
environments. Collectively, these experiments demonstrate the potential 
usefulness of this procedure for modeling aspects of impaired cognition in 
schizophrenia and may serve as a potential starting point for pre-clinical efforts 
aimed at discovering and developing novel, pro-cognitive drugs to improve the 






1.1 Why study impaired cognition in schizophrenia? 
Schizophrenia is a severely debilitating neuropsychiatric disorder whose 
essential characteristics include hallucinations, delusions, paranoia, 
inappropriate affect and cognitive deficits. The term ‘cognitive deficits’ describes 
functional deficiencies or reduced capacities for cognitive operations that span 
multiple domains, including attention, mnemonic processing, and verbal memory. 
Cognitive impairments are persistent, are present in the majority of 
schizophrenics (between 55-85%), and predict functional outcomes more 
accurately that the severity of psychosis (Green 1996; Keefe, Eesley et al. 2005). 
Cognitive deficits are considered to be elemental ‘state-characteristics’ and are 
conceptualized as predisposing factors for disease onset rather than the 
secondary consequence of florid symptoms (Green and Braff 2001; Heaton, 
Gladsjo et al. 2001). Cognitive impairments can be detected in children at risk for 
psychosis; they become more pronounced during the disease prodrome, and 
worsen during first-break psychosis. Thereafter, the severity of impaired 
cognition either remains constant or further deteriorates- even in the face of 
illness phases marked by substantial improvements in the severity of psychosis 
(Heaton, Gladsjo et al. 2001). Presently, the American Psychiatric Association 
defines the primary treatment goals for persons with schizophrenia as the 
reduction of psychotic symptoms and the prevention of injurious behavior (APA 
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2006).  In parallel, the majority of preclinical research efforts geared towards 
antipsychotic drug discovery to date, have focused on the determination 
antipsychotic mechanisms for the alleviation of florid psychotic symptoms. 
Despite Kraepelin’s early emphasis on the cognitive components of 
schizophrenia, efforts directed at determining cognition-enhancing treatment 
strategies for the disease have been initiated only recently (Green and Braff 
2001; Green, Nuechterlein et al. 2004). The pervasiveness of cognitive 
impairments and their impact on multiple functional domains necessitates the 
development and application of novel, pro-cognitive drugs targeted explicitly 
towards improving cognition in schizophrenia.  
Impaired attention processing is evident in schizophrenia and represents a 
prime target of therapeutic intervention for several reasons discussed below. The 
following paragraphs will define attention processing, review the role of impaired 
attention in schizophrenia, and describe the application basic neuroscientific 
techniques, including animal models, towards the problem of schizophrenia. 
Subsequently, the relevant neurobiological components of attention and 
schizophrenia will be addressed. I will then review the currently available 
treatments for schizophrenia and discuss their mechanisms of action. Finally, the 
discussion will describe how this body of knowledge can be applied towards an 
animal model of the cognitive deficits in schizophrenia. 
1.2 What is attention?  
Attention is defined as the ability to detect, select and process relevant 
stimuli while filtering out irrelevant stimuli. Attention is a non-unitary construct that 
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involves multiple processes and capacities comprised of several interrelated 
components, including sustained attention, divided attention, and selective 
attention. Experiments assessing sustained attention in humans typically 
measure a subject’s ability to detect and report the occurrence of rarely and 
unpredictably occurring stimuli over an extended period of time. A subject’s 
capacity to sustain attention is thought to be limited by multiple factors including 
finite attentional resources and limited processing capacities. During testing, 
attentional resources can be taxed or over extended through the manipulation of 
task parameters to increase cognitive demands and produce performance 
decrements. Such manipulations include the successive rather than 
simultaneous presentations of signal or non-signal events to necessitate 
cognitive switching, the variation of stimulus features (i.e. intensity or duration) to 
prevent the establishment of detection criteria, the randomization of signal or 
non-signal event types, the increased rate of stimulus presentations, and the 
variable timing of trial occurrences (Parasuraman 1986; Parasuraman 1987). 
Collectively, these manipulations are thought to extend the cognitive demands of 
task performance beyond those of simple stimulus detection by limiting the 
implementation of routine-based strategies, necessitating additional processing 
(i.e. symbolic or conditioned significance of signals), and imposing the guided 
allocation of cognitive resources (Sarter, Givens et al. 2001).  
1.3 The role of impaired attention in schizophrenia 
Attentional deficits in schizophrenia can be ascertained through clinical 
observation and have been characterized using a variety of attention tasks. 
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Impairments in attention have been reported consistently in patients with 
schizophrenia since the earliest accounts of the illness by Kraeplin and Bleurler 
(Hoenig 1983). Generally, schizophrenics perform approximately ~1-2 standard 
deviations worse than control groups on commonly used tests assessing 
attention, working memory and executive functioning (Heinrichs 2005).  
Attentional impairments can be accentuated during stressful or cognitively 
demanding situations and are indicative of heterogeneous impairments, including 
deficits in stimulus detection, selection and filtering (Cattapan-Ludewig, Hilti et al. 
2005).  
The clinical presentation of attentional deficits can be illustrated with the 
following examples: a 21 year old male diagnosed with schizophrenia noted 
apparent difficulties in stimulus detection and the allocation of attentional 
resources that contributed to academic difficulties: “...it’s like I’m in class and 
trying to pay attention to the prof…my mind goes elsewhere…and then I miss the 
point.” Alternatively a 28 year old female dual-diagnosed with schizophrenia and 
substance abuse disorder described apparent gating deficits that contributed to 
vocational difficulties “...I was working behind the counter and then it was like all 
of a sudden, everything (got real loud) and it felt like it was all coming at me at 
once…I couldn’t handle it and took off…” (unpublished). Preclinical experiments 
have substantiated such anecdotal observations with data describing 
impairments in various aspects attention processing. For example, deficits in 
attention and related cognitive processes have been detected in nearly all 
varieties of the Continuous Performance Task (i.e. CPTX, CPT degraded, and 
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CPT continuous pairs) (van den Bosch, Rombouts et al. 1996; Elvevag, 
Weinberger et al. 2000; Cattapan-Ludewig, Hilti et al. 2005; Braff 1993;Javitt, 
Shelley et al. 2000). Continuous performance tasks require the subject to detect 
and respond to a rarely and unpredictably occurring target stimulus (or set of 
stimuli) while inhibiting responses to distracting, non-target stimuli. CPT 
performance is commonly used to assess sustained attention and its dependent 
measures (i.e. commissions, omissions and reaction time) are used to gauge a 
subject’s ability to rapidly detect and select target stimuli and discriminate non-
target stimuli (Rosvold,  et al. 1956). Depending on the task-version, 
schizophrenics demonstrate impaired stimulus detection, increased incorrect 
responses to non-target stimuli, and delayed reaction times (references above).  
Importantly, and as will be discussed later, valid measures of sustained attention 
can be ascertained in animals through the use of tasks with demands that bear  
some analogy to those of the CPT (McGaughy and Sarter 1995; Robbins 2002; 
Bushnell 1998).  
1.4 Challenges in the development pro-cognitive drugs for schizophrenia 
and alternative research approaches: what to model  
Recent insights into the cognitive deficits of schizophrenia and current 
advancements in basic, preclinical neuroscience have not been paralleled by 
advancements in drug development. Hymen and Fenton have described a 
“translational bottleneck” which exists between clinical- and preclinical-science 
(Hyman and Fenton 2003).  This bottleneck refers to the difficulties in shifting the 
recent advancements in the fundamental pharmacology, neural circuitry, and 
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psychology of schizophrenia into the discovery of novel pro-cognitive drugs for 
schizophrenia (Hyman and Fenton 2003). This is due, at least in part, to a lack of 
well-defined targets as a focus for pre-clinical research, the use of animal models 
incapable of detecting cognitive impairments or improvements, and attempts to 
model disease components that bear little consequence to improved functional 
outcomes in patients. Further contributing to this failure are unsuccessful 
experimental approaches based on ‘holistic animal models’ that attempt to 
reproduce the entire clinical syndrome. Such models target non-specific clinical 
endpoints (i.e. positive symptoms) (Nielsen, Lyon et al. 1983; Castner and 
Goldman-Rakic 2003), that are rooted in traditional psychiatric diagnostic tools 
(i.e. the DSM-IV; Kilts 2001). Alternatively, other models have attempted to 
replicate poorly understood aspects of the disease such as its etiology (Weiss 
and Feldon 2001; Meyer, Feldon et al. 2005). The primary goal of such 
experimentation has been the discovery of comprehensive ‘monotherapies’ for 
what are in fact, very complex and heterogeneous clinical entities. As an 
alternative, more suitable experimental objectives (such as specific cognitive 
components of the disease) can be derived from the domains of cognitive 
impairment set forth by the National Institute of Mental Health Measurement and 
Treatment Research to Improve Cognition in Schizophrenia (MATRICS). 
MATRICS has determined seven separable domains of cognitive impairment that 
are evident in schizophrenia: attention, speed of processing, working memory, 
verbal learning and memory, visual learning and memory, reasoning and problem 
solving (Nuechterlein, Barch et al. 2004). This system is based on the 
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fractionation of schizophrenia’s symptoms into discrete elements that can be 
addressed with a high degree of precision and specificity.  The determination of 
these cognitive factors represents a step towards the identification of appropriate 
targets that can be explored to facilitate the development of new drugs to 
enhance cognition in schizophrenia (Green, Nuechterlein et al. 2004).  
The following experiments will focus on sustained attentional processing in 
an animal model of schizophrenia. Sustained attention processing in 
schizophrenia represents an optimal target of experimentation for several 
reasons. First, sustained attention processing is a well-defined cognitive 
construct that is essential for a variety of other cognitive operations and has been 
well characterized in schizophrenia. Second, sustained attentional processing is 
amenable to study in animals and thus, in animal models of the disease; 
attentional impairments can be reproduced and assessed within animals with 
high fidelity through the application of tasks that bear remarkable analogy to 
those used in humans. Third, sustained attention processing possesses a 
relatively well-defined neurobiology that serves to facilitate experimentation and 
to operate as a discernable target for the development of novel drugs. Lastly, 
measures of attention processing in humans predict ‘real-life’ vocational and 
interpersonal outcomes in patient populations (references above).  
1.5 Measuring attention in rats 
The present experiments utilize an operant sustained attention task that 
requires the animal to report rarely and unpredictably occurring signals of varied 
durations over an extended period of time and to discriminate signal- from non-
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signal events. Although alternative measures of attention in rats are available 
(i.e. divided attention; Turchi and Sarter, 1997), the sustained attention task is 
utilized as a matter of experimental convenience as it requires less time for 
acquisition (~3 months). The focus of this thesis on sustained attetention does 
not imply that only sustained attention is disrupted in schizophrenia, but rather, 
represents an efficient way to study one important aspect of this illness. 
Validation of this task as a measure of sustained attention performance was 
based on experiments conducted by McGaughy and Sarter (1995) and  Bushnell 
et al. (1997). Manipulations of task parameters described above (i.e. signal 
duration, inter-trial interval, background ‘noise’, and randomization of signal and 
non-signal events) are known to affect task performance in a manner analogous 
to human tasks. Complete task methodology, including animal shaping, is 
described in the methods section of each subsequent chapter. Briefly, utilizing an 
operant chamber equipped with two retractable levers, a houselight, a signal light 
and reward port animals are required to indicate the presence or absence of a 
signal by pressing the left lever for signal events and the right lever for non-signal 
events. Correct responses to signal trials (hits) and non-signal trials (correct 
rejections) are followed by the presentation of a water reward. Incorrect 
responses signal trials (misses) and non-signal trials (false alarms) are not 
rewarded. Half of all animals are trained using reverse response rules (e.g. the 
right lever scores hits, the left lever scores misses). Importantly, this task 
provides a direct measure of false alarms, or discrete claims by the subject for 
the presence of a signal, when in fact, no signal was presented. Each session 
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consists of 162 trials divided equally between signal and non-signal events to 
promote trial type unpredictability. Signal and non-signal trials occurred randomly 
with 9±3 s inter-trial intervals to limit the prediction of trial type or trial onset. 
Signals consist of single light flashes of variable duration (500 ms, 50 ms, 25 
ms); durations are varied for the purpose of preventing the establishment of fixed 
detection criteria. As expected, the number of detected trials declines in concert 
with diminishing signal duration reflecting a vigilance decrement. It is important to 
note that chance-level performance of this task is characterized by uniform 
detection rates of 50% for all signal durations accompanied by 50% correct 
rejections. Performance criteria consists of at least 70% correct responses to all 
500 ms signal-trials and to non-signal trials, with fewer than 25 omitted trials per 
session. Overall levels of attention performance are calculated using the 
Vigilance Index (VI = [(h-f)/2*(h+f)-(h+f)2]). VI is derived from the Sensitivity Index 
described by Frey and Colliver (1973), but calculated based on the relative 
number of hits and false alarms rather than the probability of such occurrences. 
Additionally VI is used expressly for describing data from tasks that include 
discrete non-signal events whereas the SI is generally not. VI values range from-
1 to 1, with a score of 1 indicating correct responses to 100% of attempted trials. 
A VI value of 0 indicates a complete inability to dissociate signal- from non-signal 
events, and reflects chance-level task performance.  




The goal of the following section is to describe the anatomical basis of the 
neurobiological systems involved in attention processing and to discuss 
hypotheses regarding the functions of these systems during normal functioning 
and under conditions of pathology, specifically in the context of schizophrenia. 
Hypotheses regarding the neurobiology of attention processing have been 
informed by data from multiple levels of analysis.  Posner and Peterson 
described the ‘anterior attention system’ as a macro anatomical network 
consisting of frontal-parietal cortical regions that influence attention processing 
(Posner and Petersen 1990). This conceptualization has been supported by 
human data demonstrating that damage to frontal or parietal regions of the cortex 
results in impaired performance (i.e. decreased hits, augmented vigilance 
decrement and slowed reaction times) on tasks that measure sustained attention 
(Rueckert and Grafman 1998, Rueckert and Grafman 1996). Corroborating data 
are provided by neuroimaging studies using intact subjects performing sustained 
attention tasks (Hager, Volz et al. 1998). These data provide evidence for a 
distributed cortical attention network that is comprised of frontal-parietal regions 
and lateralize primarily in the right hemisphere.   
Additional neuroimaging data, as well as neuro-pathological data from 
Alzheimer’s patients, implicates subcortical structures in attention processing. 
These structures include those located in the ventral pallidum (Paus 1997). The 
basal forebrain cholinergic system (BFCS) is thought to be of particular 
importance in this regard (Sarter and Bruno 1997; Sarter, Hasselmo et al. 2005). 
The cholinergic basal forebrain is a crucial component of the neuronal circuitry 
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mediating attentional processing (Chiba, Bucci et al. 1995; Voytko 1996; Everitt 
and Robbins 1997; Sarter and Bruno 1997). The basal forebrain cholinergic 
system is the most anterior of the major ascending neuromodulatory systems 
and it projects to all areas and all layers of the cortex (Woolf 1991, see Figure 
1.1). The neuroanatomical organization of the BFCS reflects its capacity to 
regulate information processing in all cortical areas, including frontal-parietal 
attentional networks, via the release of acetylcholine. In humans cortically 
projecting cholinergic neurons are situated along the medial wall of the globus 
pallidus within the horizontal and vertical limbs of the diagonal band. The BFCS 
and is comprised of cholinergic neurons in the nucleus basalis of Meynert, the 
substantia inominata and the magnocellular preoptic nucleus. Analogously in 
rodents, cortical cholinergic projections originate in the substantia inominata and 
nucleus basalis magnocellularis. These neurons are approximately 20-30μm in 
size and display a multi-polar morphology (Saper 1984).  
Cortical cholinergic projections comprise two major pathways, one medial 
and one lateral (Saper 1984). The medial pathway arises in the medial septal 
nucleus, substantia innominata and the medial diagonal band. It courses dorsally 
along the genu of the corpus callosum and terminates primarily in the prefrontal 
and cingulated cortices and extends to the hippocampal formation via the fornix. 
The lateral pathway consists of those axons arising from neurons in the medial 
septum, diagonal band, and magnocellular preoptic nucleus and terminating 
primarily in the entorhinal and pyriform cortices. Cortically projecting neurons 
terminating in the prefrontal cortex (PFC) demonstrate a rough topographic 
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organization, with the most rostal neurons of the nMB projecting to the medial 
prefrontal regions, and neurons arising from medial and posterior areas 
terminating in lateral prefrontal regions. Collectively, these nuclei comprise the 
main source of cholinergic innervation of the cortex, with particularly dense 
innervation layers 1, 3, and 5. The earliest hypotheses of cholinergic functions 
based on these neuroanatomical data, and those describing the non-uniform 
distribution of cholinergic soma, described the basal forebrain cholinergic 
neurons as the rostral extension of a unitary ‘reticular activating system’ 
comprised also of brainstem nuclei and mediating general states of arousal. 
Notably, current evidence has determined that cholinergic neurons possess a 
modular organization and are arranged in longitudinally oriented, structurally 
distinct bands that have been hypothesized to possess the capacity to influence 
discrete cortical regions independent of one another (Zaborszky 2002).   
1.7 Functions of the basal forebrain cholinergic system 
Evidence indicates that the integrity of the basal forebrain cholinergic 
system is required for normal attentional operations and capacities. Experiments 
have demonstrated that selective depletion of cortical cholinergic inputs 
(produced by infusions of the selective immuno-toxin 192-IgG saporin) results in 
cortical cholinergic deaffrentation and impaired performance in animals 
performing a sustained attention task (McGaughy, Kaiser et al. 1996). These 
deficits manifest specifically with respect to decreased hits on signal trials.  Intact 
performance of non-signal trials indicates that such impairments can not readily 
be described in terms of indiscriminant ‘fundamental executive problems’ 
 12
 
because the ability to process basic response contingencies remains intact. 
Instead the detection-specific characteristics of these impairments are indicative 
of impaired attentional capacities. Further evidence implicating cortical 
cholinergic transmission in attention processing has been derived from 
behavioral-dialysis experiments demonstrating augmented increases in cortical 
ACh during performance of tasks with explicit attentional demands, but not tasks 
that control for motor and reward retrieval aspects of performance (Arnold, Burk 
et al. 2002).  
Neurophysiological data indicate that cortical cholinergic transmission 
biases cortical information processing towards sensory, rather than associational 
inputs (Hsieh, Cruikshank et al. 2000) and at the same time selectively inhibits 
responses to weak inputs while enhancing, or at least suppressing to a lesser 
degree, responses to strong inputs (Metherate and Ashe 1995). These actions 
are thought to enhance the ‘signal to noise’ ratio during stimulus processing, thus 
facilitating stimulus detection and discrimination.  
1.8 Schizophrenia and cortical acetylcholine: the mesolimbic link 
Cholinergic neurons in the basal forebrain are thought to be influenced by 
multiple input systems and are known to receive glutamatergic, GABAergic, 
noradrenergic, serotonergic, dopaminergic, and cholinergic innervations. These 
contacts are thought to arise from a variety of structures including the PFC, the 
amygdala (Zaborszky, Leranth et al. 1984), the NAC (Zaborszky and Cullinan 
1992), the locus coeruleus (Zaborszky, Cullinan et al. 1993), the VTA (Gaykema 
and Zaborszky 1996), the dorsal raphe nucleus (Gasbarri, Sulli et al. 1999), and 
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the pedunculo pontine gigantocellular nucleus (Jones and Cuello 1989). To 
explain the individual and interacting contributions of each system in modulating 
the excitability of basal forebrain cholinergic neurons is beyond the scope this 
discussion and beyond the author’s comprehension. Instead, the following 
paragraphs will focus primarily on the role of mesolimbic networks in modulating 
cortical cholinergic transmission. These systems have been selected as the 
focus of this discussion due to their putative role in the pathogenesis of 
schizophrenia, their neuroanatomical relationships to the basal forebrain 
cholinergic system, and their relevance to psychostimulant-based models of 
schizophrenia.   
Dysregulated (i.e. hyperactive) mesolimbic dopamine transmission is 
considered a hallmark of schizophrenia and has been substantiated by 
neuroimaging studies in schizophrenic patients  (including non-medicated, first-
episode populations (Breier, Su et al. 1997; Laruelle, Abi-Dargham et al. 1999), 
and by data demonstrating the efficacy of dopamine antagonists for attenuating 
psychotic symptoms (described below). The precise contributions of abnormal 
mesolimbic dopamine transmission to the attentional impairments in 
schizophrenia remain unsettled. However, abnormal dopamine transmission in 
the nucleus accumbens has been hypothesized to mediate aberrant cortical 
cholinergic transmission and thus, may influence attentional processes and 
capacities.  
Importantly, the mesolimbic dopamine system can influence cortical 
cholinergic transmission via multiple pathways. This modulation is thought to 
 14
 
occur either mono-synaptically via direct, presumably dopaminergic contacts on 
cholinergic neurons (Gaykema and Zaborszky 1996), or trans-synaptically via 
dopaminergic regulation of multiple output structures that synapse in the basal 
forebrain (i.e. the prefrontal cortex and nucleus accumbens). Of particular 
interest are the medium-spiny neurons arising in the accumbens shell and 
terminating in the basal forebrain. These projection neurons represent the 
majority of inputs into the basal forebrain (Zaborszky and Cullinan 1992) and are 
met with a high density of basal forebrain GABA receptors (Gao, Hornung et al. 
1995). Medium-spiny projection neurons are likely GABAergic and are thought to 
influence the excitability of cholinergic neurons both directly via mono-synaptic 
connections (Zaborszky and Cullinan 1992), and trans-synaptically via the 
regulation of basal forebrain interneurons (Zaborszky, Cullinan et al. 1991).   
Hypotheses regarding the contributions of NAC GABAergic transmission 
in regulating basal forebrain excitability have been formulated based on the 
capacity of systemic or intra-basalis administration of benzodiazepine receptor 
agonists or inverse agonists to modulate cortical cholinergic transmission in a bi-
directional manner (Moore, Sarter et al. 1993; Moore, Sarter et al. 1995).  
Furthermore, additional experiments have demonstrated that the ability of 
benzodiazepine receptor partial inverse agonists to augment cortical cholinergic 
transmission is moderated by the administration of dopamine antagonists 
(Moore, Fadel et al. 1999). GABAergic inputs from the NAC are thought to 
converge with glutamatergic inputs from multiple sources, including reciprocal 
inputs from the prefrontal cortex, to regulate the excitability of basal forebrain 
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cholinergic neurons. Likewise, the effects of glutamatergic transmission in the 
basal forebrain have been explored. Intra-basalis infusions of glutamate 
antagonists or agonists have been shown to attenuate or augment cortical 
cholinergic transmission in response to food stimulus (Fadel, Sarter et al. 2001).  
Furthermore, experiments demonstrating that intra-basalis infusions of NMDA or 
APV (an NMDA antagonists) affected sustained attention performance in rats by 
increasing the number of false alarms, and decreased the number of hits, 
respectively (Turchi and Sarter 2001).   
Despite anatomical evidence demonstrating direct dopaminergic 
projections from the VTA to cholinergic basal forebrain neurons, the influence of 
these projections on cortical cholinergic transmission remains poorly understood. 
Acute administration of AMPH increased dopamine transmission in the NAC by 
700%, and augmented cortical cholinergic transmission by 150%. Curiously, 
these effects were unaltered by administration of D1 or D2 antagonists into the 
basal forebrain. However, intrabasalis infusions of glutamatergic antagonists or 
GABA agonists successfully attenuated AMPH-induced augmentations in cortical 
cholinergic transmission (Arnold, Fadel et al. 2001). Additional evidence 
suggests that activation of D2 receptors in the nucleus accumbens attenuates 
cortical cholinergic transmission following intra-accumbens administration of 
NMDA (Brooks and Bruno 2007). Thus dopamine is thought to exert its influence 
on cortical cholinergic transmission primarily via regulation of NAC output 
neurons- particularly on D2 receptors in the high-affinity state. Collectively, these 
data indicate that GABAergic projections from the NAC to the basal forebrain 
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may represent a neural substrate by which abnormal mesolimbic dopamine 
transmission can result in aberrant cortical cholinergic transmission, thus 
contributing to schizophrenic pathology. The ability of repeated-AMPH 
administration to produce psychotic like symptoms (discussed below) is thought 
to be mediated, at least in part, by this neural circuitry. 
1.9 Evidence for abnormal cortical cholinergic transmission in 
schizophrenics 
Converging lines of evidence have implicated abnormal cortical 
cholinergic transmission in the neurobiology of schizophrenia. Alterations in the 
distribution of nicotinic and muscarinic receptors in cortical regions of 
schizophrenic brains have been reliably demonstrated (Breese, Lee et al. 2000; 
Crook, Tomaskovic-Crook et al. 2001; Adams and Stevens 2007). The 
involvement of cholinergic transmission in the pathogenesis of schizophrenia has 
been further substantiated by genetic linkage studies showing abnormalities in 
the region of chromosome 15 coding for the α-7 nicotinic receptor in 
schizophrenics (Freedman, Coon et al. 1997). Abnormal cholinergic transmission 
in schizophrenia is thought to result from dysregulation rather than overt 
pathology. Neuropathological studies comparing post-mortem tissue of 
schizophrenics to that of control or Alzheimer’s groups failed to demonstrate any 
gross pathological abnormalities of the basal forebrain cholinergic neurons of 
schizophrenic patients (el-Mallakh, Kirch et al. 1991). Furthermore, there does 
not appear to be a decreased enzymatic capacity for schizophrenics to 
synthesize acetylcholine (Powchik, Davidson et al. 1998), although data 
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examining the high-affinity choline transporter, known to be the rate limiting step 
in acetylcholine synthesis, is currently unavailable.  
Pharmacological evidence also implicates dysregulated acetylcholine 
transmission in schizophrenia. Second-generation antipsychotic medications, 
including clozapine, have high-affinity antagonistic properties at muscarinic 
receptors and are metabolized into active compounds that affect cortical 
cholinergic transmission. It is thought that the ability of these drugs to modulate 
cortical cholinergic transmission may contribute to their therapeutic actions, 
particularly with regard to their moderate pro-cognitive effects (Li, Huang et al. 
2005; Davies, Compton-Toth et al. 2005; Crook, Tomaskovic-Crook et al. 2001). 
Despite these findings, hard evidence of cortical cholinergic dysregulation in 
schizophrenics remains elusive due to technological limitations prohibiting the 
direct assessment of cholinergic transmission in humans. Multiple groups have 
put forth hypotheses regarding the precise nature of cortical cholinergic 
dysregulation in regards to specific disease states; the following discussion 
serves to describe two separate and opposing theories that address this matter. 
One theory purported by Tandon et al. (1991) suggested that cholinergic 
hyperactivity contributed to the affective and social symptoms in schizophrenia, 
whereas decreased cholinergic transmission resulted in the manifestation of 
florid psychosis. Support for these hypotheses was provided by data 
demonstrating the ability of acute administration of muscarinic antagonist to 
improve scores on a negative symptoms scale. Sarter et al. (2005) separately 
interpreted muscarinic down-regulation in schizophrenics as evidence of 
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cholinergic hyperactivity, but hypothesized that cortical cholinergic hyperactivity 
resulted in a breakdown of sensorimotor gating mechanisms that escalated into 
psychotic symptoms. This ‘hyper-cholinergic’ hypothesis of schizophrenic 
psychosis was corroborated by data indicating that chronic exposure to 
cholinomimetic agents (i.e. cholinesterase inhibitors) can potentially result in 
psychotic symptoms in humans and that these effects can be treated 
successfully with antipsychotic medications (Sarter, Nelson et al. 2005). Despite 
their differences, both of these hypotheses predict that drugs that ‘normalize’ 
cholinergic transmission will improve schizophrenic symptoms. Several studies 
have determined the effects of adjunct treatment with cholinesterase inhibitors 
(which results in increased extra-cellular concentrations of acetylcholine) on 
cognitive and psychotic symptoms in schizophrenics. By and large, the results of 
these studies have been negative, with only a few groups reporting non-
significant trends for cognitive improvement  and generally no improvement on 
the severity of psychosis (Bora, Veznedarolu et al. 2005; Buchanan, Summerfelt 
et al. 2003; Freudenreich, Herz et al. 2005; Mazeh, Zemishlani et al. 2006; 
Sharma, Reed et al. 2006). Importantly, many of these studies were conducted 
as open-label designs, with only a few being double-blind and placebo controlled. 
Moreover, these studies have frequently included heterogeneous subject 
populations including geriatric patients or patients with heterogeneous disease 
durations. Further complicating the interpretation of these data are those studies 
allowing the co-administration of anti-cholinergic agents (i.e. biperdine) or the 
primary administration of antipsychotics with cholinergic antagonist properties 
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(i.e. clozapine or chlorpromazine). Oddly, those studies that did not allow for anti-
cholinergic drugs to be co-administered had primarily negative findings and those 
that permitted the use of anti-cholinergic agents reported the most trends for 
positive improvements. The outcomes of these studies should not be interpreted 
to indicate that cholinergic dysregulation is not involved in the pathogenesis of 
schizophrenia.  Rather, it should be concluded that these data do not support the 
hypothesis that the cognitive impairments of schizophrenia can be treated with 
cholinesterase inhibitors.  
1.10 Current treatments for schizophrenia 
Presently, the available medications for schizophrenia are divided into two 
categories, first-generation drugs (FGAs, sometimes called typical 
antipsychotics) and second-generation drugs (SGAs, also referred to as atypical 
antipsychotics).The primary characteristics distinguishing these two classes of 
drugs are their relative propensities for inducing extrapyramidal side effects (i.e. 
parkinsonism and tardive dyskinesia)  and their relative affinities for D2 and 
serotonin 5-HT2A receptors (Seeman 2002). FGAs possess a higher affinity for 
D2, and SGAs possess a higher affinity for 5-HT2A (Pretorius, Phillips et al. 2001). 
Both classes of drugs are lipophylic, readily cross the blood brain barrier, and are 
metabolized by cytochrome P450 enzymes (Linnet and Olesen 1997; Fang, 
McKay et al. 2001). The individual mechanisms of action for haloperidol and 
clozapine are discussed in more detail below.  
1.11 First-generation drugs: focus on haloperidol 
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Haloperidol is a first-generation antipsychotic drug that is effective for the 
treatment of psychotic symptoms. The antipsychotic effects of haloperidol (and 
all first-generation drugs) are generally attributed to its antagonism of D2 
receptors. Haloperidol is a potent D2 receptor antagonist with a D2 binding 
affinity 50 times greater than that of chlorpromazine (Lieberman 2006). D2 
receptor occupancy produced by haloperidol is known to predict the clinical 
efficacy of first-generation drugs. Utilizing PET imaging in first-episode 
schizophrenic patients, Kapur and colleagues demonstrated that 65-70% of D2 
occupancy is required for an optimal clinical response. Occupancy of ≥72% was 
found to abnormally augment prolactin levels and D2 receptor occupancy beyond 
78% was found to induce extrapyramidal symptoms (Kapur, Zipursky et al. 
2000).  High affinity D2 receptors (D2 High) have garnered a good deal of 
attention recently, and are thought to be the primary target for first-generation 
drugs including haloperidol (Seeman, Schwarz et al. 2006). Haloperidol is known 
to affect other neurotransmitter systems and has been shown to be a low-affinity 
antagonist for all muscarinic receptor subtypes as well as to act as an antagonist 
for several classes of histamine receptors (Bymaster, Calligaro et al. 1996). 
Haloperidol is not known to affect cortical cholinergic transmission in passive, 
non-performing rats (Ichikawa, Dai et al. 2002), and has not been shown to alter 
the distribution of muscarinic or nicotinic receptors in the cortex (Terry, Gearhart 
et al. 2006).  
The effect of first-generation antipsychotic drugs on impaired cognition in 
schizophrenia remains controversial. Only a few studies have shown that first-
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generation drugs exert cognitive benefits schizophrenic patients, with the majority 
of experiments demonstrating no change in cognition or even an exacerbation of 
cognitive impairments (Saeedi, Remington et al. 2006). However, accurate 
interpretation of the available literature is impeded by multiple factors. First, much 
of the available data are confounded by the inclusion of dose-ranges that would, 
by modern standards, be categorized as high (e.g. >15 mg per day). The range 
of dosing represents critical design variable since administration of FGAs is 
thought to produce inverted U-shaped dose response patterns, with low-to-
moderate doses resulting in cognitive improvements and higher doses producing 
impairments (Strauss, Lew et al. 1985). Furthermore, high-dose administration of 
first-generation drugs is known to increase the incidence and severity of 
extrapyramidal symptoms. Extrapyramidal symptoms may contribute to poor 
cognitive performance and are commonly treated with adjunct administration of 
anti-cholinergic agents (i.e. benztropines) that could further impair cognition 
(McGurk, Green et al. 2004). Additional concerns arising from basic design flaws 
(i.e. unequal group sizes, non-randomized drug assignments, lack of placebo 
control groups, lack of drug naïve groups, unequal proportion of male to female 
inclusion, inconsistent dose ranges, and variable illness durations) have severely 
hindered the interpretation of these data and have made accurately assessing 
the pro-cognitive effects of FGAs extremely difficult.   
To address these issues and make a quantitative assessment of the 
available literature, Mishara and Goldberg (2004) conducted a meta-analysis of 
studies spanning almost 50 years to examine clinical studies comparing the 
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effects of FGAs with placebos or non-treatment conditions on various domains of 
cognition (e.g. attention, executive functions, memory, and others).  The group 
determined effect sizes for experiments comparing first-generation drugs 
treatments with placebo, or non-medicated conditions. Based on calculations of 
224 effect sizes from 36 studies, first-generation drugs were shown to improve 
cognition above levels seen in placebo groups. The collective Cohen’s  ‘d-score’ 
of 0.22 was sufficient to surpass the criteria for a small effect size (Mishara and 
Goldberg 2004). The largest positive effects of treatment in these studies were 
observed on measures of attention, automatic processing, memory and 
perceptual processing. Not surprisingly, treatment with neuroleptics impaired 
motor functions on a variety of tasks (i.e. Perdue Pegboard, tapping task). 
Collectively, these results have provided evidence in support of the hypothesis 
that FGAs produce modest improvements across multiple domains of cognition. 
Importantly, these findings are not the result of experimental artifacts and are not 
limited to meta-analytic studies. Recently, several well controlled studies have 
extended these findings.  Harvey, et al. (2005). performed experiments 
controlling for dosing and adjunct treatments found first-generation drugs 
improved multiple domains of cognitive impairment (Harvey, Rabinowitz et al. 
2005) . Similar effects were demonstrated by Rollnik, et al. (2002) who found that 
over the course of 3 months, neurocognitive functioning in schizophrenics is 
moderately responsive both first- and second-generation drugs (Rollnik, 
Borsutzky et al. 2002). These data demonstrate the moderate pro-cognitive 
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effects of low doses of first-generation antipsychotics and indicate that the effects 
of FGAs on cognition warrant further investigation. 
1.12 Second-generation drugs: Focus on clozapine 
Clozapine is considered to be the prototypical second-generation 
antipsychotic drug based on its weaker affinity for D2 receptors and reduced risk 
for causing extrapyramidal symptoms. Clozapine’s mechanisms of action are 
complex and not fully understood. Clozapine is generally considered to be a 
potent antagonist for certain receptor types including those for acetylcholine (all 5 
muscarinic types and α-7nicotinic) and serotonin (5-HT2a, 5-HT 2c,  5-HT 6,), and a 
weaker antagonist for others (D2 and α2). Its low propensity for inducing 
extrapyramidal side effect has been attributed to its lower affinity for D2 receptors 
and the high un-binding rate (K off) of clozapine from dopamine receptors 
(Seeman 2002; Kapur and Seeman 2001). Studies examining clozapine’s actions 
at muscarinic receptors have demonstrated both antagonistic and agonistic 
properties, including antagonism of M2, M3, and M5 receptors, and partial 
agonist actions at M1, M2, and M4 receptors. The degree to which clozapine 
functions as an muscarinic agonist or antagonist is thought to depend on a 
variety of factors such as high- or low- receptor density,  the relative number of 
reserved receptors, and the type of preparation utilized ex vivo (clonal cell lines 
transfected with muscarinic receptors, or rat brain tissue preparations) (Kenakin, 
Bond et al. 1992). Additional factors affecting clozapine’s possible effects include 
its metabolism into active moieties including N-desmethylclozapine (Li, Huang et 
al. 2005). Multiple in vivo microdialysis studies have characterized the effects of 
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clozapine on ACh in cortex, nucleus accumbens and striatum. Using triple-micro 
dialysis in the presence of a cholinesterase inhibitor, Parada, et al. (1997) 
demonstrated that clozapine augmented extra cellular ACh in a dose-response 
fashion in the all three areas of interest. These effects were largest in the PFC 
with the smallest increases shown in the striatum (Parada, Hernandez et al. 
1997). Using cholinesterase free preparations, Ichikawa et al. (2002) 
demonstrated that clozapine increased in cortical ACh without affecting levels in 
the nucleus accumbens or striatum. The precise mechanisms underlying 
clozapine’s ability to preferentially increase cortical ACh remain speculative; 
generally, these effects have been attributed to antagonism of M2 and M4 auto-
receptors in the nucleus basalis magnocellularis, which projects to the cortex but 
not to the striatum or nucleus accumbens. Alternative explanations attribute 
these effects to increased cholinesterase density in accumbens and striatal 
regions relative to the cortex. The heightened density of striatal cholinesterase 
could result in the rapid hydrolysis of ACh, preventing any measurable increases 
from being detected.  Previous hypotheses attributing these effects specifically to 
antagonism of muscarinic autoreceptors have not been supported by 
experiments demonstrating undiminished cholinergic transmission in the 
hippocampi of M2/M4 knock out mice following administration of second-
generation drugs. Although notably, the ability of scopolamine to increase ACh 
via autoreceptor antagonism was markedly attenuated in these animals 
(Tzavara, Bymaster et al. 2006)). These results were taken to indicate that 
muscarinic auto-receptor antagonism is not necessary for second-generation 
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drugs to facilitate cholinergic transmission. Separate experiments utilized a 
variety of receptor antagonists (i.e. 5-HT2a, 5-HT2c, 5-HT6, and D2) to 
determine the contributions of antagonism of individual monoamine receptor 
types on ACh levels in the hippocampus (Shirazi-Southall, Rodriguez et al. 
2002). Administration of several drugs produced only modest increases of ACh 
that did not parallel those of clozapine administration. These data indicate that 
clozapine’s ability to increase ACh cannot be attributed to any singular 
mechanism, but may be the result of complex interactions of multiple receptors or 
some unknown mechanism. (Shirazi-Southall, Rodriguez et al. 2002). Although it 
remains difficult to conceptualize the specific interactions of clozapine on 
acetylcholine receptors, the ability of clozapine to preferentially increase cortical 
ACh while not affecting transmission in the striatum may account for a portion of 
clozapine’s pro-cognitive effects (described below), as well as its low propensity 
to induce extra-pyramidal symptoms.  
1.13 Comparing first- and second-generation drugs 
Compared to the relatively small number of experiments that demonstrate 
improved cognition using first-generation treatments, evidence in support of the 
pro-cognitive effects of second-generation antipsychotics is more abundant.  
Multiple studies have determined that second-generation drugs (i.e. clozapine) 
produce measurable cognitive benefits in schizophrenia, including improved 
attention, verbal fluency and executive functions (for review see: Meltzer and 
McGurk 1999). However, the presumed superiority of second-generation drugs 
over first-generation drugs remains a topic of contention. Many of the studies 
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making direct comparisons between first- and second-generation drugs suffer 
from many of the same methodological weaknesses addressed above. The 
major limitation of these studies remains the use of inappropriately high doses of 
FGAs relative to SGA doses. In addition, such studies are seldom able to 
dissociate the benefits of symptomatic improvement, the reduced occurrence of 
extrapyramidal symptoms, or the avoidance of adjunct anti-Parkinsonian drugs, 
from cognitive improvements, per se. Other experimental confounds arise when 
considering the ‘drug-switching’ design that is commonly employed. 
Schizophrenics are seldom treatment free before entering into a study and as a 
result, no drug-free baseline data are available. Studies frequently change 
treatments from FGAs to SGAs often do so without counterbalancing for order 
effects and use an insufficient washout period. Likewise, these studies often fail 
to consider the effects of repeated practice on task performance.   
A few experiments are notable exceptions that permit a more accurate 
assessment of first- versus second-generation drug effects. Purdon et al (2000) 
compared the effects of haloperidol and second-generation drugs (olanzapine 
and risperidone) on neurocognitive impairment in early-phase schizophrenics 
over the course of 12 months. The results demonstrated superior effects of 
olanzapine over risperidone and haloperidol, with risperidone and haloperidol 
producing the same magnitude of cognitive benefits (Purdon, Jones et al. 2000).  
Similarly, separate experiments have demonstrated that the cognitive 
improvements on measures of attention, verbal fluency and digit span, did not 
differ between groups treated with either first-generation drugs (haloperidol, 
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perazine, etc.) or second-generation drugs (i.e. clozapine, olanzapine, etc.) 
(Rollnik, Borsutzky et al. 2002), however this study was conducted with a small 
number of subjects. A large scale, long term study conducted by Keefe, et al. 
(2004) utilized a randomized, double-blind experimental design to compare low 
dose treatment with haloperidol (~5 mg per day) to treatment with the second-
generation drug olanzapine over the course of two years. This study showed 
significant improvements in neurocognitive function in both haloperidol and 
olanzapine treatment groups on a variety of tasks (i.e. CPT, working memory 
task and verbal learning test). Although olanzapine demonstrated superiority on 
the weighted composite score of all measures, the composite scores assessing 
cognitive improvement indicate that the advantage of olanzapine or haloperidol is 
negligible. Furthermore, the improvements demonstrated by subjects treated with 
low-doses of haloperidol suggest that previous results showing exacerbation of 
cognitive impairments may be ascribed to the excessively high dose ranges 
used. Despite the methodological complications evident in much of the literature, 
the available evidence supports the hypothesis that both first- and second-
generation antipsychotic drugs can improve multiple domains of impaired 
cognition in schizophrenia. As such, animal models attempting to assess 
impaired cognition in schizophrenia should also be sensitive to these 
improvements. 




Amphetamine administration can produce psychotic symptoms that 
closely resemble those observed in paranoid schizophrenia; this condition is 
known as amphetamine psychosis (Ellinwood 1969; Ellinwood 1970).  Similar to 
schizophrenia, the psychotic symptoms associated with AMPH include 
hallucinations, delusions, paranoia, flattening of the affect, and avolition. AMPH-
psychosis typically initiates during acute drug intoxication (not withdrawal), is 
generally brief, and spontaneously remits. Hallucinations in AMPH-users usually 
subside in less than two days and the symptoms of paranoia and delusions 
generally desist in approximately 1-2 weeks. Following the remission of AMPH-
psychosis, psychotic symptoms can be readily reinstated through subsequent 
exposure to small doses of AMPH or following exposure to stressful stimuli (Sato 
1992).   
The first reports of psychosis in AMPH-users were initially described in by 
Young and Scoville in 1938. However, due to the rarity of the condition, AMPH-
psychosis was generally dismissed as interesting clinical anomaly. In 1959, 
Connell’s seminal Maudsley monograph reported that that AMPH-psychosis 
occurred with greater frequency than was commonly believed (Connell 1959). 
However, Connell’s conclusion that AMPH-psychosis could not be discriminated 
from schizophrenia was controversial and was contested on the basis that the 
observed psychoses were potentially idiosyncratic (i.e. the result of preexisting 
schizophrenia) or had been produced by other substances that were abused 
concurrently with AMPH. Slater (1959) noted that patients with AMPH-psychosis 
displayed a greater prevalence of visual hallucinations, emotional reactivity, and 
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anxiety than was typically observed with schizophrenia (Slater 1959). 
Additionally, Bell (1965) postulated that the two conditions were 
phenomenologically distinct and that a differential diagnosis could be formulated 
upon the presence of symptoms related to thought disorder (Bell 1965). 
To address these issues in controlled clinical settings, multiple prospective 
studies were undertaken to further characterize the symptoms of AMPH-
psychosis and to determine if the condition could be produced in individuals who 
had been carefully prescreened for the exclusion of preexisting psychotic 
disorders (Angrist and Gershon 1970; Griffith 1968; Bell 1973). Using diagnostic 
methods set forth by the American Psychological Association and by Schneider 
(1957), these studies unequivocally demonstrated that the full spectrum of 
schizophrenic symptoms including paranoid delusions, hallucinations (auditory, 
visual, olfactory, and tactile), and thought disorder occurred in the majority of 
patients administered AMPH or methylated AMPH.  In fact, the symptoms of 
AMPH-psychosis replicate those of schizophrenia with such fidelity that they 
meet the DSM diagnostic criteria for paranoid schizophrenia. In summary, the 
utilization of AMPH-psychosis as a model of schizophrenia was originally based 
upon the ability of amphetamine to produce paranoid schizophrenic-like 
symptoms in healthy individuals, to ‘trigger’ the manifestation of  psychosis in at 
risk individuals, and to exacerbate psychotic symptoms in chronically ill patients 
(Yui, Ikemoto et al. 2000; Lieberman, Kane et al. 1987; Lieberman, Kane et al. 
1987; but see Barch and Carter 2005). Data from multiple human studies were 
summarized in a review by Janowsky (1979), who concluded that the induction of 
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AMPH-psychosis in healthy individuals represents a “pharmacologic parallel” of 
schizophrenia and is therefore suitable for the study of schizophrenia. 
Beyond the identical clinical presentations of AMPH-psychosis and 
schizophrenia, the central hypothesis providing the basis for experimentation with 
this model posits that these two conditions share common neural underpinnings. 
Sensitization of the mesolimbic dopamine system has been studied extensively 
in this regard. Repeated, intermittent, escalating exposure to AMPH results in 
potentiated neurobiological and behavioral responses during administration of 
subsequent smaller challenge doses (Robinson and Becker 1986; Paulson, 
Camp et al. 1991). Importantly, animals exposed to repeated, escalating AMPH 
display sensitized mesolimbic dopamine transmission in response to AMPH 
challenges (Paulson and Robinson 1995) these neuronal changes are thought to 
contribute to altered behavioral profiles (e.g. overt motor stereotypies, 
perseverative responding, impulsivity) seen in AMPH-pretreated animals (Segal 
and Kuczenski 1992; Paulson and Robinson 1995). The contributing role of 
sensitization for humans with AMPH-psychosis is less clear and remains 
controversial. However there is evidence to suggest that AMPH-psychosis is the 
end result of a developing process whereby the severity of anxiety worsens 
during successive drug binges until finally culminating in a full-blown episode of 
paranoid psychosis. In fact, some reports indicate that following the first-break 
episode of AMPH-psychosis, subsequent drug-induced episodes are of 
intensified severity (Gawin and Khalsa, 1996).   
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Historically, primary experimentation utilizing of AMPH-models of 
schizophrenia has focused chiefly on predictive validity. AMPH-models have 
been used extensively to estimate the potency of dopamine antagonists and their 
efficacy for ameliorating florid psychotic symptoms. Critics of psychostimulant-
based models have noted that these models are unable to replicate the entire 
disease entity, specifically with regards to reproducing or even exploring the 
etiological or developmental components of schizophrenia. Additionally, 
Weinberger and Lipska have questioned the future heuristic value of AMPH-
models as well as their utility for developing non-dopaminergic drugs based on 
the incorrect perception that such models rely principally upon ‘dopamine-in, 
dopamine out’ logic (Lipska and Weinberger 2000). Such criticisms are 
unfounded and based upon the assumption that the psychotogenic effects of 
AMPH stem purely from dopaminergic mechanisms. A simple examination of 
AMPH pharmacology reveals that amphetamine’s mechanisms of action are 
diverse and involve multiple neurotransmitters beyond dopaminergic 
mechanisms. Furthermore, these criticisms do not pose limitations to paradigms 
targeting specific disease components while assessing well-defined constructs 
with behavioral measures that do not directly reflect, and are not critically 
dependent upon mesolimbic dopamine transmission (e.g. attention processing). 
In fact, a rudimentary understanding of the functional and neuroanatomical 
substrates of schizophrenia’s cognitive deficits makes it apparent that the utility 
of psychostimulant models can be readily expanded and applied to target 
neurotransmitter systems that bear relevance for schizophrenia’s cognitive 
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deficits, specifically those critical for attentional processing. In fact, repeated 
exposure to AMPH has been shown to augment cortical cholinergic transmission 
in response to AMPH challenges (Nelson, Sarter et al. 2000), and has been 
demonstrated to result in attentional impairments in rats (Fletcher, Tenn et al. 
2007; Dalley, Theobald et al. 2005).   
1.15 Summary of experiments 
The above discussion forms the rationale for experiments exploring the 
role of cortical cholinergic transmission in the attentional deficits observed in a 
repeated-AMPH model of schizophrenia, and furthermore, justifies experiments 
designed to assess the ability of first- and second-generation antipsychotic drugs 
to attenuate these impairments. The main points of these experiments are 
summarized below.  
Experiment 1: 
The purpose of Experiment I was to characterize the effects of a repeated 
escalating dosing regimen of AMPH on sustained attention performance in rats. 
Rats were trained in a sustained attention task and then treated with saline or in 
accordance with an escalating dosing regimen of AMPH (1-10 mg/kg). 
Performance was assessed during the pretreatment and withdrawal periods and 
following the subsequent administration of AMPH "challenges" (0.5, 1.0 mg/kg). 
Compared with the acute effects of AMPH, AMPH "challenges," administered 
over 21 days after the pretreatment was initiated, resulted in significant 
impairments in attentional performance. Fos-like immunoreactivity (Fos-IR) in 
selected regions of these rats' brains was examined to test the hypothesis that 
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AMPH-sensitized attentional impairments are associated with increased 
recruitment of basal forebrain cholinergic neurons. These data provide limited 
evidence of dysregulation of the basal forebrain cholinergic system by showing 
that in AMPH-pretreated and -challenged animals, an increased number of Fos-
IR neurons were observed in the basal forebrain. The majority of these neurons 
were cholinergic. The evidence supports the hypothesis that abnormally 
regulated cortical cholinergic inputs represent an integral component of neuronal 
models of the attentional dysfunctions of schizophrenia. The results from this 
experiment formed the basis for subsequent experiments directly examining the 
role of cortical cholinergic transmission in this animal model of schizophrenia.  
Experiment 2: 
Experiment II provided evidence in support of the hypothesis that 
pretreatment with AMPH results in cortical cholinergic dysregulation.  This 
dysregulation contributes to, rather than results from, the impaired attentional 
performance observed in an animal model of the cognitive deficits of 
schizophrenia. Using in vivo microdialysis methods, cholinergic transmission 
during AMPH-challenges was assessed in the prefrontal cortices of attentional 
task-performing and non-performing rats pretreated with an escalating dosing 
regimen of AMPH or saline. In non-performing rats, pretreatment with AMPH did 
not affect the increases in ACh release produced by AMPH-challenges. In 
contrast, the increases in ACh release that are normally associated with attention 
task performance in rats were attenuated following AMPH-pretreatment and 
AMPH-challenges. This was already apparent before task-onset, suggesting that 
 34
 
the observed performance impairments were a result of cholinergic 
dysregulation. These findings indicate that the demonstration of repeated AMPH-
induced dysregulation of the prefrontal cholinergic input system depends on 
interactions between the effects of repeated AMPH exposure and performance-
associated recruitment of this neuronal system. Experiment II expands current 
paradigms used to investigate the neuronal mechanisms contributing to the 
cognitive impairments of schizophrenia by demonstrating that in order to show 
dysregulation in a neuronal system of interest, it is sometimes necessary to 
actively recruit that system using tasks known to be mediated by, or critically 
dependent on that system.  
Experiment 3: 
There are currently no bench-mark drugs available for the use in validating 
an animal model of schizophrenia’s cognitive deficits. As a result, present efforts 
geared towards the development of pro-cognitive drugs for schizophrenia 
requires the use of paradigms sensitive to the moderate pro-cognitive effects of 
currently available antipsychotic drugs. Experiment III tests the hypothesis that 
moderate pro-cognitive effects of low dose sub-chronic treatment with haloperidol 
(HAL; 0.025 mg/kg 0.2% acetic acid, s.c.) or clozapine (CLOZ; 2.5 mg/kg in 0.2% 
acetic acid, s.c.) can be detected by a paradigm assessing sustained attention 
performance in a repeated-AMPH model of schizophrenia. Using the same 
paradigm as the first two studies, this experiment first replicated the findings 
shown in Experiment I indicating that in response to AMPH-challenges; the hit 
rate of AMPH-pretreated rats was robustly impaired. In contrast, in AMPH-
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pretreated animals receiving haloperidol or clozapine, the attentional impairment 
produced by the challenges were attenuated. Collectively, these data lend 
predictive-validity to this model of impaired cognition in schizophrenia and 
demonstrate the potential usefulness of this paradigm for the development and 





























Figure 1.1: Diagrammatic representation of the basal forebrain cholinergic 
system. The cholinergic basal forebrain (BF) receives multiple sources of input 
including GABAergic (blue) inputs from the nucleus accumbens (NAC), 
dopaminergic input (purple) from the ventral tegmental area (VTA), noradrenergic 
(orange) input from the locus coeruleus (LC), cholinergic input (red) from the 
pedunculo pontine gigantocellular nucleus (PPG). The basal forebrain sends 
cholinergic projections to all areas and all layers of the cortex. The sources of 
input and targets of output depicted in this diagram are not exhaustive, but rather 
represent the major neurotransmitter systems system relevant to the present 






SENSITIZED ATTENTIONAL PERFORMANCE AND FOS-IMMUNOREACTIVE 




The consequences of repeated exposure to psychostimulants have been 
hypothesized to model aspects of schizophrenia. This experiment assessed the 
consequences of the administration of an escalating dosing regimen of 
amphetamine (AMPH) on attentional performance. Fos-like immunoreactivity 
(Fos-IR) in selected regions of these rats’ brains was examined to test the 
hypothesis that AMPH-sensitized attentional impairments are associated with 
abnormal recruitment of basal forebrain cholinergic neurons. Rats were trained in 
a sustained attention task and then treated with saline or in accordance with an 
escalating dosing regimen of AMPH (1–10 mg/kg). Performance was assessed 
during the pretreatment and withdrawal periods and following the subsequent 
administration of AMPH “challenges” (0.5, 1.0 mg/kg). Brain sections were 
double-immunostained to visualize Fos-IR and cholinergic neurons. Compared 
with the acute effects of AMPH, AMPH “challenges”, administered over 2 months 
after the pretreatment was initiated, resulted in significant impairments in 
attentional performance. In AMPH-pretreated and -challenged animals, an 
increased number of Fos-IR neurons was observed in the basal forebrain. The 
majority of these neurons were cholinergic. The evidence supports the 
hypothesis that abnormally regulated cortical cholinergic inputs represent an 
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integral component of neuronal models of the attentional dysfunctions of 
schizophrenia.  
2.2 Introduction 
Sensitization of mesolimbic dopamine systems is considered to be a 
neuropathologic hallmark of schizophrenia (Lieberman, Sheitman et al. 1997; 
Laruelle 2000) and thus of animal models of this disease (Robinson and Becker 
1986). Schizophrenic patients exhibit increased AMPH-induced displacement of 
dopamine D2 receptor ligands during periods when positive symptoms manifest 
and intensify, but not during remission (Abi-Dargham, Gil et al. 1998; Laruelle, 
Abi-Dargham et al. 1996; Laruelle, Abi-Dargham et al. 1999). Moreover, the 
dopaminergic system of first-episode psychotic patients may already be 
maximally up-regulated (Strakowski, Sax et al. 1997). The effects of repeated 
AMPH exposure, particularly the sensitized effects of subsequent AMPH-
challenges, have served as a model in research on the role of sensitized 
dopamine systems in the mediation of psychosis. Furthermore, AMPH-sensitized 
animals exhibit behavioral and cognitive abnormalities that model aspects of 
psychosis (Castner, al-Tikriti et al. 2000; Seeman, Tallerico et al. 2002; Tenn, 
Fletcher et al. 2003). 
Attempts to reduce the complex symptoms of psychosis to dysfunctions in 
elementary cognitive operations have focused on the disruption of attentional 
processes and capacities and related executive functions (McGhie and Chapman 
1961; Braff 1993; Andreasen, Paradiso et al. 1998; Gray 1998; Kapur 2003; 
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Venables 1964). Moreover, lasting cognitive, particularly attentional, impairments 
in schizophrenia patients have emerged as a new and distinct treatment target 
(Braff and Light 2004). Little is known, however, about the long-term 
consequences of AMPH-sensitization on attentional performance. Likewise, the 
neuronal systems underlying the cognitive consequences of AMPH-sensitization 
are poorly understood. Based on extensive evidence on the role of the cortical 
cholinergic input system in attentional functions (Sarter, Hasselmo et al. 2005),on 
the regulation of cortical cholinergic transmission by dopaminergic systems 
(Moore, Fadel et al. 1999), and on the available evidence suggesting 
abnormalities in the regulation of cortical cholinergic inputs in schizophrenia 
(Crook, Tomaskovic-Crook et al. 2001; Tandon 1999), the attentional 
impairments of schizophrenia have been hypothesized to be mediated 
specifically via abnormally reactive cortical cholinergic inputs (Sarter, Hasselmo 
et al. 2005). The finding that repeated AMPH administration sensitizes cortical 
acetylcholine (ACh) release corresponds with this hypothesis (Nelson, Sarter et 
al. 2000). 
The experiment described here was designed to determine the 
consequences of repeated AMPH administration on attention performance. 
Performance in this task reflects the status of cortical cholinergic transmission 
(Arnold, Burk et al. 2002; McGaughy, Decker et al. 1999; McGaughy and Sarter 
1995; McGaughy, Kaiser et al. 1996;  Turchi and Sarter 2001). Once animals 
achieved criterion performance, they were treated with saline or AMPH in 
accordance with a 40-day escalating dosing treatment regimen that included 
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days without AMPH administration to model aspects of “runs” and “crashes” 
observed in AMPH abusers (Paulson, Camp et al. 1991). The administration of 
escalating doses of AMPH did not produce neurotoxic effects but was 
demonstrated by Paulson, et al.(1991) to yield lasting (> 1 year) behavioral 
sensitization. Such lasting, sensitized effects of AMPH pretreatment are thought 
to model the ability of low doses of AMPH to trigger psychotic periods following 
long withdrawal periods in AMPH abusers (Robinson and Becker 1986; 
Nuechterlein, Dawson et al. 1994; Moghaddam 2002; Muller 2004). Furthermore, 
selected brain regions, particularly the region of the cortically projecting 
cholinergic neurons in the nucleus basalis of Meynert and substantia innominata 
(nbM/SI) of the basal forebrain, were inspected for Fos-immunoreactivity (IR) to 
test the hypothesis that the effects of ‘AMPH ‘challenges’ on attentional 
performance are associated with increased activity of cortical cholinergic inputs. 
2.3 Methods 
Animals: Sixteen male Fischer/Brown Norway hybrid rats (aged 3 months and 
weighing 229±19 g (Mean±SEM) at the beginning of the experiment; Harlan, 
Indianapolis, Indiana) were housed individually in single-standard cages in a 
humidity and temperature-controlled environment accredited by the American 
Association of Laboratory Animal Care (Ohio State University, Townshend Hall). 
All animal care and experimental procedures were approved and supervised by 
the Ohio State University Institutional Laboratory Animal Care and Use 
Committee. Lighting followed a 12-hour light-dark cycle (lights on at 6 am). 
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Testing occurred between 8:00 am and 5:30 pm. Animals were handled 
extensively before testing and were water deprived by limiting access to water to 
an 8-min period that followed the completion of the daily behavioral test session. 
Food was provided ad libitum. 
Apparatus: Behavioral training and testing were conducted using 12 operant 
chambers (MedAssociates, East Fairfield, Vermont). Each chamber was outfitted 
with two retractable levers, three panel lights (2.8 W), one house light (2.8 W), 
and a 2900-Hz sonalert tone generator with the water dispenser located on the 
same wall as the panel lights and levers. Operant chambers were housed within 
sound-attenuating compartments. 
Behavioral Training: Training took place 7 days per week. After being trained to 
lever press for water in accordance with a fixed-ratio (FR) 1 schedule of 
reinforcement, subjects were placed in darkened (houselights off) operant 
chambers for 20 minutes before task onset. Rats were first trained to discriminate 
between signal (illumination of the central panel light for 1 sec) and non-signal 
(non-illumination) events. Two seconds following an event, both levers were 
extended and remained available for 4 sec or until a lever press occurred. If no 
lever press occurred after 4 sec, an omission was scored and the intertrial 
interval (ITI; 12±3 sec) was reinstated. On signal trials, a left lever press was 
scored as a hit, and 0.25-mL water was delivered as reward; depression of the 
right lever was considered an incorrect response and scored as a miss. During 
non-signal trials, a right lever press was scored as a correct rejection, and 
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animals again received water reward. During non-signal trials, a left lever press 
was considered an incorrect response and scored as a false alarm. Animals were 
not rewarded for incorrect responses. If a rat failed to respond correctly for three 
consecutive trials, up to three correction trials were presented during this stage of 
training. During a correction trial the ITI was reinstated and the trial was repeated 
up to three times. If a rat failed to respond correctly during these trials, a forced-
choice trial was initiated that was designed to block the development of side 
biases. A forced-choice trial consisted of a signal or non-signal event, followed by 
the extension of only the correct response lever into the chamber. During a 
forced-choice trial the extended lever remained active for 90 sec or until a press 
occurred. In the event that the forced-choice trial was a signal event, the central 
panel light remained lit for as long as the lever was active. The presentation of 
signal and non-signal trials was pseudo-randomized (162 trials/session, plus 
correction and forced-choice trials). After 3 consecutive days of 70% correct 
responses to signal and non-signal trials and less than 25 omissions, animals 
progressed to the second phase of training. During this phase, the duration of 
signals was decreased to 25, 50, or 500 msec and correction and forced choice 
trials were eliminated. Sessions consisted of 27 trials of each of the three signal 
lengths and 81 trials of the non-signal events, yielding a total of 162 trials per 
session. Each session was divided into three blocks of 27 signal and 27 non-
signal trials. Each signal type was presented nine times per block. After reaching 
a criterion of 59% correct responses to signal and non-signal trials and less than 
25 omissions for three consecutive sessions, houselights were illuminated 
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throughout the session and the ITI was decreased to 9±3 sec (see Figure 2.1). 
Illumination of the houselights requires the animals to focus on the stimulus panel 
and thus represents a crucial step in the acquisition of this sustained attention 
task. The drug treatment regimen was initiated after animals reached the final 
criterion of greater than 70% correct responses for 500 msec signals, greater 
than 70% correct responses during non-signal trials, and fewer than 25 
omissions per session, for at least 3 consecutive sessions.  
Pretreatment Regimen and Challenges: After reaching performance criterion, 
animals were randomly divided into two groups. Animals were given either d-
amphetamine sulfate (AMPH; 1–10 mg/kg intraperitoneally i.p.); drug 
concentrations include salt weight; dissolved in 1 mL/kg of 0.9% saline; Sigma, 
St. Louis, Missouri) or vehicle (0.9% saline; 1 mL/kg) twice daily, with 
approximately 8 hours separating the two injections. Animals received the first of 
the two daily injections at approximately 8:00 am in the testing room and were 
immediately placed in their operant chambers for 20 min before task onset. 
Following the completion of operant testing, animals were promptly returned to 
their home cages. The second dose of drug or vehicle was given in the home 
cage at approximately 4:00 pm. The AMPH doses were administered in elevating 
increments over the course of 40 days in accordance to the regimen described in 
(Paulson, Camp et al. 1991; Figure 2.2); AMPH was administered every day of 
the week excluding weekends to mimic purposely the pattern of abuse seen in 
AMPH-abusers (Paulson, Camp et al. 1991). Animals were given injections of 
saline on weekends. Animals treated with AMPH exhibited high levels of 
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omissions (> 90% of all trials) following doses ≥2.0 mg/kg, but they completed 
significantly more trials during the drug-free weekends (< 20% omissions). To 
control for the potentially confounding consequences of substantial differences in 
the amount of behavioral practice between the two groups of animals, saline-
treated animals were placed into the chambers for 1 hour on weekdays without 
being allowed to perform; however, similar to animals undergoing AMPH 
pretreatment, saline-treated animals performed the task on weekends. 
Following completion of the pretreatment regimen, animals underwent a 
20-day drug-free period consisting of twice-daily saline injections and continued 
operant testing. Saline was administered to avoid potential performance changes 
due to termination of the injection procedure. The length of the withdrawal period 
was based on the observations by Paulson and Camp et al. (1991) that the 
symptoms of behavioral depression were most pronounced within the first couple 
of days of withdrawal, and that behavioral sensitization was fully developed 2 
weeks following completion of the pretreatment regimen. As detailed later, the 
performance of AMPH-pretreated rats was almost completely recovered by the 
end of this period. 
Subsequently, the effects of AMPH were assessed in AMPH and saline-
pretreated animals. Animals received 0.5 mg/kg AMPH on days 61 and 81 (with 
day 1 being the first day of the pretreatment regimen) and 1 mg/kg AMPH on 
days 71 and 86 (see Figure 2.2). The selection of these “challenge” doses was 
based on the observation that an acute dose of 1.0 mg/kg (which was the first 
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dose given as part of the pretreatment regimen) did not significantly alter the 
animals’ performance and on the hypothesis that AMPH-sensitized performance 
should be sensitive to the detrimental effects of even smaller doses. Subsequent 
to the administration of these AMPH doses, animals were placed in their operant 
chambers for a 20-min acclimation period followed by a standard behavioral test 
session. 
Immunohistological Analysis: At the conclusion of the test session on day 86, 
animals were immediately anesthetized with pentobarbital (100 mg/kg IP) and 
transcardially perfused with 100 mL of ice-cold heparinised saline followed by 
300 mL of 4% paraformaldehyde in 0.1 mmol/mL phosphate-buffered saline 
(PBS; pH 7.4). The brains were removed and postfixed in paraformaldehyde 
solution for 4 hours (with shaking) at 4°C and stored in 30% sucrose in PBS (pH 
7.4) for 72 hours. The brains from six animals per group were processed for 
immunohistochemical analyses. 
Coronal sections (50 μm) were cut using a cryostat microtome (Leica CM 
3050 S; Leica Microsystems, Chantilly, Virginia) and stored in cryoprotectant 
solution (15% glucose, 30% ethylene glycol, and 0.04% sodium azide in 0.05 
mmol/mL PBS, pH 7.4) at -20°C until further processing. Sections were thawed, 
washed twice in 0.1 mmol/mL PBS for 5 min, and incubated with 0.3% H2O2 for 
10 min to block endogenous peroxidase. After washing with PBS, the sections 
were incubated with blocking solution (10% goat serum in 0.1 mmol/mL PBS) 
with constant shaking for 30 min followed by overnight incubation with rabbit anti-
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Fos antibody (H-125:sc-7202; Santa Cruz Biotechnology, Santa Cruz, California) 
diluted 1:1000 in 0.1 mmol/mL PBS containing 1% goat serum and 0.3% triton X-
100 at 4°C. The following day, sections were washed in PBS three times for 5 
min and incubated with 1:2000 diluted biotinylated goat antirabbit 
immunoglobulin G (IgG; Vector Labs, Burlingame, California) for 2 hours at room 
temperature. After washing in PBS, the sections were incubated with avidin-
horseradish peroxidase complex (Vectastain ABC Kit, Vector Labs, Burlingame, 
California) for 1 hour at room temperature. Sections were washed again in PBS 
and staining was developed with 3-3’-diaminobenzidine (DAB) and in the 
presence of 0.01% nickel chloride. Stained sections were mounted onto gelatin 
coated slides; after air drying, the slides were dehydrated and coverslipped with 
Permount (Biomedia, Foster City, California). Omission of the primary antibody 
from this procedure eliminated Fos-like immunoreactivity (Fos-IR). 
To assess whether basal forebrain cholinergic neurons express Fos-IR, 
nBM sections were double-immunostained to reveal choline acetyltransferase 
(ChAT) and Fos-IR. The sequential immunostaining procedure revealed first 
ChAT-IR with DAB and second Fos-IR with DAB/Ni. Briefly, sections were 
blocked with 10% donkey serum (Chemicon International, Temecula, California) 
and sequentially incubated with goat-anti-ChAT antibody (1:2000; Chemicon 
International) for ChAT staining and rabbit anti-Fos antibody (1:1000) for c-Fos. 
Appropriate secondary antibodies (1:3000 diluted biotinylated donkey anti-goat 
IgG or 1:2000 diluted biotinylated donkey anti-rabbit IgG; Jackson 
Immunoreseach Laboratories, Westgrove, Pennsylvania) were used after the 
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respective primary antisera. Overnight incubations at 4°C were carried out for 
primary antibodies, and incubations were made for 2 hours at room temperature 
for secondary antibodies. Dilutions of all antibodies were made in 0.1 mmol/mL 
PBS containing 1% donkey serum and 0.3% triton X-10. The avidin-biotin 
peroxidase method using the Vectastain ABC kit was employed to stain and 
visualize the brown reaction product for ChAT with DAB and the grayish-black 
reaction product for Fos with DAB/Ni. No cross-reactivity was observed between 
the antibodies, and adequate controls were included by reversing the order of 
primary antibodies or omitting the primary or secondary antibodies. 
Sections were analyzed using an Olympus AX 70 microscope (Olympus 
America, Melville, New York) equipped with an Olympus Magnafire digital 
camera; digital photographs were captured and processed using Olympus 
Magnafire software (Olympus America, Melville, New York). Microscopical 
examinations were performed by an experimenter (VP) who remained blind to 
the animals’ pretreatment condition. Three sections per region of interest were 
selected for analysis: dorsal striatum (DS; between 1.60 and 1.30 mm anterior to 
bregma), nucleus basalis of Meynert and substantia innominata (nbM/SI, SI; 1.20 
mm posterior to Bregma), frontoparietal cortex (PC, 1.40–1.70 mm posterior to 
bregma), and ventral tegmental area (VTA; 4.8–5.2 mm posterior to bregma; 
(Paxinos 1998). Fos-IR neurons in these areas were counted in the right 
hemispheres of three brain sections per brain at 10× magnification. Counts were 
made inside predefined areas per region; DS: 0.80 mm2; nBM/SI: 0.36 mm2; PC: 
0.64 mm2; VTA: 0.16 mm2 (see Figure 2.7 for an illustration of sampling areas). 
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The average count from 3 sections per region per animal was used for statistical 
analysis.  
Data Analysis: The total number of hits (h), correct rejections (cr), misses (m), 
false alarms (fa), and omissions were calculated for the entire behavioral session 
and for each block of 54 trials. Based on these values, the relative number of hits 
(h = h/(h + m) and correct rejections (cr = cr/(cr + fa) were calculated. In addition, 
the vigilance index (VI), an overall measure of sustained attention performance, 
was calculated based on the relative number of hits and false alarms using the 
formula: VI = (h-fa) / (2(h fa) - (h+fa)2)). This index is similar to the sensitivity 
index (Frey 1973) except that omitted trials are excluded from the calculation. 
Values for VI can vary from +1.0 to -1.0, with +1.0 indicating that all responses 
were scored as hits or correct rejections, 0 indicating an inability to discriminate 
between signal and non-signal events, and -1 indicating that all responses to 
signals were misses and all responses to non-signals were false alarms. The 
index was calculated for each signal duration (VI500,50,25). Hits and correct 
rejections were analyzed using angularly transformed values (Zar 1999). 
Performance data from the last 3 days before the start of the pretreatment 
regimen were used for baseline comparisons. Performance during the 
pretreatment period was not analyzed except for data from the 2-day off- drug 
sessions. Data from the first and second off-drug days were collapsed over 2 
weeks, resulting in 3 blocks of data. The 20-day drug-free period following 
pretreatment was divided into two time periods (days 1–10 (W1) and days 11–20 
(W2)) and analyzed to assess the time course of effects of AMPH withdrawal. 
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Because the subsequent administration of AMPH was expected to produce 
augmented performance effects when compared with the first exposure to 
AMPH, the effects of both doses of AMPH, collapsed over the two tests of the 
individual doses, were compared with the effects of the first administration of 
AMPH (1.0 mg/kg). Data depicting the number of Fos-IR neurons are expressed 
as Mean±SEM per group and the four anatomic regions of interest. Group-based 
comparisons of the average number of Fos-positive cells were conducted using 
planned, two-tailed, unpaired Student t tests. Mixed factor analysis of variance 
(ANOVAs) were used to assess the effects of pretreatment, block, signal duration 
and AMPH on hits, misses, false alarms, correct rejections, omissions and 
response latencies (time from lever extension to lever press). Post hoc 
comparisons were made using the Least Significant Difference (LSD) for within-
subject comparisons. The reported statistical results reflect Huyn-Feldt-corrected 
degrees of freedom. Exact p values are reported as recommended by 
(Greenwald 1996). Statistical analyses were performed using the SPSS/PC+ 
11.5 Version (SPSS, Chicago, Illinois). 
2.4 Results 
Baseline performance before the pretreatment phase: The baseline performance 
of the animals designated for pretreatment with AMPH or saline, respectively, did 
not differ during the last three sessions before the pretreatment phase (hits, 
correct rejections, omissions; all main effects and interactions involving the factor 
“Group”; p >0.05). The animals’ performance was signal duration-dependent 
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(F(2,56) = 176.81; p < 0.001; see Figure 2.3). Animals omitted a relatively small 
proportion of trials (6.56±0.72/session), and the number of omissions increased 
over blocks of trials (F(1.42,19.85) = 9.07; p =0.004).  
Drug-free weekend performance during the pretreatment period: As described 
earlier, animals undergoing the AMPH-pretreatment regimen were given saline 
on weekends, and saline-treated animals were placed into the operant chambers 
on weekdays without being allowed to perform the task. During drug-free 
weekends, the omission rate in AMPH-treated animals was sufficiently low to 
permit a meaningful analysis of their performance on those days (averaged per 
animal over 2 weekends, yielding 3 blocks of data). 
In terms of overall performance (VI), the animals undergoing AMPH-
pretreatment were impaired compared with saline-treated control animals 
(F(1,14) = 18.84; p =0.001). This effect interacted with signal duration (F(2,28) = 
19.94; p < 0.001; Figure 2.3). Multiple comparisons indicated that VI500 and VI50 
values differed between the groups (VI500: F(1,15) = 53.06; p < .005; VI50: F(1,15) 
= 89.79; p < 0.01; VI25: F(1,15) = .227; p =0.607). All animals performed better on 
the second drug-free day (F(1,14) = 18.52; p =0.001; day 1: 0.18±0.15; day 2: 
0.22±0.13); however, the difference in performance between the two groups was 
consistent across the three blocks of weekend data (all interactions involving 
group and week, p >0.14). The significant interaction between group and signal 
duration on VI was based on similar effects revealed in the analysis of hits 
(F(1.92,26.93) = 32.06; p < 0.001). The animals’ non-signal performance 
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remained unaffected by ongoing treatment (all effects and interactions involving 
group: p >0.12).  
Animals undergoing AMPH-pretreatment exhibited an increased number 
of omissions that interacted with day (first vs. second drug-off day) and week 
(F(2,280) = 5.76; p =0.008). As illustrated in Figure 2.4, this interaction was due 
to a relatively high number of omissions in AMPH-treated animals on the first off-
day during the last two weekends of the pretreatment period when compared 
with their omission rate on the first off-day during weeks 3–4 (LSD = 14.22; p 
=0.015), and with the omissions generated by AMPH-treated animals on the 2nd 
off-day during weeks 5–6 (LSD = 16.09; p < 0.001) and by saline-treated animals 
on both days during this late pretreatment phase (t(14) < 0.001). 
Attentional performance during the withdrawal period: The performance of the 
two groups during the 20-day withdrawal period differed significantly (F(1,14) = 
12.51; p =0.003; VI for saline animals: 0.26±0.02; AMPH: .15±.02). Furthermore, 
all animals improved their performance from W1 to W2 (F(1,14) = 11.65; p 
=0.004), but post hoc analyses indicated that this improvement was primarily due 
to the recovery in AMPH-pretreated rats (F(1,8) = 16.69; p =0.004; saline-
pretreated: LSD = 0.01; p =0.44; AMPH-pretreated: LSD = 0.06; p =0.04; Figure 
2.5). Although all animals maintained signal duration-dependent performance 
(F(2,28) = 372.07; p < 0.001), the effects of group and signal duration interacted 
(F(2,28) = 24.57; p < 0.001). Multiple comparisons failed to locate this interaction, 
however (Figure 2.5).  
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Although the overall rate of omissions remained small in both groups of 
animals (F(1,14) = 1.01; p =0.33; saline-pretreated: 6.63±0.89 
omissions/session; AMPH-pretreated: 5.43±0.79), significant interactions 
between group and W1/W2 and group and block and among group, block, and 
W1/W2 were found (all p< 0.03). Collectively, these complex interactions 
reflected an increase in omissions in AMPH-pretreated animals during W2 when 
compared with W1, a less pronounced increase in omissions across trial blocks 
in these animals when compared with saline-pretreated animals, and a 
normalization of the block-related increase in omissions in W2 when compared 
with W1 in AMPH-pretreated animals. 
Effects of AMPH challenges on attentional performance: The administration of 
1.0 mg/kg AMPH as a challenge produced impairments in performance in AMPH-
pretreated animals when compared with the acute effects of this dose. The first 
administration of this dose (which was the first dose given during the 
pretreatment regimen) did not affect their performance when compared with their 
baseline performance before the pretreatment regimen (all p >0.41; Figure 2.6). 
Likewise, in animals pretreated with saline, administration of AMPH as a 
“challenge” (which was their first AMPH-exposure) did not affect their 
performance when compared with the effects of the very first AMPH exposure in 
the other group of animals (all p >0.05; Figure 2.6). 
The main effect of the 1.0 mg/kg AMPH-challenge on the animals’ overall 
performance (VI; F(1,8) = 14.46; p =0.005) was due to a lower hit rate following 
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the AMPH-challenge (F(1,8) = 26.31; p =0.001; first administration of 1.0 mg/kg 
(averaged over all signal durations): 57.56±4.86% hits; 1.0 mg/kg challenge: 
36.97±5.47% hits). The decrease in hits following the AMPH-challenge occurred 
across all signal durations (F(2,16) = 1.05; p =0.37; Figure 2.6) and blocks 
(F(3.51, 28.10) = 0.18; p =0.93). The relative number of correct rejections (Figure 
2.6 and the number of omissions did not differ between the first and the 
challenge administration of AMPH (all p >0.12). Omissions remained generally 
low (7.98±1.73 omissions/session). 
Moreover, the administration of a smaller dose of AMPH (0.5 mg/kg) as a 
challenge produced impairments in performance when compared with the 
innocuous effects of the very first exposure to 1.0 mg/kg AMPH. This effect 
interacted with the blocks of trials and reached significance in the analysis of the 
overall performance (VI: F(1.71,13.69) = 7.33; p =0.009; Figure 2.7), but not hits 
(F(2,16) = 2.84; p =0.09; not shown). This significant interaction was due to a 
significantly lower performance following AMPH-challenge during the middle 
block of trials (block 2: t(8) = 3.44; p =0.009; p >0.25 for blocks 1 and 3; Figure 
2.7). No other performance measure was affected as a result of the challenges 
with 0.5 mg/kg AMPH.  
The impairment in attentional performance produced by AMPH-challenges 
in AMPH-pretreated animals may have been confounded by a lower baseline 
performance at the end of the withdrawal period. The performance during the last 
three sessions before the administration of the challenges differed only in one 
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respect from the animals’ baseline performance before the first AMPH exposure. 
There was a significant interaction between signal duration and the two baselines 
on hits (F(2,16) = 3.68; p =0.048), but multiple comparisons failed to reveal 
significant differences for individual signal durations. 
Finally, to substantiate hypotheses about the nature of the effects of 
AMPH-sensitization (see Discussion), response latencies (time period from lever 
extension to lever press) were analyzed. Compared with the latencies observed 
before the pretreatment period, neither the very first administration of AMPH (1.0 
mg/kg) nor the administration of this dose as a challenge altered response 
latencies (F(1.60,12.81) = .27; p =0.72). Latencies did not differ by trial type 
(signal vs. non-signal trials) or response type (hits, misses, false alarms, correct 
rejections), and there were no interactions between treatment and trial 
type/response type (all p >0.43). Animals required 909.35±44.13 ms to press a 
lever. 
Fos-immunoreactivity (IR): In saline-pretreated animals, considerable Fos-IR was 
found in the frontoparietal cortex, caudate/putamen, and VTA (Figure 2.8). In the 
nbM/SI region, Fos-IR cells were only found sporadically in saline-pretreated 
rats, and they were primarily situated in the SI portion of the basal forebrain 
(Figure 2.8 and Figure 2.9). In AMPH-pretreated animals, significant increases in 
the number of Fos-IR cells were found in the nbM/SI (t(1,10) = 7.30; p < .0001), 
frontoparietal cortex (t(1,10) = 4.40; p =0.002), and VTA (t(1,10) = 5.99; p < .001) 
but not the caudate-putamen (t(1,10) = 1.15; p =0.27; see Figure 2.8). Double-
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immunolabeling indicated that approximately 80% of Fos-positive cells in the 
nbM/SI region were also ChAT-positive (Figure 2.9). Fos-IR cells that were not 
also ChAT-positive were intermingled with double-labeled cells and also primarily 
located in the SI region.  
2.5 Discussion 
The main findings of our study indicate that as a result of AMPH-
pretreatment with an escalating dosing regimen, the administration of doses of 
AMPH that did not produce significant effects on attentional performance when 
given acutely resulted in substantial impairments in attentional performance 
when administered as challenges. We also recorded the performance of animals 
at drug-off days during the pretreatment period and during the withdrawal period; 
these data assist in interpreting the effects of AMPH challenges. Furthermore, in 
AMPH-pretreated and AMPH-challenged rats, the number of Fos-positive 
neurons was found to be increased in the basal forebrain, and the majority of 
these neurons were cholinergic. The discussion will focus on the nature of the 
behavioral and attentional effects of AMPH challenges, the significance of the 
Fos-data, and the relevance of these findings for models of the cognitive 
impairments of schizophrenia. 
This experiment utilized a more extensive pretreatment regimen and a 
longer withdrawal period than previous studies addressing cognitive 
consequences of repeated AMPH exposure (Kondrad and Burk 2004). As 
discussed in the literature, short pretreatment periods, consisting of the 
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intermittent administration of relatively low doses of AMPH, have been fruitful in 
psychostimulant-sensitization research (Robinson and Becker 1986), but they do 
not adequately model the escalation of AMPH doses in AMPH abusers and the 
“runs and crashes” that are associated with the emergence of psychotic 
symptoms in humans and analogous symptoms in animal models (Angrist 1994; 
Kuczenski and Segal 1997; Castner and Goldman-Rakic 2003). Furthermore, the 
administration of escalating doses and longer withdrawal periods produces 
lasting neurochemical changes, without generating neurotoxic effects, that differ 
qualitatively from those achieved by shorter pretreatment regimens (Paulson, 
Camp et al. 1991; Paulson and Robinson 1995). 
Our demonstration of AMPH-sensitized attentional impairments cannot be 
readily attributed to overt behavioral effects. Given the overwhelming evidence 
on AMPH-sensitized locomotor activity and stereotypies, the possibility that such 
effects confounded the present impairments in attentional performance needs to 
be carefully considered. AMPH-challenges did not affect the animals’ 
performance in non-signal trials and, although suppressing the hit rate, AMPH-
challenges did not abolish the effects of signal duration on this measure. Putative 
consequences of sensitized locomotion or stereotypies would be expected to 
manifest primarily as side- or lever biases, or randomized lever selection, and to 
result in a high number of omissions. As indicated by the relatively short 
response latencies, and as confirmed by observations, animals positioned 
themselves in front of the correct rejection lever (while withdrawn) and, upon 
signal detection, switched to the hit lever, awaiting its extension into the 
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chamber, therefore producing similar latencies for all responses. AMPH-
challenges did not affect response latencies and thus may not have altered this 
behavior. Thus, sensitized locomotor activity or stereotypies, increased switching 
behavior (Evenden and Robbins 1983) or complex changes in lever-choice 
behavior (Evenden and Robbins 1983) appear highly unlikely to have occurred 
as a result of AMPH challenges. Likewise, it is noteworthy that such doses of 
AMPH do not affect visual discrimination performance per se (Andrews and 
Holtzman 1988). Collectively, it is difficult to envision how the selective 
impairments in performance observed following AMPH challenges could have 
been due to fundamental changes in the animals’ behavior. 
Our findings and the discussion presented here also suggest that 
sensitized locomotor activity or increased stereotypies, and possibly the 
associated increases in striatal dopamine release (Paulson and Robinson 1995), 
do not represent necessary consequences of AMPH-pretreatment but that their 
manifestation may depend on the absence of behavioral or operant constraints. 
As demonstrated by Wolgin and colleagues, repeated AMPH-induced 
stereotypies and appetitive behaviors, if interfering continuously with goal-
directed behaviors or operant performance, are increasingly suppressed, in part 
as a result of the acquisition of counteracting operant contingencies (Hughes, 
Popi et al. 1998; Wolgin 2000; Wolgin 2002). Our data indicate that during the 
pretreatment period, omissions increased substantially in AMPH-treated animals, 
as seen during the first of the two drug-off days and during the final 2 weeks of 
pretreatment. These omissions may have reflected in part the transient 
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manifestation of overt behavioral effects of higher doses of AMPH, rather than 
the effects of acute withdrawal, because increased omissions were not observed 
during the withdrawal period. 
The decrease and eventual disappearance of AMPH-induced overt 
behavioral effects in continuously performing subjects contrasts with the 
demonstration of persistent AMPH-sensitized impairments and may be of 
significance for the usefulness of AMPH-sensitization as a model for 
schizophrenia-associated cognitive dysfunction. The focus on the cognitive 
consequences of AMPH-sensitization not only enhances the face validity of the 
animal model, but the sensitized attentional effects may be mediated via 
abnormally regulated neuronal systems that overlap only partly with the 
sensitized striatal systems that have been traditionally in the focus of research on 
AMPH-sensitized locomotor activity. 
The exact mechanisms that mediated the AMPH-challenge-induced 
decrease in the animals’ ability to detect signals remain speculative. In terms of 
signal-detection theory, a parallel downward shift of the signal duration-hit curve 
may indicate a conservative shift in the animals’ decision criterion. Such a shift 
could result from increased costs for false alarms, decreased costs for misses, or 
both, or from decreased benefits for hits (Swets 1982). The costs for misses and 
false alarms were identical (no reward), however, and the absence of changes 
on omissions do not support the speculation that the rewarding effect of hits was 
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diminished after AMPH-challenges. Likewise, the number of correct rejections, 
which resulted in identical reward, remained unchanged. 
An alternative source of an increasingly conservative criterion is a 
decreasing expectation of signal occurrence (Swets 1970). Because of the 
absence of factual changes in signal probability in this experiment, multiple 
mechanisms—including impairments in monitoring perceptual (particularly visual 
channels) and, more generally, source monitoring, or general fragmentation of cognitive 
operations—may have contributed to the manifestation of a more conservative 
criterion. Impairments in the ability to monitor the frequency and distribution of 
signal events could result in the underestimation of signal probability, and thus in 
changes in performance indicative of a shift toward a more conservative criterion. 
It is intriguing that signal detection impairments observed in schizophrenic 
patients tested in sustained attention tasks have been attributed to similar 
impairments in cognitive operations (Braff 1993; Keefe, Arnold et al. 1999; Li 
2002; Braff and Light 2004; van den Bosch, Rombouts et al. 1996) and that such 
impairments may also contribute to the attentional and executive symptoms 
observed in chronic amphetamine abusers (Rogers, Everitt et al. 1999; Ornstein, 
Iddon et al. 2000). 
This experiment was not designed to assess comprehensively the 
increases in Fos-expression following repeated AMPH exposure (Ostrander, 
Badiani et al. 2003; Uslaner, Norton et al. 2003) but to determine Fos-IR primarily 
in the cholinergic basal forebrain of AMPH-pretreated, AMPH-challenged, and 
task-performing animals. In saline-pretreated rats, Fos-positive cells were rarely 
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seen in the nbM section of the cholinergic basal forebrain. In contrast, Fos-
positive cells were distributed more evenly in the nbM/SI area in AMPH-
pretreated animals. There is little evidence in support of discrete differences 
between the topographic organization of these two structures (Zaborszky 2002), 
although the projections from the nucleus accumbens (Mogenson, Swanson et 
al. 1983) and amygdala (Jolkkonen, Miettinen et al. 2002) appear to contact SI 
neurons preferentially. Thus, the increase in the number of Fos-positive cells in 
the ventral section of the cholinergic basal forebrain may reflect the transsynaptic 
consequences of a sensitized mesolimbic system on basal forebrain cholinergic 
neurons. 
Our data, together with prior findings indicating mesolimbic influences over 
cortical cholinergic transmission (Moore, Fadel et al. 1999; Neigh-McCandless, Kravitz 
et al. 2002; Neigh, Arnold et al. 2004), AMPH-sensitized cortical ACh release (Nelson, 
Sarter et al. 2000), and the role of cortical cholinergic inputs in attention (see 
Introduction), correspond with the hypothesis that the cortical cholinergic input system is 
an integral branch of neuronal circuitry involved in the mediation of the attentional effects 
of psychostimulant sensitization. These data indicate that the attentional consequences 
of repeated AMPH exposure in rats may serve as a model to investigate further the role 
of the cortical cholinergic input system in the cognitive symptoms of schizophrenia and 
for the test of the potential therapeutic significance of cholinergic modulators (Tzavara, 






Figure 2.1 Schematic illustration of the sustained attention task. A session 
consisted of 162 signal or non-signal trials. Two seconds following a signal or 
non-signal event levers extended into the operant chamber. Correct responses in 
signal trials (left lever presses: hits) and non-signal trials (right lever presses: 
correct rejections) were rewarded, and incorrect responses (misses and false 
alarms, respectively) were not. The intertrial interval (ITI) was variable to limit the 










Figure 2.2 Experimental time line of escalated AMPH or saline pretreatment and 
challenge doses.  Animals received AMPH or saline twice a day during the 
pretreatment phase, once before the daily training session and again 8 hours 
later (the ordinate depicts the dose that was given twice daily; each dot depicts 
one day and dose; see Methods and Materials for details). Control animals 
received vehicle throughout the pretreatment regimen and, similar to AMPH-













Figure 2.3: Drug-off day performance of rats during the pretreatment phase 
(M±SEM). amphetamine (AMPH)-treatment resulted in an impairment of the 
overall performance (indicated by the “vigilance index” (VI)) during drug-off days 
when compared with the performance of saline-treated animals. The effect on VI 
was largely due to a decrease in hits that was most pronounced in trials 
presenting the longest (500 msec) signals, possibly because of “floor”—effects 






















Figure 2.4 Omission data from the final two drug-free periods during 
pretreatment. During the last two, 2-day drug-off periods, the omissions in 
AMPH-treated animals were relatively high on the first when compared with the 
second drug-off day, possibly reflecting the acute effects of, or immediate 
withdrawal from, relatively high doses of AMPH administered during the later part 












Figure 2.5: Average overall performance (vigilance index; (VI)) of amphetamine 
(AMPH)- and saline-pretreated animals during the the 20-day withdrawal period. 
Pretreatment with AMPH resulted in an impaired performance as indicated by VI. 





Figure 2.6. Effects of 1.0 mg/kg AMPH-challenges on the relative number of hits 
and correct rejections. The figure depicts the relative number of hits (at left) and 
correct rejections (at right) of animals at baseline (before any drug administration; 
“baseline”), following the first administration of amphetamine (AMPH; 1.0 mg/kg) 
at the beginning of the pretreatment regimen (“first AMPH”), and following the 
administration of this dose as a challenge (“AMPH-AMPH”). Furthermore, the 
effects of this dose given as a “challenge” to vehicle-pretreated rats are shown 
(“VEH-AMPH”). The effects of first AMPH and VEH-AMPH did not differ from 
baseline performance. In contrast, the administration of AMPH-challenges in 
AMPH-pretreated rats produced a significant decrease in hits but did not affect 































very first 1 mg/kg exposure
0.5 mg/kg challenge
Figure 2.7 Comparison between the effects of the administration of 0.5 mg/kg 
following the drug-free period (“challenge”) and the first administration of 1 mg/kg 
of AMPH. In the analysis of effects on overall performance (VI), the smaller dose 
of AMPH given as a challenge resulted in a significant impairment in 
performance when compared with the acute effects of twice the amount of drug. 
The reason for a significant difference specifically during the second block of 












Figure 2.8. Number of Fos-immunoreactive (IR) neurons in the four regions of 
interest (see Methods for counting and averaging procedures). In animals 
pretreated and challenged with amphetamine (AMPH), compared with saline-
pretreated and AMPH-‘challenged’ animals, significant increases in Fos-IR were 
found in all regions except the caudate/putamen. The increase in Fos-IR neurons 
in the nucleus basalis of Meynert/substantia innominata (NbM/SI) region was 
particularly robust. The majority of Fos-IR neurons in the latter region were also 




























Figure 2.9 Schematic illustration of the sampling area and photomicrographs of 
Fos-immunoreactivity in the basal forebrain of a saline- (A) and an amphetamine 
(AMPH)-pretreated (C) animal. (B)The region in the basal forebrain shown in (D) 
which includes the dorsal substantia innominata and the medioventral part of the 
nucleus basalis of Meynert. A section, from an AMPH-pretreated rat, that was 
double-immunostained for Fos (see the blackish nuclei) and choline 
acetyltransferase (ChAT; see the reddish-brown cytoplasm) (E). Approximately 
80% of all Fos-positive cells in this area were also ChAT-positive (see arrows). 






TOWARD A NEURO-COGNITIVE ANIMAL MODEL OF THE COGNITIVE 
SYMPTOMS OF SCHIZOPHRENIA: DISRUPTION OF CORTICAL 
CHOLINERGIC NEUROTRANSMISSION FOLLOWING REPEATED 
AMPHETAMINE EXPOSURE IN ATTENTIONAL TASK-PERFORMING, BUT 
NOT NON-PERFORMING, RATS 
 
3.1 Summary 
Impairments in attentional functions and capacities represent core aspects 
of the cognitive symptoms of schizophrenia. Attentional performance has been 
demonstrated to depend on the integrity and activity of cortical cholinergic inputs. 
The neurobiological, behavioral, and cognitive effects of repeated exposure to 
psychostimulants model important aspects of schizophrenia. In the present 
experiment, prefrontal acetylcholine (ACh) release was measured in attentional 
task-performing and non-performing rats pretreated with an escalating dosing 
regimen of amphetamine (AMPH) and following challenges with AMPH. In non-
performing rats, pretreatment with AMPH did not affect the increases in ACh 
release produced by AMPH-challenges. In contrast, attentional task 
performance-associated increases in ACh release were attenuated in AMPH-
pretreated and AMPH-challenged rats. This effect of repeated AMPH exposure 
on ACh release was already present before task-onset, suggesting that the loss 
of cognitive control that characterized these animals' performance was a result of 
cholinergic dysregulation. The findings indicate that the demonstration of 
repeated AMPH-induced dysregulation of the prefrontal cholinergic input system 
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depends on interactions between the effects of repeated AMPH exposure and 
cognitive performance-associated recruitment of this neuronal system. Repeated 
AMPH-induced disruption of prefrontal cholinergic activity and attentional 
performance represents a useful model to investigate the cholinergic 
mechanisms contributing to the cognitive impairments of schizophrenia. 
3.2 Introduction 
As reflected by the NIMH Initiative 'Measurement and Treatment Research 
to Improve Cognition in Schizophrenia' (MATRICS), the determination of the 
neuronal abnormalities that underlie the cognitive impairments of schizophrenia 
and the development of novel pro-cognitive treatments are pressing research 
objectives. Based on the fundamental role of attentional processes for learning 
and general cognitive control, attentional dysfunctions have been considered a 
central and even essential characteristic of schizophrenia (McGhie and Chapman 
1961; Braff 1993; Braver, Barch et al. 1999; Braff and Light 2004; Keefe, Bilder et 
al. 2006; Nuechterlein, Dawson et al. 1994; Venables 1964). 
Attention describes the cognitive states and operations that govern the 
readiness for the detection of changes in the stimulus situation, the selection of 
such changes over irrelevant 'noise' for further processing, and the management 
of attentional resources for the detection and processing of competing stimuli. 
Substantial evidence supports a crucial role of the cortical cholinergic input 
system in the mediation of attentional functions and capacities (Everitt and 
Robbins 1997; Sarter, Givens et al. 2001; Sarter, Hasselmo et al. 2005). 
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Removal of cortical cholinergic inputs produces persistent impairments in 
attentional performance. Furthermore, attentional performance is associated with 
increases in cortical acetylcholine (ACh) release that are not observed in animals 
performing tasks controlling for the non-attentional aspects of performance 
(McGaughy, Kaiser et al. 1996; Himmelheber, Sarter et al. 1997; Turchi and 
Sarter 1997; Himmelheber, Sarter et al. 2000; McGaughy, Everitt et al. 2000; 
Passetti, Dalley et al. 2000; Turchi and Sarter 2000; Dalley, McGaughy et al. 
2001; Kozak, Bruno et al. 2006).The available evidence indicates that the cortical 
cholinergic input system mediates not one particular aspect of attention but 
supports a range of attentional abilities, including sustained, selective, and 
divided attention. 
Although reduced muscarinic receptor densities in the cortex of 
schizophrenics have been reported (Crook, Tomaskovic-Crook et al. 2000; 
Crook, Tomaskovic-Crook et al. 2001; Hyde and Crook 2001; Raedler, Knable et 
al. 2003; Newell, Zavitsanou et al. 2007), the status of cortical cholinergic 
neurotransmission in schizophrenia remains poorly understood. Owing in part to 
the lack of methods capable of assessing dynamic aspects of cholinergic 
dysregulation in humans, the potential contribution of cholinergic dysregulation to 
the cognitive symptoms of patients is unknown. 
Repeated exposure to psychostimulants has long been known to produce 
psychotogenic effects in humans (Bell 1965; Bell 1973; Kokkinidis and Anisman 
1981; Kokkinidis and Anisman 1981; Snyder, Aghajanian et al. 1972; Snyder 
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1973; Wallis, Mc et al. 1949; Caton 2000). Furthermore, the effects of repeated 
psychostimulant exposure in healthy humans and animals model important 
neurobiological, behavioral, and cognitive aspects of schizophrenia (Robinson 
and Becker 1986; Lieberman, Sheitman et al. 1997; Castner and Goldman-Rakic 
1999; Laruelle 2000; Castner and Goldman-Rakic 2003; Kapur 2003; Segel 
1978; Strakowski, Sax et al. 1997; Yui, Goto et al. 1999), including the deficits in 
sensorimotor gating and attentional processing (Crider, Solomon et al. 1982; 
Tenn, Fletcher et al. 2003; Martinez, Parikh et al. 2005; Sarter, Nelson et al. 
2005). Furthermore, repeated psychostimulant exposure models the sensitization 
of the mesolimbic dopamine system that has been demonstrated in never-
medicated patients and during psychotic periods (Abi-Dargham, Gil et al. 1998; 
Laruelle, Abi-Dargham et al. 1996; Strakowski, Sax et al. 1997; Laruelle, Abi-
Dargham et al. 1999; Laruelle 2000). Based on evidence suggesting close links 
between the mesolimbic dopamine system and basal forebrain cholinergic 
neurons (Moore, Fadel et al. 1999; Neigh-McCandless, Kravitz et al. 2002; 
Neigh, Arnold et al. 2004; Zmarowski, Sarter et al. 2005), abnormal regulation of 
the cortical cholinergic input system has been hypothesized to represent an 
integral component of the dysregulated forebrain systems responsible for the 
cognitive symptoms of schizophrenia (Sarter, Hasselmo et al. 2005). Previous 
findings indicating psychostimulant exposure-induced alterations in the regulation 
of basal forebrain cholinergic neurons are consistent with this hypothesis 
(Nelson, Sarter et al. 2000; Martinez, Parikh et al. 2005). However, this evidence 
does not form the basis for hypotheses describing unidirectional, causal 
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relationships between dysregulated dopaminergic and cholinergic systems. 
Escalating bidirectional interactions between abnormally regulated mesolimbic 
projections to the basal forebrain and prefrontal cortex, and aberrant cholinergic 
recruitment of prefrontal neurons projecting to mesolimbic regions may ultimately 
be responsible for the disruption of prefrontal-mesolimbic information processing 
that is widely hypothesized to underlie the cognitive symptoms of schizophrenia. 
The present focus on the regulation of the prefrontal cholinergic input system is 
based on the extensive evidence linking this system to fundamental attentional 
processes. 
The current experiment utilized an escalating dosing pretreatment regimen 
of amphetamine (AMPH) that is known to generate neurobiological and 
behavioral characteristics resembling psychostimulant psychosis (Paulson, 
Camp et al. 1991). This regimen produces lasting psychomotor sensitization 
without yielding neurotoxicity (Robinson and Camp 1987; Paulson, Camp et al. 
1991; Paulson and Robinson 1995; Robinson, Jurson et al. 1988). Importantly, 
psychomotor sensitization, locomotor hyperactivity, or stereotypies are not 
observed in attentional task-performing rats following the repeated administration 
of AMPH, perhaps as a result of the constraining of the animals' behavior by the 
operant and attentional requirements of the task (Martinez, Parikh et al. 2005). 
Furthermore, it is important to note that the administration of AMPH-challenges is 
thought to model the role of stressors in eliciting psychotic episodes, and/or in 
revealing a sensitized mesolimbic system (Moghaddam 2002; Robinson and 
Becker 1986) that can trigger active disease periods (Ventura, Nuechterlein et al. 
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1989; Lieberman, Sheitman et al. 1997; Yui, Goto et al. 1999, Ujike and Sato 
2004; Sato 1992; Sato, Numachi et al. 1992). 
The present study was designed to determine the effects of pretreatment 
and challenge with AMPH on ACh release in the medial prefrontal cortex (mPFC) 
in animals performing a task taxing attentional capacities and in animals that did 
not perform a task. This experiment was guided by the general hypothesis that in 
order to demonstrate the abnormal regulation of a neurotransmitter system, 
recruitment of that system, by behavioral and cognitive operations relevant to 
that system, is required. The results support this hypothesis and indicate that 
repeated exposure to AMPH disrupts the regulation of cholinergic projections to 
the prefrontal cortex and thereby cognitive task control. Furthermore, these 
findings indicate the usefulness of experiments designed to measure the effects 
of repeated AMPH exposure on cognitive performance and, simultaneously, 
performance-associated increases in ACh release, as a model for research on 
the neuronal mechanisms underlying the cognitive symptoms of schizophrenia as 
well as on the development of novel treatments for the cognitive symptoms of 
this disorder. 
3.3 Methods 
Animals: Twenty-four male Fischer-344/Brown–Norway F1 hybrid rats (Harlan 
Sprague–Dawley, Indianapolis, IN), weighing between 300 and 350 g at the 
beginning of behavioral training, were housed individually in a temperature 
(23°C)- and humidity (45%)-controlled environment with a 12:12 light/dark cycle 
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(lights on at 0700 hours). Animals were handled extensively before the beginning 
of training. Food (Rodent Chow, Harlan Teklad, Madison, WI) was available ad 
libitum, whereas water was available only during behavioral training as reward 
(below) as well as for 8 min in the home cage following daily operant training. 
Animal care and experimentation were performed in accordance with protocols 
approved by the University Committee On Use and Care of Animals of the 
University of Michigan (UCUCA). 
Apparatus: Behavioral training was conducted using 12 operant chambers (Med-
Associates, St Albans, VT), each enclosed within a sound-attenuating 
compartment and equipped with three panel lights (2.8 W), two retractable levers 
and a water dispenser delivering 30 l water per reward into a cup located 
between the two levers. A house light (2.8 W) was located on the rear wall. 
Signal presentation, lever operation, water delivery, and data collection were 
controlled by a PC running Med-PC for Windows software (V 4.1.3; Med-
Associates). 
Behavioral Training: Training methods and evidence in support of the validity of 
performance measures in terms of reflecting sustained attention performance 
have been previously described (McGaughy and Sarter 1995; McGaughy and 
Sarter 1998). It should be noted that the use of this particular task in this 
experiment does not necessarily imply that performance of specifically this task 
would uniquely activate the cortical cholinergic input system; rather, this form of 
attention can be more readily trained and tested in rats when compared with 
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more complicated tasks designed to assess other aspects of attention, such as 
divided attention (Turchi and Sarter 1997; Turchi and Sarter 2000). 
Training occurred between 08:00 and 18:30 hours 7 days a week. Animals 
were initially trained to lever press for water in accordance with a modified FR-1 
schedule. Following at least three consecutive sessions of over 120 reinforced 
lever presses, animals advanced to the second stage of task acquisition. Animals 
were first trained to discriminate between signal (1 s illumination of the central 
panel light) and non-signal (no illumination) events. Two seconds following the 
occurrence of a signal or non-signal, both levers were extended into the operant 
chamber and remained active for 4 s or until a lever press occurred. During 
signal trials, a left lever press was scored as a hit, whereas a right lever press 
was scored as miss. Conversely, during non-signal trials, a right lever press was 
scored as a correct rejection and a left lever press was scored as a false alarm. 
Half of all animals were trained to acquire the task using reversed response 
rules. Hits and correct rejections were rewarded, whereas false alarms and 
misses were not. During this stage of training, incorrect responses resulted in the 
initiation of correction trials. During correction trials, the previous trial was 
repeated up to three times. If an animal continued to respond incorrectly, a 
forced-choice trial was initiated by presenting the correct lever only following a 
signal or non-signal event. Correction and forced-choice trials served to facilitate 
the acquisition of response rules and prevent the development of a side bias. 
Once animals achieved at least three consecutive days of stable 
performance defined as ≥59% correct responses to both signal- and non-signal 
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events, they advanced to the third stage of task acquisition. Signal duration was 
shortened and signals were presented for 25, 50, or 500 ms. The sequence of 
signal duration and the occurrence of signal and non-signal trials were pseudo-
randomized to yield 27 trials per signal duration and 81 non-signal trials. 
Correction trials and forced trials were discontinued, and the intertrial interval 
(ITI) was shortened from 12±3 to 9±3 s. As will be further detailed below, 
measures of performance included the relative number of hits (hits/hits+misses), 
calculated for each signal length, and the relative number of correct rejections 
(correct rejections/correct rejections+false alarms). Once animals achieved at 
least 3 days of stable performance, defined as ±70% hits to 500 ms signals, 
±70% correct rejections, and ≤50% omissions to 25 ms signal), they began 
training in the final task (see Figure 3.1a). House lights were illuminated 
throughout the session. This important final modification requires that animals 
constrain their behavior to maintain persistent orientation toward the intelligence 
panel. Each session lasted approximately 40 min. The pretreatment regimen was 
initiated after animals maintained criterion performance (≥70% hits to 500 ms 
signals, ≥70% correct rejections, and ≤20% omissions) for 3 consecutive days. 
Measures of performance included hits, misses, correct rejections, false 
alarms, and omissions. The relative number of hits and correct rejections was 
calculated as described above. To obtain an overall index of performance that 
reflects the performance in trials involving signals as well as non-signal events, 
the vigilance index (VI) was calculated based on the relative number of hits (h) 
and false alarms (fa) using the formula: VI=(h-fa)/[2(h+fa)-(h+fa)2]). This index is 
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comparable to the sensitivity index (SI) (Frey 1973)except that VI is based on the 
relative number of hits and false alarms, whereas SI is calculated using the 
probabilities for hits and false alarms. Thus, VI values are not confounded by 
errors of omission. Values for VI can vary from +1.0 to -1.0, with +1.0 indicating 
that all responses were scored as hits or correct rejections, 0 indicating an 
inability to discriminate between signal and non-signal events, and -1 indicating 
that all responses to signals were misses and all responses to non-signals were 
false alarms. The index was calculated for each signal duration (VI: 500, 50, 25 
ms). Finally, errors of omission were recorded. Performance measures were 
calculated collectively for the entire session as well as separately for each of four 
task blocks (10 min each; see Figure 3.2). 
Pretreatment Regimen and Challenges: After reaching performance criterion, 
animals were randomly divided into two groups (n=7 each) designated to be 
pretreated with AMPH or vehicle (saline; SAL). Animals were administered either 
d-AMPH sulfate (1–10 mg/kg; i.p.; concentrations included salt weight; dissolved 
in 1.0 ml/kg of 0.9% saline; Sigma, St Louis, MO) or saline (1.0 ml/kg i.p.) twice 
per day, with approximately 8 h separating the two injections (Figure 3.1b). 
Animals received the first injection at approximately 08:00 hours and were placed 
immediately into the test chambers. Task onset was 20 min post-injection. 
Following the completion of the test session, animals were promptly returned to 
their home cages. The second dose of drug or vehicle was given in the home 
cage at approximately 16:00 hours. AMPH doses were administered in elevating 
increments over the course of 40 days (Paulson, Camp et al. 1991). All animals 
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were given injections of saline on weekends to mimic the 'runs and crashes' 
known to foster psychostimulant-induced psychoses (see Figure 3.1b; for 
references see Introduction). Following AMPH doses of 2 mg/kg or higher, task 
performance was disrupted and animals omitted all trials. In order to control for 
the potentially confounding effects of substantially lower amounts of task practice 
in AMPH-treated animals, animals treated with vehicle were placed in the testing 
chambers but not allowed to perform for an equivalent number of sessions during 
weekdays, whereas AMPH-treated animals received doses >2 mg/kg (Martinez, 
Parikh et al. 2005). Both saline- and AMPH-treated animals performed the task 
on weekends. 
In our previous experiment employing this AMPH regimen in task-
performing animals (Martinez, Parikh et al. 2005), we found that following 
termination of the pretreatment regimen, AMPH-treated animals' performance 
required about 2 weeks of continued training to return to baseline, reflecting the 
general behavioral depression observed during this period of withdrawal 
(Paulson, Camp et al. 1991). As this experiment was not designed to study 
aspects of withdrawal, and in order to implant guide cannula (for the later 
insertion of microdialysis probes) relatively close to the actual microdialysis test 
sessions, surgery was conducted 7 days into this withdrawal period. The daily 
testing continued until surgery (below) and resumed following 5 days of post-
surgery recovery during which food and water were available ad libitum. All 
subsequent testing was conducted in operant chambers modified to 
accommodate the procedures for microdialysis (see below). 
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The effects of AMPH-challenges were determined following the 
administration of 1.0 mg/kg of AMPH. This dose is the first dose given during the 
pretreatment regimen and was observed earlier not to produce acute effects on 
attentional performance (Martinez, Parikh et al. 2005). Likewise, this dose did not 
affect the performance of saline-pretreated animals when given as a 'challenge' 
(Martinez, Parikh et al. 2005). Therefore, significant differences between the 
effects of 1.0 mg/kg when given as a challenge to animals pretreated with AMPH 
or vehicle can be attributed to the differential pretreatment history. Thus, final 
comparisons were based on data from animals pretreated with SAL or AMPH 
and challenged with either SAL or AMPH, resulting in four treatment conditions 
and groups (SAL/SAL; AMPH/SAL; SAL/AMPH; AMPH/AMPH). 
Non-Performing Rats: Non-performing animals (n=10) were handled extensively 
using procedures identical to task-performing rats, including the daily transport 
between home cages and operant chambers and the number and the timing of 
injections of AMPH (n=6) or SAL (n=4). However, the task was never activated 
for these animals and, as water reward was not delivered, they were not water 
deprived. Similar to task-performing animals, non-performing animals underwent 
stereotaxic surgery 7 days following the cessation of pretreatment. Animals were 
allowed to recover for 5 days and then resumed the handling procedures for the 
remainder of the withdrawal period. The effects of AMPH- or saline-challenges 
on ACh release were determined 33.6±6.4 days (M±SEM) after completion of the 
pretreatment period (in order to match the interval that was required for 
performing rats; see below). 
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Surgical Methods: Surgery was performed under aseptic conditions. Initial 
anesthesia was induced with 4–5% isoflurane by placing the animal in an 
anesthetic chamber (Anesco/Surgivet, Waukesha, WI). Gas was carried via 
oxygen at a flow rate of 0.6 ml/min. Animals were also given a preoperative 
injection of an antibiotic (Amikacin, 100 mg/kg; s.c.). Heads were shaved using 
electric clippers and cleaned with 70% ethanol and iodine tincture. Ophthalmic 
ointment was applied to lubricate the eyes. Animals were then mounted into a 
stereotaxic instrument (David Kopf, Tujunga, CA). Isoflurane was administered 
via a face mask at 1.5–2% for the duration of surgery. Microdialysis guide 
cannula (0.38 mm o.d.; Sci Pro, Sanborn, NY, USA) were implanted dorsal to the 
prelimbic region of the right hemisphere at the following coordinates: AP (from 
Bregma: 2.9 mm, ML: 0.6 mm, DV: 0.6 mm (from dura). After surgery, rats were 
returned to their home cages and allowed to recover for 5 days with free access 
to food and water. Thereafter, the water deprivation schedule resumed and 
animals were returned to behavioral training until they regained performance 
criterion (if applicable). Before daily test sessions, the dummy stylets were 
removed and polyethylene tubing was attached in order to habituate the animals 
to performing while being dialyzed. 
Microdialysis Methods: Following recovery, animals resumed operant training in 
chambers modified to accommodate microdialysis procedures. The modified 
operant chambers used to measure ACh release in task-performing rats featured 
a taller recessed water delivery area (9.0 X 5.0 cm, height X width) to allow 
access for animals with a probe inserted and inlets and outlets attached, and to 
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accommodate the liquid swivels, syringes and pumps outside the chambers. This 
was performed in order to allow collection of dialysates outside of the chambers 
without interfering with the animals' ongoing performance. 
Furthermore, the length of the test sessions was set to 40 min to 
correspond exactly with the timing of four dialysate collections (10 min each). 
Procedures designed to foster habituation to microdialysis procedures, 
particularly the tethering during task performance, were initiated at this point. 
Because of the subsequent requirement for extended pretask microdialysis 
discard periods (3 h), the collection of four baseline dialysates, and an additional 
two dialysates following drug treatment and before task onset (see Figure 3.2), 
rats were placed in the operant chambers 240 min before task onset. The 
houselight was illuminated for the entire time the animals were in the operant 
chambers. 
After being transferred to the modified operant chambers, animals were 
retrained to a performance criterion (≥60% hits to 500 ms signals, ≥65% correct 
rejections, and ≤20% omissions for three consecutive sessions). This criterion 
was more lenient than for the original acquisition (above), because the 
performance of tethered animals was more variable and slightly impaired relative 
to the performance of non-tethered animals. As these animals required a 
relatively large number of sessions to meet performance criterion, on average 
34.7±3.7 days elapsed between completion of the pretreatment period and the 
first microdialysis session. Animals were dialyzed at least twice, first following the 
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administration of saline and 6±1 days later following the administration of AMPH. 
Considering evidence suggesting that even a single dose of AMPH produces 
sensitizing effects (Vanderschuren, Schmidt et al. 1999), the effects of saline-
'challenges' were always tested first. In the event that dialysis sessions preceded 
by saline administration did not result in detectable levels of ACh as a result of 
probe failure or severed tubing, a maximum of two additional sessions were 
conducted in order to generate a complete data set for each animal. Repeated 
insertion of probes over a period of weeks, up to four insertions, was repeatedly 
demonstrated to generate similar basal ACh release levels (see Results) 
sensitive to the blocking of voltage-regulated sodium channels with tetrodotoxin 
(Moore, Sarter et al. 1993; Moore, Sarter et al. 1995; Moore, Stuckman et al. 
1995; Moore, Stuckman et al. 1996; Moore, Fadel et al. 1999). 
Before insertion of a concentric microdialysis probe into the brain (Model 
MAB4; membrane o.d.: 0.24 mm; membrane length: 3.0 mm; Sci Pro), probe 
recovery was determined in vitro by placing the probe into a 1.0 pmol ACh 
solution and collecting for 10 min. Probes that were used exhibited recoveries of 
≥9%. Probes were perfused at a rate of 2.0 μl/min with artificial cerebrospinal 
fluid, pH 6.9±0.1, containing the following (in mM): 126.5 NaCl, 27.5 NaHCO3, 
2.4 KCL, 0.5 NA2SO4, 0.5 KH2PO4, 1.2 CaCl2, 0.8 MgCl2, and 5.0 glucose. Note 
that the perfusion medium did not contain an acetylcholinesterase inhibitor. 
Dialysate collections were frozen at -80°C until ACh contents were 
determined using high performance liquid chromatography coupled with 
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electrochemical detection (ESA, Chelmsford, MA), using a mobile phase 
containing 50 mM sodium phosphate. ACh was separated from choline on UniJet 
microbore analytical column (Bioanalytical Systems Inc. (BASi), West Lafayette, 
IN) and catalyzed on a post-column solid-phase reactor containing 
acetylcholinesterase and choline oxidase. ACh was hydrolyzed to acetate and 
choline, and choline oxidized to hydrogen peroxide and betaine. The amount of 
hydrogen peroxide corresponding to ACh was then detected using a 'peroxidase-
wired' glassy carbon electrode with an applied potential of -200 mV (Huang, 
Yang et al. 1995). The concentration of ACh was calculated by integrating the 
area under the peak and fitting this value to a regression line containing values of 
ACh that were in the expected range of the in vivo dialysates. The detection limit 
of this system averaged 2 fmol/15 μl. 
Histological Verification of Probe Placements: Within 1 week following the last 
microdialysis session, animals were given an overdose of sodium pentobarbital 
and underwent cardiac perfusion with 0.1 M of phosphate buffer followed by 4% 
buffered formalin. The brains were post-fixed in formalin overnight, and 
transferred to a 30% sucrose phosphate buffer solution. Sections (40 μm thick) 
surrounding the probe and cannula sites were mounted, stained with cresyl 
violet, and examined for probe placements. 
Statistical Methods: Statistical analyses for performance and dialysis data were 
conducted using mixed model analysis of variance (ANOVAs). As basal ACh 
release data did not differ between groups (see Results), the effects of the 
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challenges on ACh release in performing and non-performing rats were 
conducted based on values expressed as the percent change values from mean 
basal ACh release (average of the last three collections before the administration 
of AMPH or saline). ACh release values were not corrected for probe recovery. 
To determine drug-induced changes in ACh release in performing rats, a mixed 
ANOVA on the effects of task (e.g. two post-drug/pre-task collections vs. four 
task-associated collections), pretreatment (AMPH or saline), and session 
(AMPH- or saline-challenge) was conducted and followed, where appropriate by 
two- and one-way ANOVAs and multiple comparisons. Task performance was 
analyzed on the basis of overall performance as indicated by VI (see above for 
calculation). In addition, the numbers of errors of omission were analyzed. The 
ANOVAs determined the effects of pretreatment (AMPH vs. saline), session 
(AMPH- or saline-challenge), and signal duration (500–25 ms) on VI and 
omissions. Significant main effects and interactions were followed by two- and 
one-way ANOVAs and Fisher's least significant difference test (LSD) for multiple 
comparisons. Exact p-values are reported for significant results, as was 
recommended earlier (Greenwald 1996). Statistical analyses were performed 
using SPSS Version 14.0 for Windows (SPSS Inc., Chicago, IL). 
3.4 Results 
Histological Findings: As illustrated in the inset in Figure 3.2, dialysis probes 
were placed into the middle layers of the pre-limbic region. In most cases, the 
active membrane extended either dorsally into the anterior cingulate cortex or 
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ventrally into the infralimbic region. Neither baseline release values nor 
performance- and/or AMPH-induced changes in ACh release systematically 
differed between these minor variations in placement, and thus evidence 
obtained from all these placements was used for final analysis. 
Effects of Repeated AMPH on ACh Release in Non-performing Rats: Basal ACh 
release did not differ between non-performing animals pretreated with AMPH and 
vehicle (F(1,8)=0.085; p>0.05; Figure 3.3), nor did basal values differ between 
session (before vehicle-'challenge' or AMPH-challenge; F(1,8)=0.006; p>0.05), 
and the two variables did not interact significantly (F(1,8)=0.09; p>0.05). Basal 
ACh release was 7.26±1.09 fmol/15 μl. Because of the absence of pretreatment 
effects on basal ACh release, the effects of vehicle- or AMPH-challenge on ACh 
release were expressed as percent change from baseline. 
Compared with the administration of vehicle, the AMPH-challenge resulted 
in a significant increase in ACh release in both saline and AMPH-pretreated rats 
(main effect of session: F(1,8)=28.28; p=0.001). The increase in ACh release that 
resulted from AMPH-challenge did not differ between animals pretreated with 
vehicle or AMPH (pretreatment: F(1,8)=0.07; p>0.05; ‘pretreatment’ X ‘session’: 
F(1,8)=0.11; p>0.05). Furthermore, ACh release did not vary over the four 
collections (T1–T4 in Figure 3.3), and this variable did not interact with 
pretreatment or session (all p>0.05). As illustrated in Figure 3.3, following saline-
'challenges', ACh release was 18.06±15.22% over baseline (averaged over T1–
T4); these values did not differ significantly from baseline values (F(1,8)=0.42; 
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p>0.05). The AMPH-challenges resulted in an increase of 210.66±35.44% over 
baseline (F(1,8)=35.13; p<0.001). Post hoc analyses indicated that AMPH 
significantly increased ACh release in both groups of animals when compared to 
the effects of saline-'challenges' (both p<0.02), and that neither the effects of 
saline- nor AMPH-challenges differed between animals pretreated with saline vs. 
AMPH (both p>0.05). Thus, the pretreatment history of non-performing animals 
did not influence the AMPH-challenge-induced increases in ACh release. 
Effects of Repeated AMPH on ACh Release in Performing Rats: Basal ACh 
release did not differ between animals pretreated with vehicle or AMPH 
(F(1,12)=2.23; p>0.05; Figure 3.4). Likewise, basal release did not differ before 
the administration of an AMPH-challenge or vehicle (F(1,12)=1.63; p>0.05) and 
the two factors (group, session) did not interact significantly (F(1,12)=1.62; 
p>0.05). Basal ACh release was 7.53±1.58 fmol/15 μl. Basal release did not 
differ between non-performing (above) and attentional task-performing rats 
(F(1,22)=0.00; p>0.05). 
Effects of AMPH-Challenges on Performance-associated ACh Release: As 
illustrated in Figure 3.2, following the administration of drug or vehicle as 
challenges, two dialysates were collected before task onset. An overall ANOVA 
on the effects of task-stage (pre-task vs. task), pretreatment, and challenge 
revealed a significant interaction between the effects of pretreatment and 
challenge (F(1,12)=31.63; p<0.001). However, there was no effect of task-stage 
and no interactions between task-stage, pretreatment or challenge (all p>0.05). 
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Thus, the effects of repeated AMPH exposure and AMPH-challenge on ACh 
release did not differ between the two collections taken before task onset and the 
four collections taken during task performance (see Figure 3.4). 
Similar to the results from previous experiments (Arnold, Nelson et al. 
2003) (Himmelheber, Sarter et al. 2000) (Kozak, Bruno et al. 2006), performance 
of the attention task increased ACh release in the mPFC over baseline. In 
SAL/SAL animals, ACh release increased by 158.28 18.49% over basal ACh 
levels during the performance of the task (F(1,6)=66.98; p<0.001; see Figure 
3.4). The performance-associated increase in mPFC ACh release is comparable 
to the increase observed previously in animals performing this task and using 
similar microdialysis conditions, including the absence of an acetylcholinesterase 
inhibitor (Kozak, Bruno et al. 2006). 
The effects of the AMPH-challenges differed significantly between groups 
of rats pretreated with SAL vs. AMPH (pretreatment challenge: F(1,12)=30.74; 
p<0.0001; main effect of challenge: F(1,12)=6.14; p=0.03; main effect of 
pretreatment: F(1,12)=3.00; p>0.05; the factor time (T1–T4) did not produce a 
main effect and did not interact with group and session; all p>0.05). Figure 3.4 
illustrates that AMPH-challenges in animals pretreated with AMPH 
(AMPH/AMPH) resulted in the attenuation of performance-associated increases 
in ACh release. Several post hoc comparisons further substantiated this result. 
The acute administration of AMPH in SAL-pretreated rats did not affect the 
elevated levels of ACh release observed in animals performing this task 
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(SAL/SAL vs. SAL/AMPH; F(1,6)=3.88; p>0.05). In contrast, the acute 
administration of, or the challenge with, AMPH in animals that were pretreated 
also with AMPH resulted in a significant attenuation of ACh release levels when 
compared with animals pretreated with SAL (SAL/AMPH vs. AMPH/AMPH 
(F(1,12)=29.62; p<0.0001). Multiple comparisons indicated that all data points 
(T1–T4) differed significantly by pretreatment (all p<0.004; Figure 3.4, lower 
graph). Averaged over all time points, performance-associated ACh release in 
SAL/AMPH animals was 235.93±27.47% over pretask baseline and 
47.89±24.42% in AMPH/AMPH rats. The attenuation of ACh release levels in 
AMPH/AMPH animals was also revealed by the within-subject comparison 
(AMPH/SAL vs. AMPH/AMPH; F(1,6)=40.83; p=0.001). 
The attenuated levels of ACh release observed in performing 
AMPH/AMPH rats did not differ significantly from release levels measured at 
baseline (before task onset and before drug treatment (F(1,6)=2.65; p>0.05). 
Moreover, a post hoc comparison between ACh release levels in AMPH/AMPH 
animals over all three phases (baseline, post-drug/pre-task, during performance) 
indicated that ACh release levels in these animals never changed from baseline 
(F(2,12)=0.79; p>0.05). 
Finally, in animals pretreated with AMPH and dialyzed following vehicle-
'challenge' (AMPH/SAL; Figure 3.4), performance-associated ACh release was 
significantly higher than in animals pretreated and 'challenged' with vehicle 
(SAL/SAL; F(1,12)=5.34; p=0.04; averaged over all time points: saline-
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pretreated: 158.28±18.49% over baseline; AMPH-pretreated: 250.92±18.44%). 
Multiple comparisons indicated that release during T3 was significantly higher in 
animals pretreated with AMPH (F(1,12)=5.20; p=0.042; the effect neared 
significance during T1; F(1,12)=4.10, p=0.06; Figure 3.4, top graph). 
Baseline performance before the administration of challenges: During the 
pretreatment period, administration of escalating doses of AMPH (Figure 3.1b) 
increasingly disrupted the animals' performance. During drug-free weekends, 
performance partially recovered. The pattern of the performance during the 40-
day AMPH-pretreatment period and during the subsequent 2-week withdrawal 
period corresponded with the evidence described previously (Martinez, Parikh et 
al. 2005). Before the challenge with AMPH or vehicle, the performance of all 
animals as measured by VI remained impaired relative to the pretreatment 
baseline (F(1,12)=5.05; p=0.04; pretreatment baseline, VI averaged over all 
signal durations: 0.24 0.03; pre-challenge baseline: 0.12 0.03; see Figure 3.1 for 
timeline and Methods for additional details). Importantly, the performance of 
AMPH-pretreated rats did not differ from saline-pretreated rats before the 
administration of the challenges (F(1,12)=0.01; p>0.05), confirming that the 
relatively low level of performance at this point was not a result of AMPH-
pretreatment but of the testing conditions, particularly the tethering procedures 
required to conduct microdialysis in task-performing animals. The number of 
trials omitted remained low and did not differ from pretreatment baseline levels 
(F(1,12)=0.02; p>0.05; pretreatment baseline: 12.1±6.0% trials omitted/session; 
pre-challenge baseline: 9.0 1.8%). 
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Performance during challenge doses: The analysis of the effects of AMPH-
challenges on performance (VI) indicated a significant interaction between the 
effects of pretreatment, session and signal duration (F(2,24)=5.27; p=0.01). 
Figure 3.5 depicts VI scores individually for the four treatment conditions and 
each signal duration. Post hoc analyses were conducted to identify the nature of 
this interaction. First, as was expected, the administration of AMPH as a 
challenge in SAL-pretreated rats (SAL/AMPH) did not affect VI (SAL/SAL vs. 
SAL/AMPH; F(1,6)=0.39; p>0.05). Likewise, pretreatment with AMPH alone did 
not affect performance (SAL/SAL vs. AMPH/SAL; F(1,12)=0.28; p>0.05). In 
contrast, the AMPH-challenge in AMPH-pretreated rats resulted in a significant 
decrease in performance compared with the administration of SAL in AMPH-
pretreated rats (AMPH/SAL vs. AMPH/AMPH; F(1,6)=7.50; p=0.03). Thus, 
interactions between the effects of pretreatment and challenge with AMPH were 
responsible for the disruption of performance. 
Figure 3.5 also illustrates the role of signal duration as a factor in the 
significant overall interaction. One-way ANOVAs indicated significant effects of 
signal duration on performance in SAL/SAL (F(2,12)=16.51; p=0.003) and 
AMPH/SAL rats (F(2,12)=9.33; p=0.004; see Figure 3.5 for multiple 
comparisons). As indicated in Figure 3.5, in SAL/AMPH animals, data variability 
prevent the demonstration of a significant effect of signal duration on VI 
(F(2,12)=3.48; p=0.07), whereas the performance of AMPH/AMPH rats was 
depressed and varied between +0.1 and -0.1 for all signal durations 
(F(2,12)=2.92; p>0.05). Thus, pretreatment and challenge with AMPH abolished 
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signal duration-dependent performance; this effect is reflected in the overall 
significant interaction between the effects of pretreatment, challenge, and signal 
duration reported above. 
A similar interaction between these three factors was found in the analysis 
of hits (F(2,24)=4.41; p=0.02), but not correction rejections (F(1,12)=1.11; 
p=0.31), indicating that the effects on VI were largely due to effects of the 
animals' ability to detect signals. This finding is consistent with the selective 
impairment in signal trial performance observed following removal of the cortical 
cholinergic input system (McGaughy, Kaiser et al. 1996).Finally, AMPH-
challenges did not affect the animals' errors of omission (F(1,12)=1.57; p=0.24). 
Omission rates remained generally low (5.54±0.76 omissions/session, averaged 
over all four groups and both test sessions). 
3.5 Discussion 
The present results indicate that in animals habituated to testing and 
microdialysis conditions but that did not perform the attentional task, 
pretreatment with an escalating dosing regimen of AMPH did not alter the effects 
of AMPH-challenges on prefrontal ACh release. In contrast, in rats performing 
the attentional task, such a challenge profoundly attenuated the increases in ACh 
release normally observed in animals performing this task- but only in animals 
that were pretreated with AMPH. Furthermore, task performance was disrupted 
in AMPH/AMPH animals. Based on post-drug and pretask ACh release values, 
the disruption of performance in AMPH/AMPH animals is concluded to represent 
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a result of the attenuation of prefrontal cholinergic activity. These results suggest 
that the effects of repeated AMPH exposure on the regulation of cholinergic 
neurotransmission in the mPFC depend on the level of recruitment of the 
cholinergic system. Below, empirical limitations and interpretational complexities 
will be discussed, followed by an evaluation of the significance of these findings 
for research on the neurobiology of sensitized cognitive impairments and animal 
models of schizophrenia. 
The present results have implications for the understanding of the 
relationships between ACh release and levels of attentional performance. 
Previous experiments indicated that increases in the demands on attentional 
performance, resulting from long-task periods or pharmacological challenges on 
performance, as opposed to increases in performance levels, correlate with 
increases in cortical ACh release in task-performing animals (Kozak, Bruno et al. 
2006; Passetti, Dalley et al. 2000). This evidence corresponds with the 
hypothesis that increases in mPFC ACh release above normal performance-
associated levels mediate the recruitment of the 'anterior attention system' and 
the resulting implementation of top-down mechanisms that counteract the 
performance decrements triggered by challenging conditions (Sarter, Gehring et 
al. 2006). Based on this hypothesis, the augmented increases in ACh release 
observed in AMPH/SAL rats, when compared with SAL/SAL animals, may reflect 
the greater demands on attentional effort required to maintain normal attentional 
performance. Thus, AMPH/SAL animals were able to perform at control levels 
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but required abnormally high levels of mPFC cholinergic activity to maintain 
performance. 
The present evidence suggests that AMPH-pretreatment and AMPH-
challenge disrupts attentional performance-associated increases in mPFC ACh 
release and therefore impaired the animals' ability to employ information 
concerning the presence or absence of a signal to guide the selection and 
execution of a response. The finding that following saline or AMPH-challenges, 
pretask ACh release levels did not differ significantly from ACh release levels 
during task performance suggests that continuous task performance, the 
expectation of performance and task onset, and/or being placed in the 
performance context, are sufficient to reveal the consequences of AMPH-
pretreatment. Moreover, this finding supports the view that following repeated 
AMPH exposure in task-performing rats, AMPH-challenges disrupt the normal 
recruitment of cholinergic inputs to the PFC and therefore results in the loss of 
cognitive control. In contrast, the results do not support the alternative view that 
repeated AMPH, via unknown mechanisms, abolished cognitive task control and 
that the low levels of ACh release were merely secondary to the 
behavioral/cognitive effects of repeated AMPH exposure. 
Previous studies demonstrated that the performance of operant schedules 
not involving explicit demands on attention do not produce significant increases 
in cortical ACh release, or produce increases that are substantially lower than 
those associated with attentional performance. For example, cortical ACh release 
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in rats performing a fixed interval 9 s schedule of reinforcement increased only by 
about 50% over baseline, despite a lever-pressing rate that was almost 10-fold 
the rate observed in sustained attention task-performing rats (Arnold, Burk et al. 
2002). Likewise, operant procedures controlling for the effects of reward rate and 
the sensory effects of stimuli indicated that these variables do not account for the 
increases in ACh release observed in attentional task-performing rats (Dalley, 
McGaughy et al. 2001; Himmelheber, Sarter et al. 1997). As the performance in 
non-cognitive procedures does not yield the levels of cholinergic activity 
observed in attentional task-performing animals, the interactions between 
recruitment of the cholinergic system and repeated psychostimulant exposure 
demonstrated in the present experiment would not be expected in animals 
performing tasks that do not tax cognitive functions. 
In AMPH/AMPH animals, VI scores varied around zero across all signal 
durations (Figure 3.5). A VI score of zero indicates a loss of the ability to 
discriminate between signal and non-signal trails. That is, responses in signal 
and non-signal trials reached chance level and the animals' performance was no 
longer controlled by the presence or absence of a signal. Therefore, the 
performance of these animals no longer involved attentional processes and the 
processing of stimulus-response rules. Levels of ACh release in AMPH/AMPH 
animals performing the attention task (present experiment) were similar to ACh 
release levels observed in rats performing simple operant procedures not 
involving cognitive operations (references above). This observation is consistent 
with the conclusion that in AMPH/AMPH rats, cognitive task control was 
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abolished. Indeed, ACh release in AMPH/AMPH rats did not increase 
significantly beyond pre-task baseline. Thus, both the behavioral data and the 
ACh release levels support the conclusion that as a result of the pretreatment 
and challenge with AMPH, the animals' ability to utilize the presence or absence 
of signals to guide the responses was drastically impaired or, in other words, 
cognitive task control was disrupted. 
As the pretreatment history of the animals did not modulate the effects of 
AMPH-challenges in non-performing animals, the present evidence provides a 
rather stark illustration of the view that the effective demonstration of abnormal 
regulation of a neuronal system requires recruitment of this system by, for 
example, demands on relevant behavioral or cognitive functions. This view 
contrasts with the widespread practice of assessing drug effects on 
neurotransmitter release, or with the status of neurotransmitter systems in animal 
models, in animals that remain passive or even anesthetized, and in the absence 
of recruitment of the neuronal system of interest (Sarter, Bruno et al. 2007). 
The mechanisms underlying such drastically different modulation of the 
cortical cholinergic input system in response to repeated AMPH exposure remain 
a subject of speculation. In non-performing but extensively habituated animals, 
repeated AMPH-induced increases in ACh release could reflect a purely 
pharmacological effect, due primarily to the release of norepinephrine (Rothman, 
Baumann et al. 2001; Vanderschuren, Schmidt et al. 1999) and dopamine 
(Robinson, Jurson et al. 1988), both of which are capable of stimulating 
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cholinergic neurons in the basal forebrain (Arnold, Fadel et al. 2001; Momiyama 
and Sim 1996; Berntson, Shafi et al. 2003; Napier, Simson et al. 1991). 
In contrast, the recruitment of prefrontal cholinergic inputs in task-
performing animals is thought to be mediated via direct prefrontal projections to 
the basal forebrain as well as via multi-synaptic circuits involving the nucleus 
accumbens and perhaps also the amygdala (Holland, Han et al. 2000; Neigh-
McCandless, Kravitz et al. 2002; Sarter, Givens et al. 2001; Sarter, Hasselmo et 
al. 2005; Zaborszky, Gaykema et al. 1997; Zaborszky 2002; Zahm 2000). 
Together with evidence demonstrating the disruption of the prefrontal modulation 
of accumbens neurons following repeated psychostimulant exposure (Goto and 
Grace 2005), the present findings suggest that repeated AMPH-exposure 
disrupts such telencephalic innervation of basal forebrain cholinergic neurons 
and thus, prefrontal ACh release. A range of neuronal mechanisms could be 
responsible for such a disruption, including abnormalities in glutamatergic and 
dopaminergic neurotransmission in prefrontal and mesolimbic regions (Giorgetti, 
Hotsenpiller et al. 2001; Lu and Wolf 1999; Peterson, Wolf et al. 2006; Prasad, 
Sorg et al. 1995) as well as structural reorganization of prefrontal and mesolimbic 
neurons (Crombag, Gorny et al. 2005; Robinson and Kolb 2004). 
As the administration of AMPH as a challenge was necessary to reveal 
the cholinergic and cognitive consequences of the pretreatment with AMPH, it 
can be speculated that these consequences were a result of interactions 
between increases in noradrenergic and dopaminergic neurotransmission and 
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the recruitment of the cholinergic system by cognitive task performance. 
Importantly, this conclusion does not imply that the dysregulatory consequences 
of repeated psychostimulant exposure remain restricted to monoaminergic 
systems; rather, the current results indicate that increases in 
noradrenergic/dopaminergic systems are necessary to reveal the cholinergic and 
cognitive consequences of prior psychostimulant exposure. In addition, the 
results indicate that AMPH-pretreatment alone (AMPH/SAL) affects performance-
related regulation of ACh release, as higher levels of ACh release were required 
to maintain normal performance levels in these animals. 
As pointed out in the Introduction, the effects of repeated AMPH exposure 
model essential neurobiological and behavioral/cognitive aspects of 
schizophrenia. The present results indicate that repeated AMPH exposure 
causes a fundamental loss of cognitive task control. Such failure of cognitive 
control has been proposed to form a general basis for the diverse cognitive 
symptoms of schizophrenia (Braver, Barch et al. 1999). Therefore, the effects of 
repeated AMPH exposure on attentional performance and performance-
associated ACh release appear to form a useful model for further investigations 
on the cholinergic mechanisms underlying the cognitive impairments of 
schizophrenia. Furthermore, as ongoing experiments indicate the sensitivity of 
this animal model in terms of detecting the pro-cognitive effects of drug 
treatments (Martinez 2006), this model may serve as a tool for research on the 
role of cholinergic mechanisms mediating the beneficial cognitive effects of 


















Figure 3.1(a): Schematic illustration of the sequences of events and the two trial 
types of the sustained attention task (a). A session consisted of 162 signal or 
non-signal trials. Correct responses in signal trials (hits) and non-signal trials 
(correct rejections) were rewarded (see arrows), whereas incorrect responses 
(misses and false alarms, respectively) were not. The ITI was variable to limit the 
animals' ability to time an event. Figure 3.1(b): Illustration of the AMPH-
pretreatment regimen and the overall timeline of main events including 
pretreatment, withdrawal period, surgery and the assessment of AMPH-
challenges on attentional performance and performance-associated ACh release 
in the prefrontal cortex. Animals were treated twice a day during the pretreatment 
phase, before the daily training session and 8 h later (the ordinate depicts the 
dose that was given twice daily; each dot depicts one day and dose; see 
Methods for details). Control animals received vehicle throughout the 
pretreatment regimen (not shown) and, similar to AMPH-pretreated rats, AMPH-
'challenges' following the 'withdrawal' period. Non-performing animals were 






Figure 3.2: Main sequence of events following surgery (top) and detailed 
illustration of events during an individual dialysis session (lower line). As detailed 
in the Methods section, animals were implanted with a guide cannula for the later 
insertion of a microdialysis probe 7 days following the completion of the 
pretreatment regimen (see also Figure 3.1b). Following a period of subsequent 
recovery and daily behavioral training under mock-dialysis conditions, animals 
underwent two sessions during which probes were inserted into the prefrontal 
cortex and perfused. Vehicle or AMPH-challenges were administered during 
these sessions. During an individual dialysis session, the probe was inserted 
early in the morning, the animal was placed into the operant chamber, and the 
probe was connected to syringes and pumps. During the next 3 h, the probe was 
perfused and dialysates were discarded. The three collections before drug 
administration were used to determine the stability of ACh efflux and basal ACh 
efflux. Following two collections after the administration of drug or vehicle, the 
task was activated and four 10-min samples were collected. The inset shows a 
representative placement of a microdialysis probe in the prelimbic region (Prl), 
superimposed over a schematic section (left) and an actual coronal section 
(probe length reflects approximately the 1 mm scales inserted in both the 











Figure 3.3: Effects of AMPH-pretreatment and AMPH-challenge on mPFC ACh 
release in non-performing rats (M±SEM). The bar graphs indicate absolute 
release levels (in fmol/15 μl) before the administration of saline (SAL) or AMPH. 
Following saline-'challenges', ACh release levels did not differ between saline- 
and AMPH-pretreated animals (a; see Results for statistical findings). AMPH-
challenges resulted in comparable increases in ACh release in animals 
pretreated with SAL or AMPH (b). Thus, in non-performing animals, the type of 









Figure 3.4: Effects of AMPH-pretreatment and AMPH-challenge on mPFC ACh 
release in task performing rats. In attentional task-performing rats, the type of 
pretreatment (saline vs. AMPH) determined the effects of the challenge (saline 
vs. AMPH) on ACh release (M±SEM). The bar graphs indicate absolute release 
levels (in fmol/15 μl) before the administration of saline (SAL) (a) or AMPH (b). 
Absolute levels of ACh release did not differ significantly between the groups or 
session, and they did not differ from animals that did not perform the task (Figure 
3.3; see Results for statistical findings). AMPH-pretreatment and AMPH-
challenge (AMPH/AMPH) resulted in a highly robust attenuation of performance-
associated increase in ACh release (b). This effect was already present during 
the two collections taken before task onset, suggesting that continuous 
expectation of task onset and performance and/or the context of performance are 
sufficient to reveal the interactions between pretreatment and challenge. This 
observation also rejects the possibility that the attenuation of performance-
associated increases in ACh release in AMPH-pretreated and -challenged 
animals represented merely secondary effects of the disruption of performance 
(*p<0.05; **p<0.005, significant differences between animals pretreated with 





Figure 3.5: Effects of AMPH-pretreatment and AMPH-challenge on overall 
attentional performance as indicated by VI (M±SEM). As a result of performing 
under dialysis conditions, including the tethering of the animals, performance was 
variable and levels of performance were relatively low when compared with the 
performance before surgery. However, AMPH-challenges resulted in significantly 
lower levels of performance in AMPH-pretreated animals when compared to the 
effects of AMPH in saline-pretreated rats. Furthermore, in contrast to SAL/SAL 
and AMPH/SAL rats (*p<0.05; multiple comparisons using LSD tests and 
conducted on the basis of significant ANOVAs), the depressed levels of 
performance of AMPH/AMPH animals did not depend on signal duration. The 
performance in SAL/AMPH animals appeared to remain dependent on signal 













DETECTION OF THE MODERATE BENEFICIAL EFFECTS OF LOW-DOSE 
TREATMENT WITH HALOPERIDOL OR CLOZAPINE IN AN AMPHETAMINE 
MODEL OF THE ATTENTIONAL IMPAIRMENTS OF SCHIZOPHRENIA 
 
4.1 Summary 
Schizophrenic patients display attentional impairments. Low- to- moderate 
dose treatments of both first- and second-generation antipsychotic drugs have 
been demonstrated to produce moderate pro-cognitive effects in patients (Keefe, 
Seidman et al. 2004; Mishara and Goldberg 2004). The effects of repeated 
exposure to amphetamine (AMPH) model certain aspects of impaired attention 
processing in schizophrenia. Previous work has demonstrated that the 
consequences of repeated AMPH and subsequent challenge dosing include 
impaired attentional performance and attenuation of task-associated cortical 
cholinergic activity. The goal of the present experiment was to define an animal 
model capable of detecting the moderate beneficial effects of low dose treatment 
with haloperidol or clozapine on attention. To this end, the present experiment 
employed a repeated-AMPH model that has been shown to produce 
performance impairments in rats performing a sustained attention task. 
Specifically, AMPH-challenges produced robustly impaired hit rates in AMPH-
pretreated rats, but not in rats pretreated with saline. Treatments with HAL or 
CLOZ attenuated these impairments. Collectively, these results indicate that the 
first-and second-generation drugs produce performance improvements 
sufficiently robust to be detected by this model. Therefore, the effects of this 
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particular AMPH pretreatment regimen on attentional performance may serve as 
a useful model for the preclinical detection and characterization of putative pro-
cognitive treatments for schizophrenia. 
4.2 Introduction 
Cognitive impairments, including deficits in attention processing, represent 
central and enduring features of schizophrenia (Elvevag and Goldberg 2000). 
They are evident in the majority of schizophrenic patients (~65-85%) and are 
known to predict vocational and interpersonal outcomes in patients (Green 1996; 
Keefe, Eesley et al. 2005). Preclinical strategies for assessing drugs to improve 
attentional impairments in schizophrenics remain unavailable. Attention refers to 
a set of cognitive processes that facilitate the detection and processing of 
relevant stimuli, and filtering of irrelevant stimuli. Impairments in attentional 
functions are thought to represent a core aspect of the cognitive symptoms of 
schizophrenia (Sarter, Hasselmo et al. 2005) and represent a target of 
intervention to improve cognition in schizophrenia. This evidence highlights the 
need for the development and application of novel treatments targeted explicitly 
towards minimizing the attentional impairments associated with the 
schizophrenia. 
The traditional views that first-generation drugs do not produce cognitive 
benefits, or that second-generation drugs produce superior cognitive benefits are 
not entirely substantiated. Meta-analyses and several well controlled experiments 
have determined that treatment with both first- and second-generation 
antipsychotics produce limited improvements on multiple domains of impaired 
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cognition in schizophrenia, particularly when administered at low doses (Mishara 
and Goldberg 2004; Harvey, Rabinowitz et al. 2005; Purdon, Jones et al. 2000; 
Rollnik, Borsutzky et al. 2002), and that the superior efficacy of second- over 
first-generation drugs may be negligible, or drug-specific in this regard (Keefe, 
Seidman et al. 2004; Keefe, Bilder et al. 2006). Because attentional impairments 
are central to impaired cognition in schizophrenia and represent a prime target of 
intervention, the present experiment employed 
Exposure to psychostimulants including amphetamine (AMPH) produces 
paranoid schizophrenic-like symptoms in healthy individuals, to ‘trigger’ the 
manifestation of latent psychosis in at risk individuals, and to exacerbate 
psychotic symptoms in chronically ill patients (Yui, Ikemoto et al. 2000; 
Lieberman, Kane et al. 1987; Lieberman, Kane et al. 1987; but see Barch and 
Carter 2005). These effects are thought to be based on the capacity of 
psychostimulant drugs to induce sensitization of the mesolimbic dopamine 
system (Robinson and Becker 1986). Abnormal regulation the mesolimbic 
dopamine system is considered to be a central characteristic of the neurobiology 
of schizophrenia, and has been evidenced by neuro-imaging data from 
schizophrenic patients (Laruelle, Abi-Dargham et al. 1996; Breier, Su et al. 1997; 
Laruelle, Abi-Dargham et al. 1999). 
Because attention processing represents a preclinical target for the 
development of pro-cognitive drugs, the present experiment assesses attention 
performance in rats using an AMPH-model of schizophrenia. Repeated, 
escalating administration of AMPH has been used to model various aspects of 
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schizophrenia in rats including mesolimbic dopamine dysregulation and 
attentional impairments (Paulson, Camp et al. 1991; Paulson and Robinson 
1995) (Martinez, Parikh et al. 2005) (Kozak 2007). This dosing regimen is meant 
to simulate the ‘runs and crashes’ pattern of abuse frequently associated with 
AMPH-induced psychosis, and is considered a putative animal model of 
schizophrenia (Robinson and Becker 1986; Segal and Kuczenski 1997). 
Furthermore, this dosing regimen has been shown to produce robust and 
persistent neurochemical and behavioral sensitization in rats without the result of 
neurotoxicity (Paulson, Camp et al. 1991; Paulson and Robinson 1995). 
Repeated, escalating AMPH-treatment followed by a drug-free period and 
subsequent administration of AMPH-challenges results in cortical deficits in 
sustained attention performance as well as dysregulation of the cortical 
cholinergic input system that is necessary for attention processing (Martinez, 
Parikh et al. 2005; Kozak 2007). It should be noted that the subsequent 
administration of AMPH-challenges used in this paradigm are thought to model 
the precipitous events (i.e. a psychological, social, or chemical stressor) known 
to elicit psychotic relapse in humans (Robinson and Becker 1986; Nuechterlein, 
Dawson et al. 1994; Moghaddam 2002; Muller 2004). 
The present experiment tests the hypothesis that moderate, sub-chronic 
administration of first- and second-generation drugs (haloperidol and clozapine) 
can attenuate the attentional impairments demonstrated in a repeated-AMPH 
model of schizophrenia. Specifically, that antipsychotic administration will 
mitigate the attenuated hit rates observed in animals pretreated and challenged 
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with AMPH. Rats were trained to perform a sustained attention task and then 
pretreated with either escalating AMPH or saline. Following a drug-free period, 
animals were administered a 10-day regimen of haloperidol, clozapine, or 
vehicle. All animals then received AMPH-challenge doses on days 1, 5, and 10 of 
antipsychotic treatment. Sustained attention performance was assessed 7 days 
per week during all points of the experiment. The present findings support the 
hypothesis that the present paradigm is sensitive to the beneficial effects of low 
doses of antipsychotic drugs. The present paradigm may prove useful for the 
development of novel drugs to treat attentional impairments in schizophrenia.  
4.3 Methods 
Animals: Forty-two male Sprague-Dawley rats (Harlan, Indianapolis, Indiana; 
aged 3 months and weighing 422±17 g (M±SEM) at the beginning of the 
experiment) were housed in single-standard cages with corn cob bedding in a 
humidity-(~45%) and temperature-(23°C) controlled environment. Testing 
occurred between the hours of 8:00 am and 5:30 pm.  Animals were handling 
extensively prior to the initiation of behavioral training. All rats were water 
deprived to approximately 95% of free-access weight.  Access to water was 
limited to a 30-minute period in the home cage following daily behavioral testing 
and approximately five additional milliliters of water reward could be earned 
during each daily session of operant testing. Food (Rodent Chow, Harlan Teklad, 
Madison, WI) was provided ad libitum in the home cage. All animal care, 
facilities, and experimental procedures were approved and supervised by the 
University Committee On Use and Care of Animals at the University of Michigan. 
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Lighting followed a 12-hour light-dark cycle (lights on at 6 am). 
Apparatus: Behavioral training and testing took place in 12 operant chambers 
(Med-Associates, St Albans, VT). Each operant chamber was enclosed within a 
sound-attenuating compartment and equipped with two retractable levers, one 
house light (2.8 W), a central panel light, and a water dispenser located in 
between the levers. Ventilation and white noise were provided by a fan mounted 
on the wall of the sound-attenuating compartment.  
Behavioral Training: Operant training took place 7 days per week. Rats were 
placed in unlit chambers for 20 minutes prior to task onset to acclimate. Animals 
were first trained to press a lever for a water reward in accordance with a 
modified fixed-ratio 1 schedule of reinforcement. During phase two of shaping, 
animals were trained to detect signals and discriminate between the presentation 
of signal events (illumination of the central panel light for 1 s) and non-signal 
events (non-illumination of light). Presentation of signal or non-signal events was 
randomized. Two seconds following the occurrence of a signal or non-signal 
event, both levers extended into the operant chamber and remained active for 
four seconds or until a response occurred. If the animal failed to respond within 4 
s the levers were retracted and an omission was scored. Immediately following a 
response (either correct or incorrect), both levers were retracted and the variable 
ITI (12±3 s) was reset (Figure 4.1).  During signal trials, depression of the left 
lever indicated a correct response and was scored as a hit whereas depression 
of the right lever indicated an incorrect response was scored as a miss. 
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Conversely, during non-signal trials depression of the left lever indicated an 
incorrect response and was scored as a false-alarm and depression of the right 
lever indicated a correct response and was scored as a correct rejection. Animals 
received water rewards only for correct responses (30 μl for each hit and correct 
rejection); incorrect responses (misses and false alarms) were not rewarded.  
During this phase of shaping incorrect responses resulted in the trial being 
repeated up to three times in the form of correction trials. If the animals continued 
to respond incorrectly following three correction trials, a forced-choice trial was 
initiated. A forced-choice trial consisted of a signal or non-signal event followed 
by extension of only the correct lever into the operant chamber for 90 s or until a 
lever press occurs. In the event that the forced-choice trial was a signal trial, the 
signal light remained illuminated for as long as the lever was extended. The 
house light was off during this shaping phase. Behavioral sessions consisted of 
162 trials per session. After 3 consecutive days of responding correctly to ≥59% 
of both signal- and non-signal trials animals progressed to the subsequent step 
of shaping.  
During the third phase of shaping, signal durations were shortened to 500, 
50, or 25 ms (27 trials per duration) and the ITI was reduced to 9±3 s. Correction 
and forced-choice trials were also eliminated. Sessions were divided into three 
blocks of 54 trials each with all signal durations occurring randomly 9 times per 
block. Animals were advanced to the final stage of shaping when their 
performance met or exceeded a performance criterion of 70% hits to the 500 ms 
signal trials, 70% correct rejections and fewer than 20 omitted trials per session. 
 112
 
During the final stage of shaping the house-light was illuminated throughout the 
entire testing session. The addition of the illuminated house-light represents a 
crucial element of testing sustained attention as it requires the animal to 
constrain its behavior and focus on the central panel light during task 
performance. Upon reaching the final criterion of ≥70% correct responses to the 
500 ms signal trials, ≥70% correct responses to non-signal trials and fewer than 
that 20 omissions per sessions for a minimum of 3 consecutive sessions drug 
treatment was initiated (described below).  
Pretreatment Regimen and Challenges: Animals were separated into two groups 
designated to receive pretreatment with either escalating AMPH (1-10 mg/kg, 
n=21) or saline (1 ml/kg, n=21). Intraperitoneal injections were administered 
twice daily, once at 9 a.m. in the operant chamber (20 minutes prior to task 
onset) and again eight hours later in the home cage environment. AMPH 
pretreatment spanned 40 days, with doses ranging from 1-10 mg/kg bodyweight 
(Figure 4.2, represents salt weight, dissolved in 0.9 % saline). AMPH was 
administered 5 days per week and with saline (0.9%, 1 ml/kg) administered on 
the weekends. The intermittency and escalation of and this dosing regimen 
purposefully mimics the “runs and crashes” pattern of abuse that is typically 
displayed by amphetamine addicts and has been shown to result in psychosis 
(Segal and Kuczenski 1997). Following the cessation of AMPH or saline 
pretreatment, all animals received saline injections for a period of 10 days. This 
10 day period of withdrawal was designed precede the administration of a 10 day 
sub-chronic antipsychotic dosing schedule. The timing of these events was 
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arranged such that the final challenge dose approximated the timing of 
challenges shown to disrupt attentional performance in Martinez et al. 2005. 
Treatment with clozapine or haloperidol: Following the ten-day drug free period, 
pretreatment groups were further subdivide into cohorts designated to receive 
haloperidol (HAL: 0.025 mg/kg), clozapine (CLOZ: 2.5 mg/kg), or vehicle 
(described below: 1 ml/kg). In patient populations D2 receptor occupancies 
between ~60-75% are required to produce antipsychotic effects (Kapur, Zipursky 
et al. 2000). The low doses used in this experiment were designated as such 
based on their capacities to produce <50% D2 occupancy (Kapur, VanderSpek et 
al. 2003). To better replicate clinical conditions requiring the repeated 
administration of antipsychotic treatment, dosing lasted 10 days. Administration 
of haloperidol, clozapine or vehicle to AMPH or saline-pretreated rats resulted in 
the following six cohorts of animals: (see Figure 4.3, N=7 per cohort): 1) AMPH-
pretreated: clozapine-treated (AMPH/CLOZ), 2) AMPH-pretreated: haloperidol-
treated (AMPH/HAL), 3) AMPH-pretreated: vehicle-treated (AMPH/VEH), 4) 
saline-pretreated: clozapine-treated (SAL/CLOZ), 5) saline-pretreated: 
haloperidol-treated (SAL/HAL), and 6) saline-pretreated: vehicle-treated 
(SAL/VEH). The timing of antipsychotic dosing relative to task onset was delayed 
to permit escalation in drug/plasma levels prior to the time of testing; clozapine, 
haloperidol, and vehicle were administered 40, 30, and 30 minutes prior to task 
onset (see Figure 4.4), respectively. All animals underwent AMPH challenge 
doses (1 mg/kg) on days 1, 5, and 10 of the antipsychotic treatment schedule 
(days 11, 16 and 21 following cessation of treatment). The timing of these 
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challenges with regard to antipsychotic treatment was originally designed with 
consideration for the commonly held belief that the benefits of acute 
antipsychotic treatment are minimal and that protracted dosing is required to 
produce an optimum therapeutic response (Gelder 2000; Sadock 2000).  
Data Analysis: Sustained attention performance yields measures of hits, misses, 
false alarms and correct rejections. These values are used to calculate the 
relative number of hits for each signal duration for signal trials (hits/hits+misses), 
and the relative number of correct rejections for non-signal trials (correct 
rejections/correct rejections+false alarms). Overall levels of performance are 
calculated using the Vigilance Index (VI = [(h-f)/2*(h+f)-(h+f)2]). VI is derived from 
the Sensitivity Index described by Frey and Colliver, but calculated based on the 
relative number of hits and false alarms rather than the probability of such 
occurrences (Frey 1973). Additionally VI is used expressly for describing data 
from tasks that include discrete non-signal events whereas the SI is generally 
not. VI values range from -1 to 1, with a score of 1 indicating correct responses to 
100% of attempted trials. A VI value of 0 indicates a complete inability to 
dissociate signal- from non-signal events, and reflects chance-level task 
performance. The number of omitted trials is also recorded.  
Antipsychotic administration spanned 10 days. Challenge doses took place on 
days 1, 5 and 10.  The days intermittent to challenge doses were examined by 
collapsing days 2,3,4 (T1) and days 6,7,8, and 9 (T2) into two time points. 
Analyses of clozapine and haloperidol treated animals were carried out using two 
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separate ANOVAs that included the factors group, time (T1 and T2) and signal 
duration.  
Analyses were carried out for each performance measure; all omnibus 
analyses were conducted using mixed designs. Generally the main effects and 
interactions of the factors pretreatment- group (i.e. AMPH- vs. saline-pretreated) 
and treatment-group (CLOZ, HAL, or VEH treatment) were examine with respect 
to the factors signal duration (500, 50, 25 ms, where applicable) and the factor 
‘time’ (described below). Baseline data were determined by averaging the final 
three days of performance prior to the start of pretreatment and conducting a 
mixed ANOVA using the factors group (AMPH- or saline-pretreated) and the 
factor signal duration. Next, the effects of acute administration of AMPH were 
determined by contrasting task performance of groups at baseline and following 
the acute administration of 1 mg/kg AMPH. Performance during the entire course 
of the 40 day escalating AMPH regimen could not be fully assessed due to high 
rates of omissions in AMPH-pretreated rats during higher doses of AMPH. 
Consequently, only data from the drug-free weekend periods were suitable for 
analyses. Saline-pretreated animals were only permitted to perform the task 
twice per week to control for potential practice effects. Data from weekends were 
averaged across the days to yield a total 5 time points. The subsequent analysis 
consisted of a mixed ANOVA that included the factors group (AMPH- vs. saline- 
pretreated), time (weekend) and signal duration. Following the cessation of 
pretreatment, both groups of animals continued to perform the task for 10 days. 
Data from these 10 days were analyzed by first collapsing data into three blocks 
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consisting of days 1-3 (P1), 4-7 (P2), and 8-10 (P3). Mixed ANOVAs for the 
factors group, time (P1, P2, and P3) and signal duration were then carried out. 
Using a similar analysis, data from P3 were contrasted with baseline data to 
determine the recovery of performance in AMPH and saline pretreated animals 
prior to challenge doses.  
The effects of challenge doses on AMPH- and saline-pretreated rats were 
determined by running multiple analyses to contrast the performance of the six 
smaller treatment cohorts across all three challenges. Each analysis was 
conducted as a mixed design comprised of the factors group, time (challenge 1, 
challenge 2, and challenge 3), and signal duration. The primary analysis 
contrasted the effects of AMPH/VEH and SAL/VEH animals. Subsequent 
analyses were conducted separately on AMPH- and saline-pretreated groups 
undergoing treatment with clozapine or haloperidol. These analyses made the 
following comparisons: 1) AMPH/HAL versus AMPH/VEH versus SAL/VEH; and 
2) AMPH/CLOZ versus AMPH/VEH versus SAL/VEH. SAL/VEH animals were 
used as a control group for two reasons (Martinez and Parikh, et al. 2005), first 
acute AMPH administration does not affect performance in drug naïve animals; 
and second, the effects of antipsychotics impair performance in saline-pretreated 
animals (below). A final analysis was then conducted to directly contrast the 
effects of haloperidol and clozapine in AMPH-pretreated animals. Where 
applicable, post hoc analyses were carried out using one-way ANOVAs and 
multiple comparisons (i.e. the Least Significant Difference Test). Post hoc tests 
generally consisted of direct comparisons between treatment groups for each 
 117
 
time point of interest, or within subject comparisons across time points. Statistical 
analyses were carried out on SPSS version 14. Prior to statistical analysis, 
percentage data underwent arcsine transformation (2*arcsine(√X)) (Zar 1999). P-
values below 0.05 indicated statistical significance; exact p-values were reported 
where recommended by (Greenwald 1996). 
4.4 Results 
Performance at baseline: Baseline performance values for animals designated to 
receive AMPH- or saline-pretreatment were calculated by averaging the three 
days prior to the initiation of pretreatment. Groups did not differ on any measure 
of performance (VI: (F(1,40)=2.53, p=0.11); percent hits: (F(1,40)=1.475, 
p=0.23); correct rejections (F(1,40)=1.15, p=0.29); omissions (F(1,40)=2.42, 
p=0.12). The performance of signal trials was duration dependent 
(F(2,80)=261,.97, p<0.001, Figure 4.4), as were VI scores (F(2,80)=247.24, 
p<0.001). Animals omitted an average of 4.00±6.02% of trials per session.  
Effects of acute-AMPH administration: AMPH-pretreated animals received 1 
mg/kg AMPH acutely on the first day of pretreatment. A within subjects analysis 
using AMPH-treated animals revealed that a single exposure of drug at this dose 
did not affect any measure of performance relative to baseline (VI: (F(1,40)=0.49, 
p=0.48, hits: (F(1,40)=0.56, p=0.49), correct rejections: (F(1,40)=2.71, p=0.06), 
omissions: (F(1,40)=2.71, p=0.10). Saline pretreated rats received an acute 1 
mg/kg dose of AMPH at the time of the first ‘challenge dose’ and their 
performance remained similarly unaffected (all p’s >0.06). Between group 
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comparisons indicated that performance following acute-AMPH exposure did not 
differ between groups (all p’s>0.48). 
 
Effects of escalating AMPH treatment and performance during drug-free 
weekends. Over the course of AMPH-pretreatment, doses of ≥2 mg/kg produced 
omission rates of ~100%. As described in the methods section, on weekends 
animals were administered saline and were capable of performing the task. Data 
from these drug free periods were analyzed by averaging values over two days, 
to yield 5 time points (1 per weekend, variable ‘week’). Compared to saline-
pretreated animals, the overall performance of animals receiving AMPH 
remained impaired during these drug-free days (VI: F(1,40)=8.84, p=0.005). This 
effect did not vary as a function of week or pretreatment (group x week: 
F(4,160)=2.07, p=0.09). The lower VI scores in AMPH-treated animals appeared 
to result from impaired performance on signal trials (main effect of group on hits: 
F(1,40)=6.29, p=0.02), however performance remained duration-dependent 
(F(2,51)=233.99, p<0.01). Further analysis of hits revealed a group X week 
interaction (F(4,160)=0.047). Post hoc comparisons between groups for each 
time point revealed significant group differences on weekend 3: (F(1,40)=6.73, 
p=0.01), weekend  4: (F(1,40)=8.98, p=0.005 and weekend 5: (F(1,40)=5.94, 
p=0.02) but not weekends 1 or 2 (both p’s >0.52; Figure 4.5).  
The performance of non-signal trials in AMPH-pretreated rats did not differ from 
that observed in saline-pretreated rats during the drug-free weekends (main 
effect of group: (F(1,40)=0.34, p=0.56). The number of trials omitted during drug-
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free weekends did not differ between groups (F(1,40)=0.516, p=0.47) and did not 
change as a function of week (F(4,160)=2.33, p=0.058; week x group: 
F(4,160)=1.59, p=0.18; M±SEM: 9.80±2.00% omissions/session).  
 
Performance during the withdrawal period: Following the stoppage of AMPH or 
saline pretreatment, all animals performed the task for a period of ten days 
(henceforth referred to as the ‘withdrawal’ period). To reiterate, here the term 
withdrawal is used specifically to describe the stoppage of treatment and does 
not refer to the psychological or physiological state of the animal. Analyses of 
these data were carried out by collapsing the first three, middle four, and last 
three days of the drug free period  into a total of three time points (factor ‘time’: 
P1=days 1-3, P2=days 4-7, P3=days 8-10). Vigilance index scores differed 
between groups as a function of time over the course of withdrawal (group X time 
interaction: F(10,72)=2.06, p=0.04). Between groups post hoc analyses at each 
individual time point determined that the overall performance of AMPH-pretreated 
rats was significantly worse than rats pretreated with saline at P1: (F(1,40)=1.88, 
p=0.017), but that the groups did not differ at P2 or P3 (both p>0.15, Figure 4.7). 
The lower VI scores in AMPH-pretreated animals at W1 appeared to result from 
to impaired performance on non-signal trials (main effect of group: F(1,40)=5.18, 
p=0.03). Multiple comparisons performed over separate time points indicated that 
AMPH-pretreated rats performed worse on non-signal trials at P1 and P2, but not 
P3: (P1: (F(1,40)=7.02, p=0.01) ; P2:(F(1,40)=4.37, p=0.04). P3: (F(1,40)=3.29, 
p=0.07)). The performance on signal trials did not differ on the basis of group 
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(percent hits: main effect of group: F(1,40)=0.87, p=0.35), but produced a group 
X block interaction  (F(2,80)=03.93, p=0.02). Post hoc comparisons examining 
each individual time point between groups were unable to reveal the locus of this 
interaction (P1: (F(1,40)=1.88, p=0.17), P2: (F(1,40)=0.01, p=0.97), P3: 
(F(1,40)=0.75, p=0.391). 
Importantly, animals’ overall performance (VI) had recovered to the 
baseline levels observed prior to the initiation of pretreatment (time: 
F(1,40)=0.37, p=0.54). Similarly, this analysis did not reveal a main effect of 
group (F(1,40)=0.02, p=0.96) but did indicate an interaction of time and group 
(F(2,80)=10.42, p=0.002). Post hoc analysis indicated that this interaction was 
non-orthogonal, and appeared to result from the performance of saline-
pretreated animals being slightly better at W3 than at baseline (baseline: 
0.34±0.03, W3: 0.40±0.04), whereas AMPH-pretreated animals showed a trend 
in the opposite direction (baseline: 0.41±0.04, W3: 0.32±0.03). By and large, all 
animals regained baseline performance prior to the initiation of antipsychotic 
treatment and the administration of AMPH-challenges. However, all animals (i.e. 
both pretreatment groups) omitted more trials at W3 than at baseline (main effect 
of time: (F(1,40)=7.4, =0.01), M±SEM: baseline: 4.00±0.92%, W3: 11.73±2.72%). 
Importantly, the number of omitted trials did not differ between groups, and was 
still well below the originally established performance criteria of ≤20% omissions.  
The above analyses reflect comparisons made between the two larger 
pretreatment groups; all subsequent analyses compare data from the 6 smaller 
treatment cohorts (see Methods). To ensure that no group differences existed 
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between the smaller cohorts, secondary between-groups analyses were 
performed for all performance measures. These tests indicated that no between 
group differences existed between the smaller cohorts prior to challenge dosing 
(all main effects of group: p’s>0.25).  
Effects of clozapine or haloperidol in animals pretreated with AMPH or saline.   
Following withdrawal, all groups of animals were administered antipsychotics or 
vehicle for 10 days, with challenge doses occurring on days 1, 5, and 10 of 
treatment. Data from the days in between the challenge doses (henceforth 
termed ‘drug-only days’) were examined to determine the differential effects of 
antipsychotic treatment in AMPH- and saline-pretreated animals. To conduct this 
analysis, drug-only days were collapsed into two time points: T1 was comprised 
of days 2,3 and 4, and T2 was comprised of days 6,7,8, and 9.  Groups were 
compared on all performance measure across the two time points (factor ‘time’). 
Two separate ANOVAs were carried out, the first compared clozapine-treated 
groups (AMPH/CLOZ, SAL/CLOZ and SAL/VEH) and the second compared 
haloperidol-treated groups (AMPH/HAL, SAL/HAL, SAL/VEH). Analysis of 
clozapine-treated groups did not reveal any group effects for overall performance 
(VI: F(2,18)=2.72, p=0.09) and the factor group did not interact with time or signal 
duration (both p’s>0.32). Subsequent analysis revealed a main effect of group on 
signal trials (hits: F(2,18)=15.55, p<0.001; Figure 4.8), with no interactions of 
time or signal duration (both p’s>0.10). Post hoc analyses determined that 
SAL/CLOZ animals performed worse than both AMPH/CLOZ and SAL/VEH 
animals across both time points (AMPH/CLOZ vs. SAL/CLOZ: (LSD=0.59, 
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p<0.001); SAL/VEH vs. SAL/CLOZ: (LSD=0.73, p<0.001)), whereas the 
performance of AMPH/CLOZ and SAL/VEH groups did not differ (LSD=0.14, 
p=0.321). Furthermore, no group effects were observed in AMPH/CLOZ, 
SAL/CLOZ and SAL/VEH on the performance of non-signal trials (correct 
rejections: F(2,18)=1.30, p=0.29; p’s for all interactions >0.35). However, a main 
effect of group arose from the analysis of omission rates (group: (F(2,18)=3.65, 
p=0.009). Post hoc analyses determined that SAL/CLOZ rats omitted significantly 
more trials than both AMPH/CLOZ animals (LSD=0.23, p=0.03) and SAL/VEH 
animals (LSD=0.33, p=0.003), while AMPH/CLOZ and SAL/VEH groups did not 
differ. 
An identical analysis was carried out for animals treated with haloperidol 
(AMPH/HAL, SAL/HAL, SAL/VEH). These analyses did not reveal any main 
group effects or interactions for any performance measure: (VI: (F(2,18)=1.39, 
p=0.27); (hits: (F(2,18)=1.15, P=0.33; Correct rejections: (F(2,18)=2.03, p=0.16); 
omissions: (F(2,18)=2.79, p=0.08). None of these effects varied as a function of 
time and all interactions with the factor group were not significant (all p’s >0.07).  
The effects of AMPH challenges in animals previously exposed to AMPH or 
saline. As described above, acute administration of 1 mg/kg AMPH did not affect 
task performance on the first day of pretreatment; however an identical dose 
produced marked performance impairments in animals exposed to escalating 
AMPH.  The following analyses compare two groups of animals AMPH/VEH and 
SAL/VEH (factor group) across all three challenges doses (factor ‘challenge’: 
Challenge 1, Challenge 2, and Challenge 3). Following the administration of 
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challenge doses, the overall performance of AMPH-pretreated rats was impaired 
relative to the performance of animals pretreated with saline (VI: F(1,12)=5.55, 
p=0.04). These effects did not fluctuate across challenge doses (F(2,24)=0.078, 
p=0.92) or interact with the factor challenge (F(2,24)=0.652, p=0.51). The group 
differences observed on VI resulted primarily from impaired performance of 
signal trials in AMPH-pretreated animals (hits: F(1,12)=5.44, p=1.05, p=0.04; 
Figure 4.6). Despite robust impairments in AMPH-pretreated animals, 
performance of signal trials remained signal duration dependent (F(2,26)=62.17, 
p<0.005), and did not interact with the factor group (F(2,24)=1.04, p=0.36). 
Performance of non-signal trials did not differ between groups (correct rejections: 
F(1,12)=3.70, p=0.08) or across challenge doses (F(2,24)=2.06, p=0.14). The 
number of omitted trials between groups did not differ (F(1,12)=1.19, p=0.66; 
4.85±1.77 omissions per session).  
Effects on haloperidol and clozapine treatment during AMPH-challenges. As 
demonstrated above, the administration of AMPH-challenges results in robust 
performance impairments in AMPH-pretreated animals. The following analysis 
examines the ability of sub-chronic administration of haloperidol or clozapine to 
attenuate these impairments. Antipsychotic administration impaired task 
performance in saline-pretreated animals. As a result, direct comparisons 
between AMPH or saline animals receiving identical antipsychotic treatments 
would be confounded by the performance deficits observed in the saline groups. 
To avoid these confounds, the SAL/VEH animals were used as a control group 
for analyses examining performance in AMPH/CLOZ and AMPH/HAL animals. 
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As described above, acute administration of a 1 mg/kg AMPH-challenge does not 
disrupt performance in drug-naïve animals. This is also the case for SAL/VEH 
animals receiving 1 mg/kg AMPH during challenge doses (all analyses relative to 
baseline: VI: (F(3,18)=0.64, p=0.53), hits: (F(3,18)=0.45, p=0.53), correct 
rejections: (F(3,18)=2.58, p=0.12), omissions (F(3,18)=1.29, p=0.31). These 
effects did not vary across challenge doses, and did not interact with any other 
factor (all p’s>0.14).  
Effects of challenge doses in AMPH/HAL, AMPH/VEH and SAL/VEH rats. The 
consequences of haloperidol administration in AMPH-pretreated rats during 
challenge doses were assessed using three separate analyses. The first 
compares the performance of AMPH/HAL with that of the impaired AMPH/VEH 
rats. The second examines AMPH/HAL animals with respect to SAL/VEH 
animals, and the third examines performance of AMPH/HAL animals during 
challenge doses with respect to their pretreatment baseline. The performance of 
AMPH/HAL rats, although slightly improved, was not significantly better than that 
of AMPH/VEH rats during AMPH-challenges (VI:(F(1,12)=4.39, p=0.056). This 
effect did not vary across the three challenge doses (F(2,24)=1.23, p=0.15) or as 
a function of signal duration (F(2,24)=0.94, p=0.40), and these factors did not 
interact (F(2,24)=0.77, p=0.47). The minor elevation in overall performance 
demonstrated by AMPH/HAL rats could not be attributed to improved 
performance on signal trials (group: F(1,12)=3.70, p=0.078) and no effects were 
seen on the performance of non-signal trials (group: F(1,12)=1.23, p=0.29). 




A second analysis was conducted to contrast the performance of 
AMPH/HAL and SAL/VEH groups. Results from this analysis indicated that that 
the performance of AMPH/HAL animals was restored to the levels observed in 
SAL/VEH animals on all measure of performance during AMPH-challenges (VI: 
(F(1,12)=0.82, p=0.38), hits: (F(1,12)=0.25, p=0.624), correct rejections: 
(F(1,12)=0.39, p=0.54), or omissions: (F(1,12)=2.43, p=0.51). These effects did 
not vary across the three challenge doses, or where applicable, on the basis of 
signal duration (all p’s>0.21). 
A third analysis was conducted within the AMPH/HAL group to determine 
if their performance during challenge doses was restored to baseline levels. 
Analysis of overall performance (VI) indicated that AMPH/HAL animals were 
significantly impaired during challenge doses relative to their performance at 
baseline (main effect of time: (F(3,18)=3.42, p=0.04). Post hoc analysis 
determined that AMPH/HAL animals were impaired relative to baseline during 
Challenge 1: (LSD=0.19, p=0.01) and Challenge 3: (LSD=0.189, p=0.040, but not 
Challenge 2: (LSD=0.155, p=0.12). However, separate analysis of signal and 
non-signal trials were unable to reveal specific differences between performance 
at baseline or during challenge doses for signal and non-signal trials (hits: 
F(3,18)=0.99, p=0.39; correct rejections: F(3,18)=1.22, p=0.33). The number of 
omitted trials did not differ between baseline and challenge doses (F(3,18)=0.66, 
p=0.44).  
Effects of challenges in AMPH/CLOZ, AMPH/VEH, and SAL/VEH rats. A similar 
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progression of statistical analyses was applied to determine the effects of 
clozapine in AMPH-pretreated animals. The following analyses first compare 
performance of AMPH/CLOZ with AMPH/VEH rats and then contrast 
AMPH/CLOZ with SAL/VEH animals. In terms of overall performance (VI), 
AMPH/CLOZ animals performed significantly better than AMPH/VEH rats (group: 
F(1,12)=4.79, p=0.049). This effect did not interact with signal duration 
(F(2,24)=1.56, p=0.23) and these improvements did not vary over the course of 
the three challenge doses (F(2,24)=2.89, p=0.08), indicating that acute 
administration of CLOZ was sufficient to counter act the detrimental effects of 
AMPH-challenges in AMPH-pretreated rats. Separate analyses were conducted 
on signal and non-signal trials. Hit rates did not show significant effects on the 
basis of group F(1,12)=3.11, p=0.10) and did not differ across challenge doses 
(F(2,24)=2.51, p=0.10). However, a three way interaction was observed for the 
factors challenge, group, and signal duration (F(4,48)=2.87, p=0.03). Post hoc 
analyses conducted on each signal duration between groups were not able to 
determine the locus of this interaction (all p’s>0.055). The performance of non-
signal trials did not differ on the basis of group for AMPH/CLOZ and AMPH/VEH 
animals (group: F(1,12)=3.77, p=0.08) and this effect did not vary as a function of 
time (F(2,24)=3.75, p=0.06). Likewise the number of omitted trials did not differ 
by group (F(1,12)=0.01, p=0.98), and the factor group did not interact with time 
(F(2,24)=1.51, p=0.24). 
A subsequent analysis was conducted to compare the performance of 
AMPH/CLOZ and SAL/VEH rats during challenge-doses. Administration of 
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clozapine in AMPH-pretreated rats restored performance to levels observed in 
saline-pretreated rats for all measures of performance. There were no significant 
group differences or interactions on any performance measure (all p’s>0.21).   
A final component of this analysis compared the baseline performance of 
AMPH/CLOZ animals to their performance during challenge doses. Treatment 
with clozapine during challenge doses counter-acted the detrimental effects of 
AMPH and allowed AMPH-pretreated animals to perform at levels analogous to 
baseline (VI: F(3,18)=1.63, p=0.21). Similar effects were demonstrated on the 
performance of signal and non-signal trials, as no difference were observed 
between baseline and challenge doses for hits (F(3,18)=1.93, p=0.21) or correct 
rejections (F(1,6)=1.41, p=0.27). 
AMPH/HAL versus AMPH/CLOZ. To directly contrast the effects of haloperidol 
and clozapine treatment in AMPH-pretreated rats during challenge doses an 
additional analysis was carried out. This was done to directly test the hypotheses 
concerning the superior efficacy of clozapine over haloperidol. This analysis 
indicates that groups treated with haloperidol and clozapine did not differ for any 
performance measure, and that these effects were consistent over all signal 
durations and challenge doses (all p’s>0.18).    
4.5 Discussion 
Similar to previous reports, escalating exposure to AMPH resulted in 
impaired performance during AMPH-challenge doses (Figure 4.6), but not during 
acute administration of the same dose (Martinez, Parikh et al. 2005; Kozak 
2007). Importantly, these impairments cannot be attributed to overt stereotypies 
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or the development of side-biases, since animals do not display these behaviors 
when engaged in sustained attention performance (Martinez, Parikh et al. 2005). 
The principle findings of this study demonstrate that low-dose treatments of 
haloperidol and clozapine effectively attenuate the attentional impairments 
observed in this repeated-AMPH model of schizophrenia. The beneficial effects 
of haloperidol were not as statistically robust as those observed with clozapine, 
however the efficacy of both drugs appeared to be largely equivalent. The 
benefits of AMPH and CLOZ treatments on performance were most robust when 
assessed using the comprehensive measure VI. However, these effects 
appeared to result primarily from improved performance on signal trials.  
The effects of clozapine treatment on attention performance were 
beneficial in AMPH-pretreated rats and detrimental in saline-pretreated rats. 
Specifically, in saline-pretreated rats clozapine administration impaired 
performance on signal trials and increased omission rates. Conversely, in AMPH-
pretreated animals the same doses of clozapine attenuated the performance 
impairments observed during AMPH-challenges and did not affect performance 
on non-challenge days. Similar impairments have been observed in rats 
performing a five choice serial reaction time task (Amitai 2007) and in humans 
performing a task measuring sustained attention. Treatment with haloperidol at 
doses producing <50% D2 occupancy did not impair performance in saline-
pretreated animals. Experiments demonstrating performance deficits following 
haloperidol administration generally use incomparably high doses, and may be of 
limited relevance to the effects observed here.   
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The present experiment applied a sub-chronic (10-day) schedule of dosing 
that was designed in part, to contrast the effects of acute and prolonged 
treatment with antipsychotics. This experimental design was based partially on 
the hypothesis that the beneficial effects of antipsychotic drugs have a delayed 
onset or lag in therapeutic efficacy. The present data demonstrate that both 
clozapine and haloperidol exert beneficial effects when administered acutely and 
that these effects did not change over the course of treatment. Although these 
results were initially surprising, a more thorough review of the literature indicated 
that the benefits of antipsychotic treatment in humans can appear on a much 
shorter timescale than conventionally expected, and in as little as 24 hours (Agid, 
Kapur et al. 2003; Kapur, Arenovich et al. 2005).  
  The exact mechanisms mediating the effects of clozapine and 
haloperidol in this model remain speculative. The hypothesis that the ability of 
these drugs to attenuate challenge-associated performance impairments results 
from D2 receptor blockade cannot be entirely excluded. That is to say, the 
performance effects observed in AMPH-pretreated animals following 
antipsychotic treatment may be a secondary consequence of D2 antagonism 
rather than pro-cognitive effects, per se. However, if the present results were a 
simple function of D2 antagonism, then the statistically more robust benefits of 
clozapine, with its weaker affinity for D2 receptors, would not be expected.  
Alternative speculations regarding the neurobiological underpinnings of 
these effects focus on the basal forebrain cholinergic system (BFCS). Evidence 
suggests that the functional integrity of the BFCS is crucial for normal attentional 
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processing (McGaughy, Kaiser et al. 1996; Everitt and Robbins 1997). Previous 
work has determined that the challenge-associated performance impairments 
demonstrated by AMPH-pretreated animals coincide with robust attenuations in 
cortical cholinergic transmission (Kozak 2007). Hypotheses regarding the 
mechanisms driving this dysregulation have implicated multiple neuroanatomical 
circuitries associated with schizophrenia and involved in regulating BFCS activity; 
including the prefrontal cortex (Zaborszky, Leranth et al. 1984), the nucleus 
accumbens (Zaborszky and Cullinan 1992), and the ventral tegmental area 
(Gaykema and Zaborszky 1996).   
Haloperidol and clozapine may normalize the aberrant mesolimbic activity 
associated with this model and allow the BFCS to be appropriately recruited to 
produce improved task performance. Despite these speculations, little is known 
regarding the effects of antipsychotic drugs on cortical cholinergic transmission in 
an operant context. Although previous work has demonstrated that clozapine, but 
not haloperidol, preferentially increases cortical cholinergic transmission, these 
experiments were carried out in passive rats and in environments that did not 
actively ‘recruit’ the basal forebrain cholinergic system (Ichikawa, Dai et al. 
2002). As demonstrated in Kozak, et al. such recruitment would be necessary for 
an accurate determination of drug effects, since data taken from passive rats 
may be drastically different from those observed in task-performing animals 
(Kozak 2007). Nonetheless, these findings may provide a basis for, or at least 
provide justification to test the hypothesis that the pro-cognitive effects of 
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antipsychotic drugs are mediated, at least in part, via the normalization of cortical 
cholinergic transmission.  
Despite the limitations of this model, its heuristic value is supported by its 
ability to detect the moderate cognitive benefits of low-dose treatment with both 
first- and second-generation antipsychotic drugs. Accordingly, model may have 
practical value as a screening and drug development tool for novel therapeutic 




















Figure 4.1: Diagrammatic representation of the drug treatment timeline. Animals 
were pretreated with either AMPH (1-10 mg/kg) or saline (1 ml/kg). Injections 
took place 5 days per week over a period of 40 days. Each dot represents the 
level of dosing that was administered twice daily. Injections took place in the 
morning prior to operant testing and again 8 hours later in the home cage.  Note 
that this regimen was intermittent, with all animals receiving saline on the 
weekends and undergoing operant testing. Following the completion of 
pretreatment, all animals received saline injections for ten days and continued 
operant testing. Pretreatment groups were then divided into smaller cohorts 
(Figure 4.3) designated to receive antipsychotic or vehicle treatment for a period 




Figure 4.2: Timeline of daily events during antipsychotic treatment. During the 
10-day period of antipsychotic treatment, animals were administered 
antipsychotics in the home cage environment. Timing of doses was staggered 
prior to testing to allow drug plasma levels to rise prior to testing. Animals were 
then transferred to the operant chambers, and then on the days of challenge 











Figure 4.3: Schematic of treatment groups. Forty-two animals were first divided 
into groups receiving pretreatment with either saline or escalating AMPH (n=21 
per group). Following pretreatment and withdrawal, pretreatment groups were 
further subdivided into cohorts designated to receive treatment with clozapine 
(2.5 mg/kg), haloperidol (0.025 mg/kg) or vehicle (1 ml/kg). This experimental 
design yielded the following 6 groups of animals (n=7 per group): AMPH-
pretreated/vehicle post-treated (AMPH/VEH), AMPH-pretreated/haloperidol post-
treated (AMPH/HAL), AMPH-pretreated/clozapine post-treated (AMPH/CLOZ), 
SAL-pretreated/vehicle post-treated (SAL/VEH), SAL-pretreated/haloperidol post-


















Figure 4.4: Performance of AMPH-and saline-pretreated groups at baseline. 
These data represent performance in AMPH- and saline pretreated groups 
averaged over a period of three days prior to AMPH- or saline-pretreatment. 
Groups did not differ on the performance of signal trials, and hit rates were signal 
duration dependent (percent hits; left panel). Similarly, animals’ performance on 













Figure 4.5: Overall performance (VI) during each of the five weekly-drug-free 
periods. Animals performed the task twice per week. Starting with the second 
drug free period, the overall performance of animals treated with AMPH was 












Figure 4.6: Performance of AMPH/VEH and SAL/VEH animals averaged over all 
three challenge doses. Compared to SAL/VEH animals, AMPH/VEH animals 
were robustly impaired on the performance of signal trials (left diagram). Notably, 
despite impairments hit-rates remained duration dependent in all animals. The 
performance of non-signal trials did not differ between groups. Acute 
administration of AMPH did not affect any measure of performance in SAL/VEH 

























Figure 4.7: Performance following the completion of pretreatment. All animals 
received saline injections and continued task performance for the 10 days 
following the termination of pretreatment. Data was analyzed by dividing the 10 
days into three blocks (P1=days 1,2,3; P2=days 4,5,6,7; P3=days8,9,10). 
Compared to saline-pretreated rats, AMPH-pretreated animals showed 
impairments in overall performance (VI) during P1. Performance then recovered 
markedly throughout the remainder of the drug--free period. Importantly, groups 











Figure 4.8: Effects of clozapine on performance in the absence of challenge 
doses (i.e. no challenge dose). Clozapine treatment lasted 10 days with 
challenge doses occurring on days 1, 5, and 10.These data reflect performance 
on the days in between challenge doses. Compared to the effects of vehicle, 
clozapine produced robust deficits on the hit rates of saline-pretreated animals. 
Pretreatment with AMPH appeared to protect animals from these deleterious 
effects (left graph). Similarly, clozapine treatment resulted in significantly 
increased rates of omitted trials in saline-pretreated rats while such impairments 























Figure 4.9: Performance effects of antipsychotic in AMPH-pretreated animals 
averaged over all challenge doses.  Treatment with both clozapine and 
haloperidol attenuated performance impairments in AMPH-pretreated rats, 
however only the effects of clozapine were statistically robust.  The performance 














The experiments included in this dissertation were designed for three 
primary purposes: 1) To characterize nature of attentional impairments in an 
animal model of psychosis, 2) To test hypotheses regarding the nature of cortical 
cholinergic transmission in this model, and 3) to determine if this model of 
impaired attention in schizophrenia was sensitive to the moderate, pro-cognitive 
effects of commonly prescribed first- and second-generation drugs. The following 
section will attempt to summarize the main experimental results and describe 
some interpretational issues faced by the present data. Subsequent paragraphs 
will then delineate the significance of these findings and their relationships to 
hypotheses regarding cortical cholinergic dysregulation and impaired cognition in 
schizophrenia. Future directions will be explored at several points in this 
discussion and several testable hypotheses regarding the effects of antipsychotic 
treatment on cortical cholinergic transmission and attentional impairments are 
outlined. Finally the discussion will conclude with speculation regarding possible 
points of therapeutic relevance for improved cognition in schizophrenia.   
5.2 Summary of findings and theoretical implications 
The consequences of repeated, escalating AMPH exposure and 
subsequent challenge doses were explored in Experiment I. The results from 
Experiment 1 indicate that in AMPH-pretreated animals, administration of AMPH-
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challenges results in marked performance impairments, particularly with regards 
to signal trials. These impairments are not evident following acute AMPH 
exposure, or following administration of AMPH-‘challenges’ in saline-pretreated 
animals. It is worth reiterating that these performance deficits cannot be 
attributed to overt motor stereotypy or side-bias. AMPH-associated impairments 
were restricted to decreased hit rates (i.e. responses to signal trials) and did not 
affect correct rejection rates or the number of omitted trials. Initially, the 
selectivity of these impairments for signal trials was surprising, as the observed 
impairment bore characteristics reminiscent of those seen following the selective 
depletion of cortical cholinergic transmission (McGaughy, Kaiser et al. 1996). 
These findings contrasted with original predictions regarding the nature of 
AMPH-associated performance impairments.  
Using a pretreatment regimen and behavioral paradigm modified for 
operant-dialysis procedures, Experiment 2 aimed first to reproduce the 
behavioral deficits seen in Experiment 1, and second to characterize the effects 
of escalating AMPH on cortical cholinergic transmission during operant testing.  
Although the AMPH-associated attention deficits in Experiment II were somewhat 
obfuscated by micro-dialysis procedures, a similar constellation of impairments 
was evident. Microdialysis data indicated that in task-performing animals, 
repeated treatment with AMPH and subsequent administration of AMPH-
challenges resulted in marked attenuation in cortical cholinergic transmission. 
Similar results were not evident in performing animals pretreated with saline or in 
untrained, non-performing, animals pretreated with AMPH. Reductions in the 
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magnitude of performance associated cortical ACh were shown to actually 
precede task initiation, indicating that the context or expectancy of task 
performance, rather than performance per se, may have been sufficient to 
produce these effects. These results seem to suggest that attenuated cortical 
cholinergic transmission contributed to, rather than resulted from, impaired task 
performance. The possible limitations of these data will be discussed. 
The results of Experiment 3 demonstrate that low doses of haloperidol and 
clozapine can attenuate the AMPH-induced attentional impairments observed in 
a putative animal model of schizophrenia. By and large, both antipsychotic 
treatments displayed equal efficacy in AMPH-pretreated animals. In saline 
pretreated rats, clozapine produced detrimental effects (i.e. decreased hits and 
increased omissions), even in the absence of AMPH-challenge doses; similar 
impairments were not evident in AMPH-pretreated animals. These data lend 
predictive validity to this model as a screening tool for drugs to improve cognition 
in schizophrenia.  
5.3 Experimental limitations and alternative interpretations of data 
The present experiments provide data to support the core hypothesis that 
cortical cholinergic dysregulation represents an integral component of the 
neurobiology underlying schizophrenic symptoms, and that cortical cholinergic 
dysregulation may contribute to cognitive aspects of the disease. However, 
several methodological limitations prohibit the direct testing of hypotheses 
regarding the relationship of cholinergic dysregulation with respect to cognitive 
variables in this model. The following section will outline various limitations of the 
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present experiments and discuss their implications for the main hypotheses of 
these studies. 
In Experiment 2, cortical cholinergic dysregulation is evident in AMPH-
pretreated task performing rats. It is worth noting that the abnormalities in 
cholinergic transmission that are observed prior to task initiation cannot be 
singularly attributed to a specific factor such as general task expectancy, 
operational context, or explicit expectancy for cognitive task demands. The 
original hypothesis that “in order to demonstrate the abnormal regulation of a 
neurotransmitter system, recruitment of that system, by behavioral and cognitive 
operations relevant to that system, is required” has not been fully substantiated 
by these data and interpretations to this end should perhaps, be tempered. The 
main point of contention arises when determining the factors contributing to this 
dysregulation. That is, any claims that these effects result explicitly from 
expected ‘cognitive demands’ are not supported, as the data do not exclude the 
possibility that expectancies for reward or increased locomotion may have similar 
consequences. To substantiate these claims would require the addition of control 
groups to account for operational context as well as the non-attentional elements 
of task performance such locomotive behaviors, reward retrieval and 
consumption, and exposure to task-related stimuli (e.g. flashing lights and 
retracting levers). It has been demonstrated that bar pressing behavior and 
reward consumption are each sufficient to produce increases in cortical 
cholinergic transmission, albeit not to the same degree as sustained attention 
performance (Arnold, Burk et al. 2002). If, in fact, the context of sustained 
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attention performance is the key variable resulting in abnormal cortical 
cholinergic transmission, then trained AMPH-pretreated animals would exhibit 
cholinergic dysregulation only when placed into operant chambers associated 
with task performance, but not when placed in familiar environments with no 
attentional contexts.  Similarly, claims that the expectancy for attentional 
demands (consequent to training history) drives the abnormal recruitment of 
cholinergic neurons could  be substantiated using AMPH-pretreated animals 
trained to perform a simple reaction time task (as described in (Apparsundaram, 
Martinez et al. 2005). This task is thought to possess only minimal attentional 
demands and is designed to control for the motoric, reward, and stimulus 
associated components of task performance. In the absence of these controls, 
‘cognition oriented’ interpretations of these data should be limited to imply that 
the challenge-associated cortical cholinergic dysregulation evident in task-
performing, AMPH-pretreated animals is the result of abnormal recruitment of the 
BFCS by operational contexts and /or expectancy to perform a task with implicit 
attentional, motoric, stimulus, and reward associated components.  
Experiment 3 applied a sub-chronic regimen of relatively low doses of 
clozapine and haloperidol. Although the effects of clozapine were more 
statistically robust, both classes of drugs were equally efficacious in attenuating 
the challenge-associated performance impairments observed in AMPH-
pretreated animals. It remains to be determined if the performance improvements 
observed following antipsychotic treatment were the result of mechanisms other 
than direct D2 antagonism, or if these effects were simply the result of 
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antipsychotic drugs correcting the dopamine perturbations produced by an 
AMPH-challenge. If D2 antagonism represents the critical variable mediating 
these effects, then task performance should have improved as a function of a 
drug’s affinity for D2 receptors. Although experimental design does not permit a 
formal test of this hypothesis (i.e. a correlation analysis),  the more robust effects 
of clozapine compared to haloperidol, in conjunction with clozapine’s lower 
affinity for D2 receptors, does not appear to support the interpretation that these 
effects were mediated solely by D2 antagonism.  
The effects of clozapine in saline-pretreated animals were distinct from the 
effects of haloperidol. The beneficial effects of clozapine could only be 
demonstrated in AMPH-pretreated rats and its effects on saline-pretreated rats 
were actually detrimental. These mechanisms underlying these deficits are 
unknown, but speculatively, could be the result of clozapine’s actions as a 
muscarinic antagonist. Interestingly, animals treated with haloperidol did not 
show performance deficits. Similar to the effects of acute treatment with AMPH, 
these findings may indicate that sustained attention performance is robust to 
minor manipulations of the dopamine system. Understanding the precise neural 
mechanisms mediating the differential effects of clozapine in saline- and AMPH-
pretreated animals could inform hypotheses regarding beneficial actions of this 
drug on attention performance.  
The 10-day antipsychotic dosing schedule was designed in part, to 
contrast the effects of acute and prolonged antipsychotic treatments, and was 
based partially on the hypothesis that the beneficial effects of antipsychotic drugs 
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have a delayed onset or lag in therapeutic efficacy. The present data 
demonstrate that both clozapine and haloperidol exert beneficial effects when 
administered acutely. Although these results were initially surprising, a more 
thorough review of the literature indicated that the benefits of antipsychotic 
treatment can appear on a much shorter timescale than conventionally expected 
(Kapur, Arenovich et al. 2005; Agid, Kapur et al. 2003).  
5.4 Alternative animal models of schizophrenia 
Alternative models attempting to reproduce aspects of schizophrenia have 
been based on etiological and developmental disease hypotheses; specifically, 
that pre- or peri-natal insults can produce developmental disturbances that confer 
susceptibility for the later development of schizophrenia.  The common goal of 
these models has been to reproduce behavioral and neurobiological 
characteristics relevant to schizophrenia through the manipulation of putative 
‘causal’ factors associated with the disease.  For example, at least some 
epidemiological evidence suggests that obstetrical complications (Takagai, 
Kawai et al. 2006), maternal infection during gestation (Limosin, Rouillon et al. 
2003), and maternal malnutrition (Brown, Susser et al. 1996) predispose the 
development of schizophrenia. These data have guided the development of 
animal models examining the behavioral and neurobiological consequences of 
early environmental and immunological insults, such as maternal deprivation 
(Ellenbroek, van den Kroonenberg et al. 1998), prenatal exposure to MAM 
(methylazoxymethanol-acetate; Featherstone, Rizos et al. 2007), or prenatal 
immunological challenges (Meyer, Feldon et al. 2005). Proponents of such 
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models note their ability to accurately reproduce hypothetical risk factors for 
schizophrenia while replicating many schizophrenia-like phenomena including 
sensorimotor gating deficits, neuroanatomical dysmorphogenesis, and 
irregularities in the dopaminergic and glutamatergic systems. 
 In addition to the etiological models described above, the cortical and 
hippocampal dysmorphogenesis observed in some schizophrenic brains has lead 
to the development of the neonatal ventral-hippocampal lesion (NNHL) model of 
schizophrenia (Lipska, Jaskiw et al. 1993). Ventral-hippocampal lesions 
produced on postnatal day 7 result in a variety of behavioral, neuro-chemical, 
and electrophysiological abnormalities that are manifested in adulthood, but are 
not apparent in pre-pubescent animals or in animals receiving hippocampal 
lesions as adults.  Similar to schizophrenia, the behavioral consequences of 
NNHLs include hyper-responsiveness to stress, novelty, and psychostimulants; 
as well as deficits in latent inhibition and sensorimotor gating (Lipska, Jaskiw et 
al. 1993; Lipska, Swerdlow et al. 1995; O'Donnell, Lewis et al. 2002; Laplante, 
Stevenson et al. 2004). 
 Furthermore, additional pharmacologic models of schizophrenia have 
been based on the psychotogenic actions of NMDA-receptor antagonists, such 
as phencyclidine (PCP). These models are thought to reproduce the 
glutamatergic dysfunction associated with schizophrenia (Tenn, Kapur et al. 
2005; Coyle 1996). Similar to the effects of AMPH, PCP administration in 
humans can exacerbate psychotic symptoms in patients and induce psychosis in 
healthy individuals. PCP treatments in rats and non-human primates have 
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likewise been shown to produce cognitive impairments, and alternations in 
neuronal systems associated with the disease (Flores 2007; Jentsch, Redmond 
et al. 1997).  
As pointed out by critics of psychostimulant-based models, the repeated-
AMPH paradigm used here fails to replicate the inducing factors of schizophrenia 
and is not capable of addressing hypotheses related to the time course of the 
illness. In certain cases any validity inherent to psychostimulant-based models 
can not be attributed to mechanisms beyond the scope of the induced dopamine 
dysregulation that is intrinsic to the model. In the simplest terms: following a 
direct manipulation to the dopamine system (i.e. administration of a dopamine 
agonist) an animal may display an abnormality in some dopamine-related 
behavior (i.e. stereotypy); that abnormality is then rectified by another direct 
manipulation of the dopamine system (i.e. a dopamine antagonist). 
Consequently, psychostimulant models have been criticized as being incapable 
of exploring disease mechanisms beyond those directly related to dopamine 
transmission. As a consequence, critics have indicated that such models could 
be of limited use for discovering novel, non-dopamine based drugs for 
schizophrenia (Geyer 2006; Lipska and Weinberger 2000). 
 Alternatively, developmental paradigms, such as the NNHL model, are 
thought to circumvent these logical constraints by engendering abnormalities in 
systems that are distinct from those they directly manipulate (Lipska and 
Weinberger 2000). Assertions that NMDA-based models share similar 
advantages have been based on data indicating that NMDA-antagonists (i.e. 
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PCP, ketamine), produce schizophrenic like characteristics that can are 
attenuated following treatment with clozapine, but not haloperidol (Geyer 2006; 
Linn, Negi et al. 2003). Because the consequences of PCP administration were 
responsive to second-, but not first-generation drugs, this evidence was taken to 
indicate that the application of NMDA-antagonist models could be applied toward 
the discovery of non- dopamine based drugs for schizophrenia (Geyer 2006). 
However, an alternative interpretation of these results reveals the same 
tautological reasoning that the author points out in psychostimulant-based 
models. Current data indicates that PCP has a high affinity for D2 and 5-HT2A 
receptors, along with affinities for dopamine and serotonin transporters (DAT and 
SRT, respectively). The fact that clozapine also possesses a high affinity for the 
same receptor sub-types once again makes it impossible to distinguish if the 
observed effects are mediated by systems distinct from those being directly 
manipulated or if they simply reflect the competition of drugs for common 
receptors.    
In AMPH-pretreated animals, robust impairments in performance 
impairments are only apparent in the presence of an AMPH-challenge. This 
effect is problematic because, as discussed above, it occludes the mechanisms 
underlying the performance improvements observed following antipsychotic 
treatment, and furthermore is not representative of the persistent impairments 
observed throughout the entire disease course in patient populations. Perhaps 
future experiments will improve upon this model by determining ways to produce 
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persistent performance deficits in AMPH-pretreated animals in the absence of a 
direct dopamine manipulation (i.e. exposure to a stressful stimulus). 
5.5 Future directions  
Recent advances in technologies used to assess cortical ACh have made 
it possible to measure changes cortical ACh on a sub-second time scale. Such 
techniques have facilitated the examination of cortical cholinergic transmission in 
relation to discrete stimuli and specific behaviors (Parikh 2007). Furthermore, use 
of these techniques has revealed that changes in cortical cholinergic 
transmission can occur on multiple time scales. Slow rising ‘tonic’ changes are 
seen in response to general task performance, whereas faster, transient changes 
are seen in response to discrete stimuli. The microdialysis procedures employed 
in Experiment 2 are incapable of making such assessments and are generally 
thought to reflect a combination of both of these components (Parikh 2007). 
Future studies utilizing this model and applying newer technologies to determine 
the precise nature of cortical cholinergic dysregulation could provide data to 
guide attempts to normalize cholinergic transmission in schizophrenia.  These 
techniques, in conjunction with the present paradigm could be employed to test 
hypotheses concerning the mechanisms by which haloperidol and clozapine 
achieved the performance-improving effects described in experiment 3; 
specifically that these drugs normalize both phasic and tonic components of 
cortical cholinergic transmission.  
5.6 Normalizing cortical cholinergic transmission and attentional 
impairments in schizophrenia 
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 It is not known whether the beneficial effects of clozapine and haloperidol 
in the present paradigm result from their antipsychotic actions or actual cognitive 
improvements. However, the more robust effects of clozapine compared to 
haloperidol, regardless of haloperidol’s higher affinity for D2 receptors suggest 
that simple D2 antagonism may not be the single variable mediating these 
benefits. Speculatively, these benefits could stem from these drugs capacity to 
normalize afferent systems regulating the excitability of the basal forebrain, their 
direct actions on various receptor subtypes (i.e. D2, M2), or any combination of 
these effects. Attempts to alleviate the attentional impairments observed in 
schizophrenia via the direct manipulation of cholinergic mechanisms have not 
been successful. This failure is thought to stem from the inability of currently 
available drugs to restore the dynamic regulation of the cholinergic transmission 
with respect to changing stimulus environments and cognitive demands. The 
success of future endeavors to improve cognition in schizophrenia may be 
contingent upon the re-regulation basal forebrain cholinergic system via tran-
synaptic modulatory mechanisms, rather than direct cholinergic agonism or 
antagonism. 
 
5.7 Concluding remarks 
Despite the experimental and interpretational challenges described above, 
the experiments included in this thesis aid in the refinement of current 
hypotheses regarding the neural mechanisms underlying schizophrenia’s 
cognitive deficits. The above experiments provide direct evidence that abnormal 
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cortical cholinergic transmission occurs in association with attentional 
impairments in an animal model of schizophrenia. Importantly, this dysregulation 
was only apparent in task performing animals. As a consequence, the 
contributions of the basal forebrain cholinergic system to schizophrenia should 
no longer be conceptualized as trait characteristics such as excesses or 
deficiencies of cortical acetylcholine, but rather, hypotheses should reflect the 
expectation that the dysregulation of the basal forebrain cholinergic system in 
schizophrenia will vary widely depending on cognitive and contextual factors. In 
order for a drug to successfully improve cognition in schizophrenia its must be 
able to restore the dynamic regulation of this system. Furthermore, because this 
present model is sensitive to the performance improvements produced by 
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